[{"Date":"Jan. 5, 2016 at 4:40 p.m. ET","Headline":"U.S. stocks snap 3-day slump, end slightly higher","Summary":"Eli Lilly & Co. shares  fell 2% in premarket trade Tuesday, after the drug company offered guidance for 2016 that was below current FactSet consensus levels. Eli Lilly said it expects revenue to range from $20.2 billion to..."},{"Date":"Jan. 5, 2016 at 10:38 a.m. ET","Headline":"Eli Lilly offers lackluster outlook for 2016","Summary":"Eli Lilly & Co. shares  fell 2% in premarket trade Tuesday, after the drug company offered guidance for 2016 that was below current FactSet consensus levels. Eli Lilly said it expects revenue to range from $20.2 billion to..."},{"Date":"Jan. 5, 2016 at 7:23 a.m. ET","Headline":"Get your \u2018wish list of stocks\u2019 ready as the bulls regroup","Summary":"Eli Lilly & Co. shares  fell 2% in premarket trade Tuesday, after the drug company offered guidance for 2016 that was below current FactSet consensus levels. Eli Lilly said it expects revenue to range from $20.2 billion to..."},{"Date":"Jan. 5, 2016 at 6:57 a.m. ET","Headline":"Eli Lilly shares fall 2% premarket as 2016 outlook lags estimates","Summary":"Eli Lilly & Co. shares  fell 2% in premarket trade Tuesday, after the drug company offered guidance for 2016 that was below current FactSet consensus levels. Eli Lilly said it expects revenue to range from $20.2 billion to..."},{"Date":"Dec. 12, 2015 at 12:01 a.m. ET","Headline":"Bank Dividends: Going Up","Summary":""},{"Date":"Jan. 19, 2016 at 8:16 a.m. ET","Headline":"Incyte's stock surges after receiving milestone payment from Eli Lilly","Summary":"Shares of Incyte Corp.  surged 4% in premarket trade Tuesday, after Eli Lilly & Co.  said it will make a $35 million milestone payment to the biopharmaceutical company following the companies' submission of a new drug appl..."},{"Date":"Jan. 21, 2016 at 12:01 a.m. ET","Headline":"Five Pharma Picks for Another Volatile Year","Summary":""},{"Date":"Jan. 23, 2016 at 9:30 a.m. ET","Headline":"Apple, Amazon headline crucial week for Wall Street quarterly results","Summary":""},{"Date":"Jan. 28, 2016 at 4:24 p.m. ET","Headline":"Stocks end higher, boosted by Facebook, oil rally","Summary":"Eli Lilly & Co  on Thursday reported adjusted earnings that met Wall Street's forecast, though revenue fell slightly short. For the fourth quarter, the pharmaceutical group said it earned 45 cents a share, against 40 cents..."},{"Date":"Jan. 28, 2016 at 9:23 a.m. ET","Headline":"Why this big baby of a market won\u2019t calm down anytime soon","Summary":"Eli Lilly & Co  on Thursday reported adjusted earnings that met Wall Street's forecast, though revenue fell slightly short. For the fourth quarter, the pharmaceutical group said it earned 45 cents a share, against 40 cents..."},{"Date":"Jan. 28, 2016 at 6:56 a.m. ET","Headline":"Eli Lilly meets earnings forecasts, sticks to 2016 guidelines","Summary":"Eli Lilly & Co  on Thursday reported adjusted earnings that met Wall Street's forecast, though revenue fell slightly short. For the fourth quarter, the pharmaceutical group said it earned 45 cents a share, against 40 cents..."},{"Date":"Jan. 29, 2016 at 7:10 a.m. ET","Headline":"Eli Lilly\u2019s revenue boosted by jacking up cost of insulin for diabetics","Summary":""},{"Date":"Feb. 27, 2016 at 12:01 a.m. ET","Headline":"9 Drug Makers That Could Boost Their Payouts","Summary":""},{"Date":"Feb. 29, 2016 at 12:01 a.m. ET","Headline":"Big Pharma Has Plenty in the Pipeline","Summary":""},{"Date":"Mar. 17, 2016 at 3:40 p.m. ET","Headline":"Eli Lilly's stock drops sharply again, to lead health care sector lower","Summary":"Eli Lilly & Co.'s stock  tumbled 4.5% in afternoon trade Thursday, bucking the sharp rally in the broader market, as it headed for the lowest close in a year. The drug maker's stock was the biggest decliner in the SPDR Hea..."},{"Date":"Mar. 21, 2016 at 4:16 a.m. ET","Headline":"China\u2019s diabetes boom promises $23 billion pot for drug makers","Summary":""},{"Date":"Apr. 5, 2016 at 12:01 a.m. ET","Headline":"Lilly Cholesterol Data Impact Merck, Esperion","Summary":""},{"Date":"Apr. 9, 2016 at 12:01 a.m. ET","Headline":"Primecap in the Spotlight","Summary":"LONDON--AstraZeneca PLC AZN and Eli Lilly and Co. LLY said they would progress a clinical trial for an Alzheimer's drug after initial human testing showed it didn't have harmful side effects. The drug, called AZD3293, is a..."},{"Date":"Apr. 8, 2016 at 3:39 a.m. ET","Headline":"AstraZeneca, Eli Lilly progess on Alzheimer's drug","Summary":"LONDON--AstraZeneca PLC AZN and Eli Lilly and Co. LLY said they would progress a clinical trial for an Alzheimer's drug after initial human testing showed it didn't have harmful side effects. The drug, called AZD3293, is a..."},{"Date":"Apr. 15, 2016 at 12:01 a.m. ET","Headline":"Best Bets in Biopharma","Summary":""},{"Date":"Apr. 23, 2016 at 8:01 a.m. ET","Headline":"Apple, Exxon expected to drag on earnings during peak week","Summary":""},{"Date":"Apr. 26, 2016 at 4:19 p.m. ET","Headline":"S&P 500 ekes out gain; Nasdaq ends lower as Apple earnings loom","Summary":"U.S. stocks on Tuesday opened modestly higher, putting the market on track to rebound somewhat after dropping in two of the past three sessions. Relatively strong oil prices  and earnings helped lead early gains. Procter &..."},{"Date":"Apr. 26, 2016 at 9:35 a.m. ET","Headline":"Dow retakes 18,000 as oil, earnings lift sentiment","Summary":"U.S. stocks on Tuesday opened modestly higher, putting the market on track to rebound somewhat after dropping in two of the past three sessions. Relatively strong oil prices  and earnings helped lead early gains. Procter &..."},{"Date":"Apr. 26, 2016 at 9:35 a.m. ET","Headline":"Dow retakes 18,000 as oil, earnings lift sentiment","Summary":"U.S. stocks on Tuesday opened modestly higher, putting the market on track to rebound somewhat after dropping in two of the past three sessions. Relatively strong oil prices  and earnings helped lead early gains. Procter &..."},{"Date":"Apr. 26, 2016 at 9:18 a.m. ET","Headline":"Ditching stocks in May could cost you plenty come autumn","Summary":""},{"Date":"Nov. 7, 2015 at 12:01 a.m. ET","Headline":"Est\u00e9e Lauder Offers Prettier Payout","Summary":""},{"Date":"Jun. 22, 2015 at 12:01 a.m. ET","Headline":"Radius Health Looks Fully Valued","Summary":""},{"Date":"Apr. 30, 2016 at 12:01 a.m. ET","Headline":"6 Healthcare Picks from a Market-Beating Veteran","Summary":""},{"Date":"May. 16, 2016 at 2:57 p.m. ET","Headline":"4 things to know about Pfizer\u2019s $5.2 billion acquisition target, Anacor","Summary":""},{"Date":"May. 20, 2016 at 8:36 a.m. ET","Headline":"Four reasons for investors to buy biotechnology stocks now","Summary":""},{"Date":"May. 21, 2016 at 12:01 a.m. ET","Headline":"This Year\u2019s Hot Graduation Gift: Stocks","Summary":""},{"Date":"Jun. 30, 2016 at 12:01 a.m. ET","Headline":"Who Will Acquire Medivation?","Summary":""},{"Date":"Jul. 6, 2016 at 12:01 a.m. ET","Headline":"Top U.S. Pharma Themes for the Second Half","Summary":""},{"Date":"Jul. 15, 2016 at 11:14 a.m. ET","Headline":"S&P 500 vies for latest technical record","Summary":""},{"Date":"Jul. 14, 2016 at 12:01 a.m. ET","Headline":"Incyte, a Biotech Acquisition Target","Summary":""},{"Date":"Jul. 18, 2016 at 11:18 a.m. ET","Headline":"U.S. benchmarks sustain rally to less-charted territory","Summary":""},{"Date":"Jul. 15, 2016 at 12:01 a.m. ET","Headline":"Big Pharma Q2 Earnings Preview","Summary":""},{"Date":"Jul. 20, 2016 at 11:17 a.m. ET","Headline":"Charting the Dow industrials\u2019 crawl to latest technical record","Summary":""},{"Date":"Jul. 19, 2016 at 12:56 p.m. ET","Headline":"Charting the S&P 500\u2019s next technical target","Summary":""},{"Date":"Jul. 19, 2016 at 12:31 p.m. ET","Headline":"Charting the S&P 500\u2019s next technical target","Summary":""},{"Date":"Jul. 22, 2016 at 11:32 a.m. ET","Headline":"Bull trend intact, Nasdaq, Dow nail first support","Summary":""},{"Date":"Jul. 21, 2016 at 11:44 a.m. ET","Headline":"S&P, Dow hold record territory amid dwindling volume","Summary":""},{"Date":"Jul. 26, 2016 at 12:50 p.m. ET","Headline":"Bull trend intact, S&P 500 stages garden-variety pullback","Summary":""},{"Date":"Jul. 26, 2016 at 12:21 p.m. ET","Headline":"Bull trend intact, S&P 500 stages garden-variety pullback","Summary":""},{"Date":"Jul. 26, 2016 at 10:03 a.m. ET","Headline":"Here\u2019s your second chance to buy into oil\u2019s recovery","Summary":""},{"Date":"Jul. 25, 2016 at 11:31 a.m. ET","Headline":"Dow industrials back for another crack at first support","Summary":""},{"Date":"Jul. 28, 2016 at 11:46 a.m. ET","Headline":"S&P 500 flatlines near record territory (that\u2019s bullish)","Summary":"Eli Lilly & Co.  said John Lechleiter will retire as chief executive and president at the end of the year. He will remain an non-executive chairman until May 31, 2017. David Ricks, president of Lilly Bio-Medicines, will as..."},{"Date":"Jul. 27, 2016 at 11:28 a.m. ET","Headline":"Charting the Russell 2000\u2019s breakout attempt","Summary":"Eli Lilly & Co.  said John Lechleiter will retire as chief executive and president at the end of the year. He will remain an non-executive chairman until May 31, 2017. David Ricks, president of Lilly Bio-Medicines, will as..."},{"Date":"Jul. 27, 2016 at 6:57 a.m. ET","Headline":"Eli Lilly CEO to retire at the end of the year","Summary":"Eli Lilly & Co.  said John Lechleiter will retire as chief executive and president at the end of the year. He will remain an non-executive chairman until May 31, 2017. David Ricks, president of Lilly Bio-Medicines, will as..."},{"Date":"Jul. 29, 2016 at 11:30 a.m. ET","Headline":"U.S. benchmarks lay technical groundwork for the next leg higher","Summary":""},{"Date":"Aug. 1, 2016 at 11:34 a.m. ET","Headline":"S&P 500\u2019s coiled spring strengthens near-term bullish bias","Summary":""},{"Date":"Aug. 3, 2016 at 11:55 a.m. ET","Headline":"S&P 500 violates support, back for a crack at the breakdown point","Summary":""},{"Date":"Aug. 2, 2016 at 12:31 p.m. ET","Headline":"Charting the S&P 500\u2019s near-term technical test","Summary":""},{"Date":"Aug. 2, 2016 at 12:09 p.m. ET","Headline":"Charting the S&P 500\u2019s near-term technical test","Summary":""},{"Date":"Aug. 5, 2016 at 11:50 a.m. ET","Headline":"U.S. jobs report does the trick \u2014 S&P 500, Nasdaq rattle cage on uncharted territory","Summary":""},{"Date":"Aug. 4, 2016 at 11:47 a.m. ET","Headline":"S&P 500 returns to the range, Dow industrials nail first resistance","Summary":""},{"Date":"Aug. 9, 2016 at 12:32 p.m. ET","Headline":"S&P 500, Nasdaq extend the break to \u2018clear skies\u2019 territory","Summary":""},{"Date":"Aug. 9, 2016 at 12:10 p.m. ET","Headline":"S&P 500, Nasdaq extend the break to \u2018clear skies\u2019 territory","Summary":""},{"Date":"Aug. 8, 2016 at 11:40 a.m. ET","Headline":"S&P 500, Nasdaq carve out latest break to record territory","Summary":""},{"Date":"Aug. 11, 2016 at 11:53 a.m. ET","Headline":"Dow industrials tag record highs, breakout attempt underway","Summary":"Eli Lilly and Co. shares  tumbled almost 6% in premarket trade Wednesday, after the company said a second late-stage trial of a breast cancer treatment failed to meet its goals. The phase 3 trial compared abemaciclib plus ..."},{"Date":"Aug. 10, 2016 at 11:54 a.m. ET","Headline":"Charting the Dow industrials\u2019 slow-motion breakout attempt","Summary":"Eli Lilly and Co. shares  tumbled almost 6% in premarket trade Wednesday, after the company said a second late-stage trial of a breast cancer treatment failed to meet its goals. The phase 3 trial compared abemaciclib plus ..."},{"Date":"Aug. 10, 2016 at 10:31 a.m. ET","Headline":"The chart that\u2019s proving crash-happy stock bears wrong","Summary":"Eli Lilly and Co. shares  tumbled almost 6% in premarket trade Wednesday, after the company said a second late-stage trial of a breast cancer treatment failed to meet its goals. The phase 3 trial compared abemaciclib plus ..."},{"Date":"Aug. 10, 2016 at 7:30 a.m. ET","Headline":"Eli Lilly says late-stage trial of breast cancer treatment failed to meet goals","Summary":"Eli Lilly and Co. shares  tumbled almost 6% in premarket trade Wednesday, after the company said a second late-stage trial of a breast cancer treatment failed to meet its goals. The phase 3 trial compared abemaciclib plus ..."},{"Date":"Aug. 12, 2016 at 11:29 a.m. ET","Headline":"Charting the U.S. markets\u2019 slow-motion breakout of the millennium","Summary":""},{"Date":"Aug. 15, 2016 at 11:40 a.m. ET","Headline":"Small- and mid-caps tag new highs, breakout attempt underway","Summary":""},{"Date":"Aug. 17, 2016 at 11:51 a.m. ET","Headline":"Dow, Nasdaq challenge first support ahead of Fed minutes","Summary":""},{"Date":"Aug. 16, 2016 at 12:36 p.m. ET","Headline":"Charting the U.S. benchmarks\u2019 pulling-teeth breakout attempt","Summary":""},{"Date":"Aug. 16, 2016 at 12:06 p.m. ET","Headline":"Charting the U.S. benchmarks\u2019 slow-motion (but still bullish) summer uptrend","Summary":""},{"Date":"Aug. 16, 2016 at 12:01 a.m. ET","Headline":"Lilly and Allergan Are Large-Cap Pharma Picks","Summary":""},{"Date":"Aug. 19, 2016 at 11:48 a.m. ET","Headline":"U.S. benchmarks\u2019 slow-motion uptrend intact amid commodity, currency cross currents","Summary":""},{"Date":"Aug. 18, 2016 at 11:41 a.m. ET","Headline":"Dow industrials rally from second successful test of 18,470 support","Summary":""},{"Date":"Aug. 22, 2016 at 7:25 a.m. ET","Headline":"Lilly, AstraZeneca Alzheimer's drug fast tracked","Summary":"AstraZeneca PLC (AZN) said Monday that the Alzheimer's drug it is co-developing with Eli Lilly & Co (LLY)  has received fast-track designation from the U.S. Food and Drug Administration, a status designed to speed up the d..."},{"Date":"Sep. 8, 2016 at 12:01 a.m. ET","Headline":"Eli Lilly Stock Can Cure What Ails Your Portfolio","Summary":""},{"Date":"Sep. 13, 2016 at 3:06 p.m. ET","Headline":"Mylan top executive pay was second-highest in industry just as company raised EpiPen prices","Summary":""},{"Date":"Sep. 22, 2016 at 11:17 a.m. ET","Headline":"Teva, Allergan Pump Up the Pipelines","Summary":""},{"Date":"Sep. 22, 2016 at 9:49 a.m. ET","Headline":"In focus: The S&P is better, but not there yet","Summary":""},{"Date":"Sep. 26, 2016 at 6:05 p.m. ET","Headline":"Pfizer Won\u2019t Split and Neither Should Investors","Summary":""},{"Date":"Sep. 30, 2016 at 1:28 p.m. ET","Headline":"Biotech stocks have plenty of catalysts around the corner","Summary":""},{"Date":"Oct. 5, 2016 at 7:13 a.m. ET","Headline":"Eli Lilly's Elanco to acquire Boheringer Inghelheim's U.S. rabies vaccine business for $885 million","Summary":"Eli Lilly and Co.  unit Elanco U.S. Inc. has agreed to acquire Boehringer Ingelheim Vetmedica Inc.'s U.S. feline, canine and rabies vaccines portfolio, in a deal valued at $885 million. The acquisition includes a manufactu..."},{"Date":"Oct. 24, 2016 at 11:38 a.m. ET","Headline":"The market in a minute: It\u2019s not time to step on the gas yet","Summary":""},{"Date":"Oct. 25, 2016 at 6:14 a.m. ET","Headline":"The Next Big Moves in Health-Care Stocks","Summary":""},{"Date":"Oct. 1, 2016 at 12:01 a.m. ET","Headline":"Health-Care Stocks Are Riskier Than They Seem","Summary":""},{"Date":"Nov. 1, 2016 at 1:27 p.m. ET","Headline":"Eli Lilly feels brief pressure after Sanders tweet about Lantus","Summary":"Eli Lilly & Co.  shares fell as much as 3% after Sen. Bernie Sanders tweeted about the company's Lantus insulin drug. Sanders \"it makes no sense that the same drug that costs $70 in France costs $450 in the US. We should r..."},{"Date":"Nov. 4, 2016 at 7:30 a.m. ET","Headline":"Merck\u2019s Alzheimer\u2019s drug data fuel hopes for new treatment","Summary":""},{"Date":"Nov. 6, 2016 at 7:26 a.m. ET","Headline":"Drug companies spend $109 million to block vote to lower drug prices","Summary":""},{"Date":"Nov. 10, 2016 at 11:26 a.m. ET","Headline":"The death of Obamacare will bring new opportunities for investors","Summary":""},{"Date":"Nov. 12, 2016 at 12:01 a.m. ET","Headline":"Pharma M&A Is on the Way","Summary":""},{"Date":"Nov. 17, 2016 at 9:28 a.m. ET","Headline":"10 biotech companies ripe for a buyout, courtesy of Donald Trump","Summary":""},{"Date":"Nov. 23, 2016 at 4:47 p.m. ET","Headline":"Dow, S&P 500 notch third straight record close","Summary":"Moody's Investors Service said Wednesday the news that an Eli Lilly and Co.  trial of a treatment for dementia in Alzheimer's disease has failed is a credit negative, but does not affect the company's A2 rating or stable o..."},{"Date":"Nov. 23, 2016 at 3:01 p.m. ET","Headline":"Why the sugar rush for stocks isn\u2019t done yet","Summary":"Moody's Investors Service said Wednesday the news that an Eli Lilly and Co.  trial of a treatment for dementia in Alzheimer's disease has failed is a credit negative, but does not affect the company's A2 rating or stable o..."},{"Date":"Nov. 23, 2016 at 11:23 a.m. ET","Headline":"Moody's says Eli Lilly failed trial is credit negative, but not enough to lower rating","Summary":"Moody's Investors Service said Wednesday the news that an Eli Lilly and Co.  trial of a treatment for dementia in Alzheimer's disease has failed is a credit negative, but does not affect the company's A2 rating or stable o..."},{"Date":"Nov. 23, 2016 at 7:47 a.m. ET","Headline":"Lilly Stock Could Have 20% Upside","Summary":"Eli Lilly and Co. shares  tumbled 14% in premarket trade Wednesday, after the company said a late-stage trial of a treatment for dementia in patients with Alzheimer's Disease failed to meet its goal. The phase 3 trial of s..."},{"Date":"Nov. 23, 2016 at 6:57 a.m. ET","Headline":"Eli Lilly shares slide premarket after company says Alzheimer's drug trial failed","Summary":"Eli Lilly and Co. shares  tumbled 14% in premarket trade Wednesday, after the company said a late-stage trial of a treatment for dementia in patients with Alzheimer's Disease failed to meet its goal. The phase 3 trial of s..."},{"Date":"Nov. 25, 2016 at 7:09 a.m. ET","Headline":"What Eli Lilly\u2019s hard fall in Alzheimer\u2019s treatment race means for its competitors","Summary":""},{"Date":"Nov. 26, 2016 at 12:01 a.m. ET","Headline":"Social-Media Coverage of Stocks Can Be Misleading","Summary":""},{"Date":"Nov. 26, 2016 at 12:01 a.m. ET","Headline":"Charting the Market","Summary":""},{"Date":"Nov. 28, 2016 at 2:24 p.m. ET","Headline":"Biogen Unfazed by Lilly Disappointment","Summary":""},{"Date":"Nov. 28, 2016 at 9:45 a.m. ET","Headline":"Biogen in promising but risky limelight after Eli Lilly\u2019s Alzheimer\u2019s drug fails","Summary":""},{"Date":"Dec. 2, 2016 at 5:18 a.m. ET","Headline":"9 Stocks to Short Now","Summary":""},{"Date":"Dec. 9, 2016 at 3:29 p.m. ET","Headline":"Biotech Bargain: Biogen On Sale After Good News","Summary":"Eli Lilly & Co.  and AstraZeneca PLC  announced Friday an agreement to develop a potential treatment for Alzheimer's disease that is currently in Phase 1 trials. As part of the agreement, Lilly will make a $30 million upfr..."},{"Date":"Dec. 9, 2016 at 12:55 p.m. ET","Headline":"Biogen gains on new Eli Lilly Alzheimer\u2019s data, as beta-amyloid hypothesis \u2018lives to see another day\u2019","Summary":"Eli Lilly & Co.  and AstraZeneca PLC  announced Friday an agreement to develop a potential treatment for Alzheimer's disease that is currently in Phase 1 trials. As part of the agreement, Lilly will make a $30 million upfr..."},{"Date":"Dec. 9, 2016 at 7:12 a.m. ET","Headline":"Eli Lilly to pay AstraZeneca $30 million as part of a collaboration on an Alzheimer's treatment","Summary":"Eli Lilly & Co.  and AstraZeneca PLC  announced Friday an agreement to develop a potential treatment for Alzheimer's disease that is currently in Phase 1 trials. As part of the agreement, Lilly will make a $30 million upfr..."},{"Date":"Dec. 9, 2016 at 7:08 a.m. ET","Headline":"Eli Lilly and AstraZeneca to co-develop Alzheimer's Disease treatment","Summary":"Eli Lilly & Co.  and AstraZeneca Plc  said Friday they have entered an agreement to jointly develop an Alzheimer's Disease treatment. The companies will work together on MEDI1814, an antibody selective for amyloid-beta 42,..."},{"Date":"Dec. 13, 2016 at 8:46 a.m. ET","Headline":"Eli Lilly plans to offer up to 40% insulin discounts for patients with the largest out-of-pocket costs","Summary":""},{"Date":"Dec. 15, 2016 at 6:58 a.m. ET","Headline":"Eli Lilly's stock jumps after profit and sales outlook exceed expectations","Summary":"Shares of Eli Lilly & Co.  surged 3% in premarket trade Thursday, after the drug maker provided an upbeat profit and sales outlook for next year. The company expected 2017 net earnings per share of $3.51 to $3.61. Excludin..."},{"Date":"Dec. 16, 2016 at 10:18 a.m. ET","Headline":"Here\u2019s where contrarian investors plan to make their money in 2017","Summary":""},{"Date":"Dec. 16, 2016 at 6:03 a.m. ET","Headline":"Eli Lilly on Sale With 3% Yield, Cheap Valuation","Summary":""},{"Date":"Dec. 20, 2016 at 11:19 a.m. ET","Headline":"Pharma Picks as Fundamentals Weaken","Summary":""},{"Date":"Dec. 20, 2016 at 8:03 a.m. ET","Headline":"How you can bottom-feed for stocks left behind in the Trump rally","Summary":""},{"Date":"Dec. 23, 2016 at 8:18 a.m. ET","Headline":"Trump health secretary nominee has bought and sold $300,000 in health care stocks while in office","Summary":""},{"Date":"Dec. 17, 2016 at 12:01 a.m. ET","Headline":"S&P 500 Dividend Growth Likely to Slow in 2017","Summary":""},{"Date":"Dec. 25, 2016 at 6:03 a.m. ET","Headline":"January is the cruelest month \u2014 for pharmacists","Summary":""},{"Date":"Dec. 27, 2016 at 12:28 a.m. ET","Headline":"Health-Care Stocks Could Gain 20% in 2017","Summary":""},{"Date":"Jan. 3, 2017 at 11:56 a.m. ET","Headline":"The real reason drug makers offer discount cards (you\u2019ll pay eventually)","Summary":""},{"Date":"Jan. 3, 2017 at 11:56 a.m. ET","Headline":"Big pharma won\u2019t stop raising prices in 2017 \u2014 it\u2019ll just do it smarter","Summary":""},{"Date":"Jan. 7, 2017 at 10:53 a.m. ET","Headline":"In the age of Uber and Lyft, it\u2019s still hard for some Americans to get to the doctor","Summary":""},{"Date":"Jan. 9, 2017 at 5:41 p.m. ET","Headline":"Five unpopular, but prudent, things for investors to do near Dow 20,000","Summary":""},{"Date":"Jan. 12, 2017 at 4:35 p.m. ET","Headline":"Nasdaq snaps 7-day win streak as stocks cool before earning season","Summary":"Eli Lilly & Co.'s stock  rallied 2.4% in midday trade Thursday, after the drugmaker confirmed a favorable court ruling related to its cancer treatment Alimta. The company said a federal appeals court upheld a district cour..."},{"Date":"Jan. 12, 2017 at 12:26 p.m. ET","Headline":"Eli Lilly's stock rallies after appeals court upholds favorable patent ruling","Summary":"Eli Lilly & Co.'s stock  rallied 2.4% in midday trade Thursday, after the drugmaker confirmed a favorable court ruling related to its cancer treatment Alimta. The company said a federal appeals court upheld a district cour..."},{"Date":"Jan. 11, 2017 at 3:14 p.m. ET","Headline":"What pharma investors ought to do after Donald Trump fires a salvo","Summary":""},{"Date":"Jan. 18, 2017 at 6:56 a.m. ET","Headline":"CoLucid's stock soars after $960 million buyout deal with Eli Lilly","Summary":"Shares of CoLucid Pharmaceuticals Inc.  soared 31% in premarket trade Wednesday, after the developer treatments for acute migraines agreed to be acquired by Eli Lilly & Co.  for $960 million in cash. Under terms of the dea..."},{"Date":"Jan. 21, 2017 at 12:01 a.m. ET","Headline":"5 Drug Stocks With Rising Dividends and Yields Up to 4.1%","Summary":""},{"Date":"Jan. 23, 2017 at 3:21 p.m. ET","Headline":"We\u2019re in the year of the biotech buyout, and here are five prime targets","Summary":""},{"Date":"Jan. 25, 2017 at 9:38 a.m. ET","Headline":"The Trump factor: Should investors be bullish or bearish \u2014 or neither?","Summary":""},{"Date":"Dec. 3, 2016 at 12:01 a.m. ET","Headline":"Top 10 Stock Picks for 2017","Summary":""},{"Date":"Jan. 28, 2017 at 7:58 a.m. ET","Headline":"Outlooks for the Age of Trump are top focus of earnings season","Summary":""},{"Date":"Jan. 27, 2017 at 11:48 a.m. ET","Headline":"Two things are happening in the U.S. stock market for the first time since 1900","Summary":""},{"Date":"Jan. 30, 2017 at 10:30 a.m. ET","Headline":"New competition took a bite out of J&J\u2019s drug sales, but don\u2019t expect the trend to dominate this earnings season","Summary":""},{"Date":"Jan. 30, 2017 at 8:44 a.m. ET","Headline":"What to expect from Pfizer earnings: competition on two fronts","Summary":""},{"Date":"Jan. 28, 2017 at 12:01 a.m. ET","Headline":"Barron\u2019s 2017 Roundtable, Part 3: 17 Picks From Three Pros","Summary":""},{"Date":"Feb. 1, 2017 at 7:00 a.m. ET","Headline":"President Trump says he wants to bring down drug prices \u2014 and uses aspirin as an example","Summary":""},{"Date":"Feb. 4, 2017 at 12:01 a.m. ET","Headline":"Analysts Upbeat on Earnings","Summary":"They take a shine to Apple, Take-Two Interactive, Eli Lilly, and Vantiv."},{"Date":"Feb. 7, 2017 at 4:42 p.m. ET","Headline":"Drug stocks dip after Spicer affirms Trump\u2019s stance on cutting costs","Summary":""},{"Date":"Feb. 18, 2017 at 1:26 a.m. ET","Headline":"Why Biotech Looks Like a Good Bet in 2017","Summary":""},{"Date":"Mar. 9, 2017 at 4:09 a.m. ET","Headline":"Trump\u2019s \u2018Obamacare Lite\u2019 presents opportunities and perils for investors","Summary":""},{"Date":"Mar. 14, 2017 at 8:31 a.m. ET","Headline":"Don\u2019t Expect Pfizer to Make a Mega Acquisition","Summary":""},{"Date":"Apr. 12, 2017 at 8:08 a.m. ET","Headline":"Incyte: Why This Biotech Beauty Can Stay Hot","Summary":""},{"Date":"Apr. 13, 2017 at 3:31 p.m. ET","Headline":"Big Pharma Earnings: What to Watch","Summary":""},{"Date":"Apr. 17, 2017 at 4:40 p.m. ET","Headline":"Stock market ends 3-session slide as bank shares rally","Summary":"Eli Lilly & Co.  shares dropped  5.5% and Incyte Corp.  shares dropped 12.7% in premarket trade Monday after the companies said that the Food and Drug Administration failed to approve their drug for moderate-to-severe rheu..."},{"Date":"Apr. 17, 2017 at 7:38 a.m. ET","Headline":"Eli Lilly and Incyte stock drops after FDA fails to approve rheumatoid arthritis drug","Summary":"Eli Lilly & Co.  shares dropped  5.5% and Incyte Corp.  shares dropped 12.7% in premarket trade Monday after the companies said that the Food and Drug Administration failed to approve their drug for moderate-to-severe rheu..."},{"Date":"Apr. 24, 2017 at 4:28 p.m. ET","Headline":"Pricey rare disease drug\u2019s launch will be likely focus of Biogen earnings","Summary":"Eli Lilly & Co.  said early Monday that its combination treatment improved survival rates for patients with advanced breast cancer, which was also the primary endpoint in a late-stage clinical trial. The study tested the c..."},{"Date":"Apr. 24, 2017 at 7:08 a.m. ET","Headline":"Eli Lilly says breast cancer combination treatment improved survival rates in late-stage trial","Summary":"Eli Lilly & Co.  said early Monday that its combination treatment improved survival rates for patients with advanced breast cancer, which was also the primary endpoint in a late-stage clinical trial. The study tested the c..."},{"Date":"Apr. 26, 2017 at 3:34 p.m. ET","Headline":"Four Biotech Picks Ahead of Earnings","Summary":"Eli Lilly & Co.  on Tuesday said it swung to a quarterly net loss, but adjusted earnings and revenue exceeded expectations. The drug maker swung to a first-quarter loss of $110.8 million, or 10 cents a share, stemming from..."},{"Date":"Apr. 25, 2017 at 4:28 p.m. ET","Headline":"Nasdaq closes above 6,000 as stock market extends rally on upbeat earnings","Summary":"Eli Lilly & Co.  on Tuesday said it swung to a quarterly net loss, but adjusted earnings and revenue exceeded expectations. The drug maker swung to a first-quarter loss of $110.8 million, or 10 cents a share, stemming from..."},{"Date":"Apr. 25, 2017 at 9:10 a.m. ET","Headline":"These stocks are sailing under the radar, but there\u2019s a case for jumping aboard","Summary":"Eli Lilly & Co.  on Tuesday said it swung to a quarterly net loss, but adjusted earnings and revenue exceeded expectations. The drug maker swung to a first-quarter loss of $110.8 million, or 10 cents a share, stemming from..."},{"Date":"Apr. 25, 2017 at 8:52 a.m. ET","Headline":"Eli Lilly swings to loss though sales rise, cuts outlook","Summary":"Eli Lilly & Co.  on Tuesday said it swung to a quarterly net loss, but adjusted earnings and revenue exceeded expectations. The drug maker swung to a first-quarter loss of $110.8 million, or 10 cents a share, stemming from..."},{"Date":"May. 1, 2017 at 12:15 p.m. ET","Headline":"Eli Lilly says it has received civil investigative demands about insulin pricing from two state attorney generals","Summary":"Eli Lilly & Co.  has received civil investigative demands related to its insulin prices from the attorney generals in Washington State and New Mexico, according to a 10-Q financial filing. The Washington State AG's office ..."},{"Date":"May. 12, 2017 at 7:35 a.m. ET","Headline":"UPDATE: Eli Lilly reports positive results in trial of migraine treatment","Summary":"Shares of Eli Lilly and Co.  jumped 1.6% in premarket trade  Friday, after the company said a late-stage study of a migraine treatment met its primary goals. The trial of galcanezumab, an investigational treatment for the ..."},{"Date":"May. 16, 2017 at 11:31 a.m. ET","Headline":"Three Top Picks in U.S. Big Pharma","Summary":""},{"Date":"May. 17, 2017 at 12:54 p.m. ET","Headline":"Johnson & Johnson Faces FDA Headwind","Summary":""},{"Date":"May. 20, 2017 at 1:23 a.m. ET","Headline":"AmerisourceBergen and AbbVie Top Barron\u2019s 500","Summary":""},{"Date":"Jun. 1, 2017 at 7:21 a.m. ET","Headline":"Eli Lilly CFO Derica Rice to retire at year end","Summary":"Eli Lilly & Co.  said premarket Thursday that Chief Financial Officer Derica Rice will retire at the end of the year after working at the company for 27 years. The company said it is considering internal and external candi..."},{"Date":"May. 31, 2017 at 7:14 a.m. ET","Headline":"Eli Lilly's late-stage bladder cancer drug met primary endpoint but will wait for mid-2018 results","Summary":"Eli Lilly & Co.  said premarket Wednesday that its urothelial carcinoma drug met the primary endpoint in a phase 3 clinical trial. The drug, Cyramza, showed a statistically significant improvement in progression-free survi..."},{"Date":"Jun. 9, 2017 at 12:02 p.m. ET","Headline":"New migraine drugs have promise \u2014 and a $8,500 price tag","Summary":""},{"Date":"Jun. 13, 2017 at 4:38 p.m. ET","Headline":"Dow, S&P 500 close at records as tech stocks rebound","Summary":"Eli Lilly & Co.  shares rose 1.5% in premarket trade Tuesday after the company said its pain drug with Pfizer Inc.  has received fast track designation from the Food and Drug Administration, which is intended to hasten the..."},{"Date":"Jun. 13, 2017 at 4:26 p.m. ET","Headline":"Blink Health drops Express Scripts in dispute over insulin prices","Summary":"Eli Lilly & Co.  shares rose 1.5% in premarket trade Tuesday after the company said its pain drug with Pfizer Inc.  has received fast track designation from the Food and Drug Administration, which is intended to hasten the..."},{"Date":"Jun. 13, 2017 at 8:53 a.m. ET","Headline":"Eli Lilly stock rises 1.5% after pain drug gets fast track designation from FDA","Summary":"Eli Lilly & Co.  shares rose 1.5% in premarket trade Tuesday after the company said its pain drug with Pfizer Inc.  has received fast track designation from the Food and Drug Administration, which is intended to hasten the..."},{"Date":"Jun. 14, 2017 at 11:12 a.m. ET","Headline":"JNJ Diabetes Data Benefit Lilly, Hurt Merck","Summary":""},{"Date":"Jun. 27, 2017 at 4:03 p.m. ET","Headline":"Merck Cholesterol Drug Could Help Unlock Value","Summary":"Alder BioPharmaceuticals Inc.  stock dropped 19.5% in extremely heavy morning trade Tuesday after the company released positive results for its late-stage migraine prevention drug. The drug, eptinezumab, met the primary an..."},{"Date":"Jun. 27, 2017 at 10:27 a.m. ET","Headline":"Alder BioPharma stock drops nearly 20% as investors shrug off positive migraine drug results","Summary":"Alder BioPharmaceuticals Inc.  stock dropped 19.5% in extremely heavy morning trade Tuesday after the company released positive results for its late-stage migraine prevention drug. The drug, eptinezumab, met the primary an..."},{"Date":"Jul. 7, 2017 at 8:06 a.m. ET","Headline":"Eli Lilly says UK Supreme Court ruled in its favor on Alimta vitamin regiment patents","Summary":"Eli Lilly & Co.  said Friday the UK Supreme Court has ruled in its favor in a patent suit with Actavis, which now trades as Allergan Plc . The court found that Actativs's products directly infringe Lilly's vitamin regiment..."},{"Date":"Jul. 12, 2017 at 10:29 a.m. ET","Headline":"Eli Lilly settlement will result in Cialis patent expiring as early as 2018, rather than 2020","Summary":"Eli Lilly & Co.  said on Wednesday that as part of a settlement with generic companies over its Cialis patent, the exclusive patent is now expected to end on September 27, 2018 at the earliest, roughly a year-and-a-half ea..."},{"Date":"Jul. 19, 2017 at 9:21 a.m. ET","Headline":"Novartis, Glaxo and Lilly Bigly Back New Biotech","Summary":""},{"Date":"Jul. 25, 2017 at 9:49 a.m. ET","Headline":"Here\u2019s why Amazon, Facebook and the gang are not going to take down this market","Summary":"Eli Lilly & Co.  reported a second-quarter net profit that rose to $1.01 billion, or 95 cents a share, from $747.7 million, or 71 cents a share, in the same period a year ago. Excluding non-recurring items, adjusted EPS wa..."},{"Date":"Jul. 25, 2017 at 6:58 a.m. ET","Headline":"Eli Lilly beats profit and sales expectations; NDA for RA treatment to be delayed","Summary":"Eli Lilly & Co.  reported a second-quarter net profit that rose to $1.01 billion, or 95 cents a share, from $747.7 million, or 71 cents a share, in the same period a year ago. Excluding non-recurring items, adjusted EPS wa..."},{"Date":"Jul. 24, 2017 at 11:33 a.m. ET","Headline":"Eli Lilly will co-develop autoimmune disease therapy under $150 million deal with Nektar","Summary":"Nektar Therapeutics  shares surged as much as 10% in premarket trade Monday after the company announced a $150 million deal with Eli Lilly & Co.  to co-develop its immunological therapy NKTR-358. The deal also includes up ..."},{"Date":"Jul. 24, 2017 at 8:15 a.m. ET","Headline":"Nektar Therapeutics surges 10% on $150 mln Eli Lilly deal","Summary":"Nektar Therapeutics  shares surged as much as 10% in premarket trade Monday after the company announced a $150 million deal with Eli Lilly & Co.  to co-develop its immunological therapy NKTR-358. The deal also includes up ..."},{"Date":"Jul. 26, 2017 at 8:15 a.m. ET","Headline":"Biogen shares surge 2% after upgrade to buy at Goldman Sachs","Summary":"Biogen Inc.  shares surged as much as 2% in premarket trade Wednesday after the company was upgraded to buy at Goldman Sachs and its price target was raised by nearly 20% to $338. Biogen shares closed at $282.96 on Tuesday..."},{"Date":"Jul. 29, 2017 at 8:03 a.m. ET","Headline":"Biotech companies lose $21 billion in research funds amid political squabbling","Summary":""},{"Date":"Jul. 31, 2017 at 7:33 a.m. ET","Headline":"Health-care fund managers say a spike in drugs and devices will produce big returns","Summary":""},{"Date":"Aug. 4, 2017 at 11:13 a.m. ET","Headline":"CVS Formulary Changes Boost JNJ, Pfizer; Hurt Lilly","Summary":"Eli Lilly & Co.  said early Friday that its migraine drug lasmiditan met its primary endpoint and a key secondary endpoint in a late-stage clinical trial. The company plans to submit for Food and Drug Administration approv..."},{"Date":"Aug. 4, 2017 at 7:50 a.m. ET","Headline":"CORRECTED: Eli Lilly & Co. says its migraine drug met primary endpoint in late-stage trial","Summary":"Eli Lilly & Co.  said early Friday that its migraine drug lasmiditan met its primary endpoint and a key secondary endpoint in a late-stage clinical trial. The company plans to submit for Food and Drug Administration approv..."},{"Date":"Aug. 10, 2017 at 3:15 p.m. ET","Headline":"Opioids are ravaging the U.S., but they\u2019re still the best pain drug we\u2019ve got","Summary":""},{"Date":"Aug. 15, 2017 at 11:18 a.m. ET","Headline":"Merck, Allergan, Lilly: Top Pharma Picks","Summary":""},{"Date":"Aug. 18, 2017 at 3:01 p.m. ET","Headline":"This market leader was the most-purchased stock by hedge funds last quarter","Summary":""},{"Date":"Aug. 30, 2017 at 3:23 p.m. ET","Headline":"Incyte shares surge 10% on news that it and Eli Lilly will re-file for arthritis drug approval","Summary":"Incyte Corp.  shares soared 10.1% in extremely heavy Wednesday trade after news that it and Eli Lilly & Co.  plan to reapply for approval of rheumatoid arthritis drug baricitinib by the end of January 2018, with a decision..."},{"Date":"Sep. 7, 2017 at 9:31 a.m. ET","Headline":"Eli Lilly to cut 3,500 jobs after part of cost cutting plan","Summary":"Eli Lilly & Co.  said it will cut about 3,500 jobs, or about 8.3% of its global workforce, as part of a streamlining plan aimed at cutting costs by $500 million a year. The drug giant expects most of the job cuts to come i..."},{"Date":"Sep. 8, 2017 at 7:15 a.m. ET","Headline":"Eli Lilly says late-stage, 12-month study showed its migraine treatment was safe, effective","Summary":"Eli Lilly & Co.  said early Friday that its migraine prevention drug had positive results in a late-stage, 12-month open-label study. The therapy, galcanezumab, showed a positive safety and tolerability profile in patients..."},{"Date":"Sep. 14, 2017 at 12:23 p.m. ET","Headline":"What you don\u2019t know about Martin Shkreli \u2014 his investing tips and strategies","Summary":""},{"Date":"Sep. 15, 2017 at 11:34 p.m. ET","Headline":"4 Buys in a Watchful Market","Summary":"Eli Lilly, Chubb, Southern Co., and Iconix Brand Group"},{"Date":"Sep. 21, 2017 at 1:33 p.m. ET","Headline":"Pfizer\u2019s Underappreciated Global Opportunity","Summary":""},{"Date":"Sep. 29, 2017 at 8:22 a.m. ET","Headline":"Eli Lilly names Joshua Smiley as new CFO","Summary":""},{"Date":"Sep. 30, 2017 at 12:39 a.m. ET","Headline":"Big Ideas, Small Stocks","Summary":""},{"Date":"Oct. 3, 2017 at 10:19 a.m. ET","Headline":"Big Questions for Big Pharma","Summary":""},{"Date":"Oct. 2, 2017 at 11:14 a.m. ET","Headline":"Lilly Faces Off With Pfizer, Novartis","Summary":""},{"Date":"Oct. 6, 2017 at 7:59 a.m. ET","Headline":"Ford Execs Sell Slumping Stock","Summary":""},{"Date":"Oct. 9, 2017 at 2:28 p.m. ET","Headline":"Ruling Goes Regeneron\u2019s Way","Summary":""},{"Date":"Oct. 9, 2017 at 10:28 a.m. ET","Headline":"Lilly Patent Win Preserves Sales Guidance","Summary":""},{"Date":"Oct. 10, 2017 at 9:23 a.m. ET","Headline":"Here\u2019s how the U.S. could deliver the events that \u2018upend\u2019 global markets","Summary":"Shares of Eli Lilly & Co.  sank 4.2% in premarket trade Tuesday, after disappointing drug trial results. The company said earlier that a phase 3 trial of its lung cancer treatment Verzenio failed to meet its primary endpoi..."},{"Date":"Oct. 10, 2017 at 8:41 a.m. ET","Headline":"Eli Lilly's stock sinks after disappointing results from late-stage trial of cancer treatment","Summary":"Shares of Eli Lilly & Co.  sank 4.2% in premarket trade Tuesday, after disappointing drug trial results. The company said earlier that a phase 3 trial of its lung cancer treatment Verzenio failed to meet its primary endpoi..."},{"Date":"Oct. 7, 2017 at 12:33 a.m. ET","Headline":"The Top-Performing Sustainable Funds","Summary":""},{"Date":"Oct. 21, 2017 at 12:01 a.m. ET","Headline":"Gold Could Reach $3,000 to $5,000 an Ounce","Summary":""},{"Date":"Oct. 23, 2017 at 12:52 p.m. ET","Headline":"Byron Wien Measures China\u2019s Tech Success","Summary":""},{"Date":"Oct. 24, 2017 at 4:29 p.m. ET","Headline":"Dow ends at record thanks to Caterpillar, 3M gains","Summary":"Eli Lilly & Co.  reported Tuesday net income of $555.6 million, or 53 cents a share, down from $778.0 million, or 73 cents a share, in the same period a year ago. Excluding non-recurring items, including asset repairment c..."},{"Date":"Oct. 24, 2017 at 9:33 a.m. ET","Headline":"Bad news for the S&P \u2014 this powerhouse of a sector may be poised for a cooldown","Summary":"Eli Lilly & Co.  reported Tuesday net income of $555.6 million, or 53 cents a share, down from $778.0 million, or 73 cents a share, in the same period a year ago. Excluding non-recurring items, including asset repairment c..."},{"Date":"Oct. 24, 2017 at 6:49 a.m. ET","Headline":"Eli Lilly beats profit and sales expectations, as diabetes sales soar 39%","Summary":"Eli Lilly & Co.  reported Tuesday net income of $555.6 million, or 53 cents a share, down from $778.0 million, or 73 cents a share, in the same period a year ago. Excluding non-recurring items, including asset repairment c..."},{"Date":"Nov. 2, 2017 at 5:30 a.m. ET","Headline":"Teva earnings: Facing down cheaper generic prices, generic competition of its own and a lot of debt","Summary":""},{"Date":"Nov. 13, 2017 at 10:59 a.m. ET","Headline":"Trump Today: President laughs as Duterte calls journalists \u2018spies\u2019","Summary":"President Donald Trump said Monday he is nominating Alex Azar as the next health and human services secretary. Azar, who formerly ran Eli Lilly & Co.'s  U.S. operations, would replace Tom Price at the department if confirm..."},{"Date":"Nov. 13, 2017 at 10:05 a.m. ET","Headline":"Trump says he's nominating former Eli Lilly executive to head HHS","Summary":"President Donald Trump said Monday he is nominating Alex Azar as the next health and human services secretary. Azar, who formerly ran Eli Lilly & Co.'s  U.S. operations, would replace Tom Price at the department if confirm..."},{"Date":"Nov. 15, 2017 at 7:22 p.m. ET","Headline":"Two Lawsuits Hit Express Scripts Unit on Pricing","Summary":""},{"Date":"Nov. 21, 2017 at 8:30 a.m. ET","Headline":"Six promising stocks to buy for the biotech rebound ahead","Summary":""},{"Date":"Dec. 9, 2017 at 12:01 a.m. ET","Headline":"Tech Scores for the NFL","Summary":""},{"Date":"Dec. 11, 2017 at 3:36 p.m. ET","Headline":"Eli Lilly hikes dividend by 8%","Summary":"Eli Lilly and Co.  said Monday its board approved an 8% hike in its quarterly dividend. The drugmaker said it will pay a 56.25 cents a share dividend in the first quarter to shareholders of record as of Feb. 15 on March 9...."},{"Date":"Dec. 13, 2017 at 7:03 a.m. ET","Headline":"Eli Lilly sets guidance for 2018, expects regulatory moves on pipeline drugs","Summary":"Drug company Eli Lilly and Co.  on Wednesday set guidance for 2018, saying it expects EPS of $4.24 to $4.34, or adjusted EPS of $4.60 to $4.70. revenue is expected to range from $23.0 billion to $23.5 billion. The FactSet ..."},{"Date":"Jan. 2, 2018 at 1:33 p.m. ET","Headline":"Buying Costco, Selling Alphabet, Verizon","Summary":""},{"Date":"Jan. 13, 2018 at 12:01 a.m. ET","Headline":"The Right Rx for Income Investors","Summary":""},{"Date":"Jan. 27, 2018 at 12:01 a.m. ET","Headline":"U.S. Companies Are Set to Go on Spending Spree","Summary":""},{"Date":"Jan. 28, 2018 at 1:10 p.m. ET","Headline":"5 biotech buyout candidates you should look at right now","Summary":""},{"Date":"Jan. 31, 2018 at 4:48 p.m. ET","Headline":"Stocks end higher, closing out best month since March 2016","Summary":"Eli Lilly & Co.  shares rose 0.6% in premarket trade Wednesday after the company reported fourth-quarter profit and revenue beats and an upbeat outlook. The company reported a loss of $1.66 billion, or a loss of $1.58 per ..."},{"Date":"Jan. 31, 2018 at 9:41 a.m. ET","Headline":"This Apple downgrade spells bad news for the stock rally","Summary":"Eli Lilly & Co.  shares rose 0.6% in premarket trade Wednesday after the company reported fourth-quarter profit and revenue beats and an upbeat outlook. The company reported a loss of $1.66 billion, or a loss of $1.58 per ..."},{"Date":"Jan. 31, 2018 at 7:14 a.m. ET","Headline":"Eli Lilly shares rise after Q4 profit, revenue beats, upbeat outlook","Summary":"Eli Lilly & Co.  shares rose 0.6% in premarket trade Wednesday after the company reported fourth-quarter profit and revenue beats and an upbeat outlook. The company reported a loss of $1.66 billion, or a loss of $1.58 per ..."},{"Date":"Feb. 2, 2018 at 7:15 a.m. ET","Headline":"Pharma giant Eli Lilly is having a cow \u2014 that is, a cattle problem","Summary":""},{"Date":"Feb. 1, 2018 at 8:28 a.m. ET","Headline":"DowDuPont Unit Dumps GE Stock, Buys Ford","Summary":""},{"Date":"Feb. 6, 2018 at 10:17 a.m. ET","Headline":"Health care stocks turn upward as market rebounds","Summary":"Health care stocks moved upward in Tuesday morning trade as the market began to reverse its previous weakness, though some pharmaceutical stocks continued to drag. The Health Care Select Sector SPDR  rose 0.8%, the SPDR S&..."},{"Date":"Feb. 10, 2018 at 12:01 a.m. ET","Headline":"Drug Tests in South Korea","Summary":""},{"Date":"Feb. 12, 2018 at 8:28 a.m. ET","Headline":"Buying United, Selling Lilly, Rambus, Tronc","Summary":""},{"Date":"Feb. 11, 2018 at 12:20 p.m. ET","Headline":"Teva stock drops on guidance, manufacturing problems","Summary":""},{"Date":"Feb. 13, 2018 at 10:04 a.m. ET","Headline":"3 Biotechs That Could Benefit From an M&A Frenzy","Summary":"Eli Lilly & Co.  said Tuesday that a phase 3 safety and efficacy study of Taltz for the treatment of ankylosing spondylitis (AS) met the primary and all key secondary endpoints. Eli Lilly said it plans to submit data for r..."},{"Date":"Feb. 13, 2018 at 7:23 a.m. ET","Headline":"Eli Lilly's Taltz meets primary endpoint in late-state trial for AS treatment","Summary":"Eli Lilly & Co.  said Tuesday that a phase 3 safety and efficacy study of Taltz for the treatment of ankylosing spondylitis (AS) met the primary and all key secondary endpoints. Eli Lilly said it plans to submit data for r..."},{"Date":"Feb. 17, 2018 at 12:01 a.m. ET","Headline":"Investing in the Future, 150 Companies at a Time","Summary":""},{"Date":"Feb. 21, 2018 at 1:48 p.m. ET","Headline":"Buying GE, Dumping GM, Cisco, DowDuPont, Lilly","Summary":""},{"Date":"Feb. 21, 2018 at 7:27 a.m. ET","Headline":"Biogen\u2019s key Alzheimer\u2019s disease drug is facing potential signs of trouble","Summary":""},{"Date":"Feb. 20, 2018 at 8:36 a.m. ET","Headline":"How a Future-Facing Fund Beat 98% of Its Peers","Summary":""},{"Date":"Mar. 10, 2018 at 12:01 a.m. ET","Headline":"How to Outrun Amazon","Summary":""},{"Date":"Mar. 21, 2018 at 4:27 p.m. ET","Headline":"Drug companies are beginning to wake up to this new risk factor","Summary":""},{"Date":"Mar. 24, 2018 at 9:07 a.m. ET","Headline":"Box CEO on Dropbox IPO: We\u2019re like Salesforce, they\u2019re like Netflix","Summary":""},{"Date":"Mar. 26, 2018 at 9:05 a.m. ET","Headline":"Biohaven shares drop 23% after migraine drug trial results","Summary":"Biohaven Pharmaceutical Holding Co. Ltd.  shares dropped nearly 23% in premarket trade Monday after the company released data from two phase 3 clinical trials for its migraine drug rimegepant. The company touted that the d..."},{"Date":"Mar. 30, 2018 at 8:18 a.m. ET","Headline":"Do drug prices affect CEO pay? Faith-based investor group wants to know","Summary":""},{"Date":"Apr. 4, 2018 at 7:22 a.m. ET","Headline":"Eli Lilly enters collaboration deal with Siligon for diabetes treatment, to take charge for in-process research","Summary":"Eli Lilly & Co.  announced Wednesday a collaboration agreement with Sigilon Therapeutics to develop cell therapies for the treatment of type 1 diabetes. Under terms of the agreement, Lilly will pay Siligon $63 million upfr..."},{"Date":"Apr. 4, 2018 at 6:56 a.m. ET","Headline":"Eli Lilly reports positive results in late-stage trial of liver cancer treatment","Summary":"Eli Lilly and Co.  said Wednesday a late-stage trial of a liver cancer treatment met its main goals. The company said patients in a phase 3 trial of Cyramza as a single agent in the second-line treatment of hepatocelluclar..."},{"Date":"Apr. 13, 2018 at 9:58 a.m. ET","Headline":"Eli Lilly's stock rallies after BMO raises rating, price target","Summary":"Shares of Eli Lilly & Co.  rallied 1.2% in morning trade Friday, after BMO Capital backed away from its bearish stance that it's kept for the past year, given the belief that previous concerns are now mostly reflected in t..."},{"Date":"Apr. 19, 2018 at 2:01 p.m. ET","Headline":"Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug","Summary":"Gilead Sciences Inc.  shares dropped 2.1% in moderate Thursday trade after a Food and Drug Administration briefing document raised safety questions about a similar Eli Lilly & Co.  and Incyte Corp.  drug. Like Eli Lilly an..."},{"Date":"Apr. 19, 2018 at 9:10 a.m. ET","Headline":"Eli Lilly, Incyte shares fall after FDA cites issues with rheumatoid arthritis drug","Summary":"Eli Lilly & Co.  shares fell 1.8% premarket and Incyte Corp.  shares dropped 4.5% premarket on Thursday after a Food and Drug Administration briefing document raised issues with their rheumatoid arthritis drug baricitinib...."},{"Date":"Apr. 24, 2018 at 9:54 a.m. ET","Headline":"A one-way bet could end in a steep selloff for this commodity","Summary":"Eli Lilly & Co.  shares dropped nearly 3% in premarket trade Tuesday after the company's rheumatoid arthritis therapy baricitinib was recommended for Food and Drug Administration approval at the 2-mg dose, but not the 4-mg..."},{"Date":"Apr. 24, 2018 at 7:30 a.m. ET","Headline":"Eli Lilly, Incyte shares drop after mixed FDA drug recommendation","Summary":"Eli Lilly & Co.  shares dropped nearly 3% in premarket trade Tuesday after the company's rheumatoid arthritis therapy baricitinib was recommended for Food and Drug Administration approval at the 2-mg dose, but not the 4-mg..."},{"Date":"Apr. 24, 2018 at 7:12 a.m. ET","Headline":"Eli Lilly raises 2018 profit view after quarterly earnings, sales beat expectations","Summary":"Drug maker Eli Lilly & Co.  on Tuesday posted quarterly earnings and sales that exceeded Wall Street's targets. Lilly said first-quarter net earnings were $1.22 billion, or $1.16 a share, swinging from a loss of $110.8 mil..."},{"Date":"May. 3, 2018 at 11:48 a.m. ET","Headline":"Teva beats first-quarter expectations but still has the same old problems","Summary":""},{"Date":"May. 3, 2018 at 9:11 a.m. ET","Headline":"Drugmakers eye a new threat to sales but say it hasn\u2019t affected them \u2014 yet","Summary":""},{"Date":"May. 10, 2018 at 9:39 a.m. ET","Headline":"\u2018Keep believing in this market\u2019 as freed Korean-Americans come home","Summary":"Eli Lilly & Co.  will buy the immuno-oncology biotech ARMO Biosciences Inc.  for about $1.6 billion in an all-cash deal, the company announced early Thursday. ARMO Biosciences shares surged 77.6% in premarket trade after t..."},{"Date":"May. 10, 2018 at 7:42 a.m. ET","Headline":"Eli Lilly will buy ARMO Biosciences for $1.6 bln","Summary":"Eli Lilly & Co.  will buy the immuno-oncology biotech ARMO Biosciences Inc.  for about $1.6 billion in an all-cash deal, the company announced early Thursday. ARMO Biosciences shares surged 77.6% in premarket trade after t..."},{"Date":"May. 15, 2018 at 6:59 a.m. ET","Headline":"Eli Lilly's cluster-headache treatment passes phase 3 test","Summary":"Eli Lilly & Co.  said Tuesday a phase 3 trial of galcanezumab for the treatment of episodic cluster headaches met its primary endpoint, and also achieved its secondary endpoint. Safety and tolerability was consistent with ..."},{"Date":"May. 14, 2018 at 8:41 a.m. ET","Headline":"President Trump\u2019s big drug price speech boosts pharma stocks","Summary":""},{"Date":"May. 24, 2018 at 1:44 p.m. ET","Headline":"A Dozen Safe and Solid Dividend Stocks","Summary":""},{"Date":"Jun. 2, 2018 at 12:01 a.m. ET","Headline":"Disney: A Little Less Magic","Summary":""},{"Date":"Jun. 12, 2018 at 7:41 p.m. ET","Headline":"Eli Lilly, AstraZeneca scrap trials of experimental Alzheimer\u2019s drug","Summary":"AstraZeneca PLC (AZN.LN) said Tuesday that it is discontinuing global clinical trials for lanabecestat, a treatment for Alzheimer's disease that the pharmaceutical company has been jointly developing with Eli Lilly & Co. (..."},{"Date":"Jun. 12, 2018 at 10:26 a.m. ET","Headline":"How investors might best play the \u2018long journey\u2019 to denuking North Korea","Summary":"AstraZeneca PLC (AZN.LN) said Tuesday that it is discontinuing global clinical trials for lanabecestat, a treatment for Alzheimer's disease that the pharmaceutical company has been jointly developing with Eli Lilly & Co. (..."},{"Date":"Jun. 12, 2018 at 2:45 a.m. ET","Headline":"AstraZeneca, Eli Lilly to halt Alzheimer's trials","Summary":"AstraZeneca PLC (AZN.LN) said Tuesday that it is discontinuing global clinical trials for lanabecestat, a treatment for Alzheimer's disease that the pharmaceutical company has been jointly developing with Eli Lilly & Co. (..."},{"Date":"Jun. 19, 2018 at 7:30 a.m. ET","Headline":"Lilly Exec Makes Biggest Insider Stock Buy in Years","Summary":""},{"Date":"Jun. 28, 2018 at 7:49 a.m. ET","Headline":"Five outperforming health-care funds and the top 10 stocks they hold","Summary":"Eli Lilly and Co.  announced positive results Thursday in a midstage trial of a treatment for Ankylosing Spondylitis, an inflammatory disease that can cause some of the vertebrae in the spine to fuse. The company said the ..."},{"Date":"Jun. 28, 2018 at 7:02 a.m. ET","Headline":"Eli Lilly reports positive results in trial of treatment for Ankylosing Spondylitis","Summary":"Eli Lilly and Co.  announced positive results Thursday in a midstage trial of a treatment for Ankylosing Spondylitis, an inflammatory disease that can cause some of the vertebrae in the spine to fuse. The company said the ..."},{"Date":"Jul. 12, 2018 at 9:13 a.m. ET","Headline":"Short to leave White House for D.C. consulting firm | Republican says time to move focus from repealing Dodd-Frank","Summary":""},{"Date":"Jul. 11, 2018 at 7:30 a.m. ET","Headline":"Big Stock Buys in IBM, Lilly by Norway\u2019s Biggest Bank","Summary":""},{"Date":"Jul. 18, 2018 at 3:26 p.m. ET","Headline":"Pfizer, Eli Lilly non-opioid pain drug nears finish line","Summary":"A new non-opioid drug for osteoarthritis pain being developed by Pfizer Inc.  and Eli Lilly & Co.  had positive early results in a phase 3 clinical trial, the companies announced on Wednesday. The drug, tanezumab, met all ..."},{"Date":"Jul. 24, 2018 at 11:36 a.m. ET","Headline":"Biogen, Eli Lilly earnings beats push industry stocks up","Summary":"Exchange-traded funds tracking the biotechnology sector rallied on Tuesday, supported by stronger-than-expected . The iShares Nasdaq Biotechnology ETF  gained 1.4%, climbing to its highest level since September 2015, while..."},{"Date":"Jul. 24, 2018 at 10:25 a.m. ET","Headline":"Biotech ETFs surge, supported by strong results from Biogen and Eli Lilly","Summary":"Exchange-traded funds tracking the biotechnology sector rallied on Tuesday, supported by stronger-than-expected . The iShares Nasdaq Biotechnology ETF  gained 1.4%, climbing to its highest level since September 2015, while..."},{"Date":"Jul. 24, 2018 at 8:15 a.m. ET","Headline":"These high-flying tech stocks are riding in Google parent Alphabet\u2019s slipstream","Summary":"Shares of Eli Lilly & Co.  shot up 6.6% in premarket trade toward the highest level in over 17 years, after the drugmaker reported second-quarter earnings and revenue that were well above expectations. Separately, the comp..."},{"Date":"Jul. 24, 2018 at 6:50 a.m. ET","Headline":"Eli Lilly's stock jumps after earnings beat, potential IPO of Elanco Animal Health","Summary":"Shares of Eli Lilly & Co.  shot up 6.6% in premarket trade toward the highest level in over 17 years, after the drugmaker reported second-quarter earnings and revenue that were well above expectations. Separately, the comp..."},{"Date":"Jul. 20, 2018 at 7:30 p.m. ET","Headline":"The Race to $1 Trillion: Can Amazon Overtake Apple?","Summary":""},{"Date":"Jul. 25, 2018 at 5:12 a.m. ET","Headline":"Dow ends 3-day losing streak as earnings lift stocks","Summary":""},{"Date":"Aug. 6, 2018 at 4:00 p.m. ET","Headline":"This stock sector most often beats analysts\u2019 estimates","Summary":""},{"Date":"Aug. 8, 2018 at 8:43 a.m. ET","Headline":"5 smart trades that will get you away from pricey tech stocks","Summary":""},{"Date":"Aug. 13, 2018 at 8:11 a.m. ET","Headline":"There\u2019s new evidence that the dominant approach to Alzheimer\u2019s may be completely wrong","Summary":""},{"Date":"Aug. 24, 2018 at 7:25 p.m. ET","Headline":"Why Health Care\u2019s Rally May Be Just Getting Started","Summary":""},{"Date":"Sep. 6, 2018 at 7:00 a.m. ET","Headline":"Eli Lilly's Elanco sets IPO terms to raise up to $1.45 billion before options","Summary":"Eli Lilly & Co.'s  Elanco Animal Health Inc.  has set terms of its initial public offering, in which the animal health company expects to raise up to $1.45 billion. Elanco said it is offering 62.9 million shares in the IPO..."},{"Date":"Sep. 7, 2018 at 6:12 p.m. ET","Headline":"The Story of Box: A Unicorn\u2019s Journey to Public Success","Summary":""},{"Date":"Sep. 14, 2018 at 3:48 p.m. ET","Headline":"These 4 major health-care stock spinoffs could make you money","Summary":""},{"Date":"Sep. 12, 2018 at 4:07 p.m. ET","Headline":"Rate Hikes Could Hurt These High-Yielding Sectors","Summary":""},{"Date":"Sep. 17, 2018 at 9:30 a.m. ET","Headline":"Teva stock surges 7% after FDA approves migraine medication","Summary":"Teva Pharmaceutical Industries Ltd.  shares surged nearly 7% in Monday premarket trade after the company's migraine therapy, intended to prevent chronic attacks of head pain along with other severe, disabling symptoms, was..."},{"Date":"Sep. 14, 2018 at 5:09 p.m. ET","Headline":"Eli Lilly Is Selling More Shares of This Biopharma Firm","Summary":""},{"Date":"Sep. 20, 2018 at 11:37 a.m. ET","Headline":"Elanco Animal Health stock soars more than 35% in trading debut","Summary":"Elanco Animal Health Inc. shares  soared more than 35% Thursday in their trading debut, after the company priced the stock above its price range. Elanco, a spinoff from Eli Lilly & Co. , issued 62.9 million shares at $24 e..."},{"Date":"Sep. 20, 2018 at 11:09 a.m. ET","Headline":"Bad news is building for this once-hot tech sector","Summary":"Elanco Animal Health Inc.  priced shares for its initial public offering above the estimated range late Wednesday. The animal drug company, which is being spun off from Eli Lilly & Co. , priced shares at $24 a piece. Earli..."},{"Date":"Sep. 20, 2018 at 8:51 a.m. ET","Headline":"Elanco\u2019s $1.7 billion IPO looks too pricey, and here\u2019s why","Summary":"Elanco Animal Health Inc.  priced shares for its initial public offering above the estimated range late Wednesday. The animal drug company, which is being spun off from Eli Lilly & Co. , priced shares at $24 a piece. Earli..."},{"Date":"Sep. 19, 2018 at 5:31 p.m. ET","Headline":"Elanco Animal Health prices IPO above expected range","Summary":"Elanco Animal Health Inc.  priced shares for its initial public offering above the estimated range late Wednesday. The animal drug company, which is being spun off from Eli Lilly & Co. , priced shares at $24 a piece. Earli..."},{"Date":"Sep. 21, 2018 at 11:59 a.m. ET","Headline":"Alzheimer\u2019s and dementia are expected to grow, and could affect minority groups more","Summary":""},{"Date":"Sep. 28, 2018 at 10:10 a.m. ET","Headline":"Panicked over Tesla? Here\u2019s the first thing you shouldn\u2019t do","Summary":"Eli Lilly and Company [s:lly] said late Thursday that the U.S. Food and Drug Administration has approved its drug Emgality for the preventive treatment of migraine in adults. Emgality is delivered via a once-a-month, self-..."},{"Date":"Sep. 27, 2018 at 8:45 p.m. ET","Headline":"Eli Lilly says FDA has approved new migraine drug Emgality","Summary":"Eli Lilly and Company [s:lly] said late Thursday that the U.S. Food and Drug Administration has approved its drug Emgality for the preventive treatment of migraine in adults. Emgality is delivered via a once-a-month, self-..."},{"Date":"Sep. 30, 2018 at 5:00 a.m. ET","Headline":"\u2018People Treat Animals Like Parts of Their Family.\u2019 Henry Schein Is Spinning Off Its Pet-Health Business","Summary":""},{"Date":"Oct. 2, 2018 at 9:00 a.m. ET","Headline":"Migraine sufferers: Help is on the way from 3 new drugs, but they\u2019ll cost $6,900 a year","Summary":""},{"Date":"Oct. 1, 2018 at 1:01 p.m. ET","Headline":"Teva Stock Is Struggling but 1 Analyst Says the Selloff Doesn\u2019t Make Sense","Summary":""},{"Date":"Oct. 4, 2018 at 5:15 p.m. ET","Headline":"Dow Drops 201 Points as Yield-Rise Fears Grip Investors","Summary":"Shares of Eli Lilly & Co.  rallied 3.1% toward a record high in premarket trade Thursday, after drugmaker announced positive results from a trial of its diabetes treatment. The company said a phase 2b trial of dual GIP and..."},{"Date":"Oct. 4, 2018 at 4:47 p.m. ET","Headline":"Stock market closes firmly lower as surge in bond yields sparks equity revaluation","Summary":"Shares of Eli Lilly & Co.  rallied 3.1% toward a record high in premarket trade Thursday, after drugmaker announced positive results from a trial of its diabetes treatment. The company said a phase 2b trial of dual GIP and..."},{"Date":"Oct. 4, 2018 at 1:36 p.m. ET","Headline":"The Dow Falls 350 Points as Yields Disturb the Peace","Summary":"Shares of Eli Lilly & Co.  rallied 3.1% toward a record high in premarket trade Thursday, after drugmaker announced positive results from a trial of its diabetes treatment. The company said a phase 2b trial of dual GIP and..."},{"Date":"Oct. 4, 2018 at 9:46 a.m. ET","Headline":"Bill Gross: This is why bonds are selling off","Summary":"Shares of Eli Lilly & Co.  rallied 3.1% toward a record high in premarket trade Thursday, after drugmaker announced positive results from a trial of its diabetes treatment. The company said a phase 2b trial of dual GIP and..."},{"Date":"Oct. 4, 2018 at 7:36 a.m. ET","Headline":"Eli Lilly's stock surges toward record after positive trials for diabetes treatments","Summary":"Shares of Eli Lilly & Co.  rallied 3.1% toward a record high in premarket trade Thursday, after drugmaker announced positive results from a trial of its diabetes treatment. The company said a phase 2b trial of dual GIP and..."},{"Date":"Oct. 5, 2018 at 3:46 p.m. ET","Headline":"Eli Lilly Stock Is Climbing on Upbeat Drug Data and an Upgrade","Summary":""},{"Date":"Oct. 9, 2018 at 12:51 p.m. ET","Headline":"5 Reasons Investors Should Take a Fresh Look at Big Pharma","Summary":""},{"Date":"Oct. 11, 2018 at 6:48 a.m. ET","Headline":"Here\u2019s why you should expect more \u2018beats\u2019 during this earnings season","Summary":""},{"Date":"Oct. 18, 2018 at 11:39 a.m. ET","Headline":"Charting a fragile recovery attempt, S&P 500 digests initial technical progress","Summary":""},{"Date":"Oct. 17, 2018 at 11:42 a.m. ET","Headline":"Charting a market recovery attempt:  S&P 500, Nasdaq venture atop 200-day average","Summary":""},{"Date":"Oct. 19, 2018 at 11:58 a.m. ET","Headline":"Charting October volatility:  S&P 500, Nasdaq whipsaw at the 200-day average","Summary":""},{"Date":"Oct. 22, 2018 at 6:00 p.m. ET","Headline":"Dow Jones Industrial Average Closes Down 127 Points, but Did You See the Nasdaq?","Summary":""},{"Date":"Oct. 22, 2018 at 11:49 a.m. ET","Headline":"S&P 500, Nasdaq nail 200-day average amid lackluster recovery attempt","Summary":""},{"Date":"Oct. 24, 2018 at 12:25 p.m. ET","Headline":"Charting a second corrective bounce, S&P 500 lifts from four-month lows","Summary":""},{"Date":"Oct. 24, 2018 at 7:12 a.m. ET","Headline":"New pain drug from Pfizer and Eli Lilly shows promise as opioid alternative","Summary":""},{"Date":"Oct. 23, 2018 at 12:49 p.m. ET","Headline":"Charting an ominous technical tilt, S&P 500 plunges from the 200-day average","Summary":""},{"Date":"Oct. 23, 2018 at 12:18 p.m. ET","Headline":"Charting an ominous technical tilt, S&P 500 plunges from the 200-day average","Summary":""},{"Date":"Oct. 26, 2018 at 11:47 a.m. ET","Headline":"Bearish momentum intact, S&P 500 tags the 10% correction mark","Summary":""},{"Date":"Oct. 25, 2018 at 12:34 p.m. ET","Headline":"Charting a primary trend shift, October downdraft inflicts extensive damage","Summary":""},{"Date":"Oct. 30, 2018 at 12:42 p.m. ET","Headline":"Charting a second dead-cat bounce, S&P 500 rises from 10% correction mark","Summary":"Shares of Dicerna Pharmaceuticals Inc.  rocketed 42% in premarket trade Monday, after the company said it will receive an upfront payment of $100 million as part of a licensing and research collaboration with Eli Lilly & C..."},{"Date":"Oct. 30, 2018 at 12:07 p.m. ET","Headline":"Charting a second dead-cat bounce, S&P 500 rises from 10% correction mark","Summary":"Shares of Dicerna Pharmaceuticals Inc.  rocketed 42% in premarket trade Monday, after the company said it will receive an upfront payment of $100 million as part of a licensing and research collaboration with Eli Lilly & C..."},{"Date":"Oct. 29, 2018 at 3:02 p.m. ET","Headline":"Pfizer earnings: Looking toward an ambitious 2022 agenda","Summary":"Shares of Dicerna Pharmaceuticals Inc.  rocketed 42% in premarket trade Monday, after the company said it will receive an upfront payment of $100 million as part of a licensing and research collaboration with Eli Lilly & C..."},{"Date":"Oct. 29, 2018 at 11:54 a.m. ET","Headline":"S&P 500 lifts to the breakdown point (2,710), latest retest underway","Summary":"Shares of Dicerna Pharmaceuticals Inc.  rocketed 42% in premarket trade Monday, after the company said it will receive an upfront payment of $100 million as part of a licensing and research collaboration with Eli Lilly & C..."},{"Date":"Oct. 29, 2018 at 7:09 a.m. ET","Headline":"Dicerna's stock rockets after licensing, research collaboration with Eli Lilly","Summary":"Shares of Dicerna Pharmaceuticals Inc.  rocketed 42% in premarket trade Monday, after the company said it will receive an upfront payment of $100 million as part of a licensing and research collaboration with Eli Lilly & C..."},{"Date":"Nov. 1, 2018 at 11:40 a.m. ET","Headline":"Charting a shooting star, S&P 500 nails the breakdown point (2,710)","Summary":""},{"Date":"Oct. 31, 2018 at 11:59 a.m. ET","Headline":"Closing out a damaging October plunge, U.S. benchmarks rise from multi-month lows","Summary":""},{"Date":"Nov. 2, 2018 at 8:04 p.m. ET","Headline":"Stock Swoon? What Stock Swoon? Consumer Confidence Up","Summary":""},{"Date":"Nov. 2, 2018 at 11:44 a.m. ET","Headline":"Market bears resurface as major U.S. benchmarks tag next resistance","Summary":""},{"Date":"Nov. 5, 2018 at 11:43 a.m. ET","Headline":"Charting a near-term holding pattern, S&P 500 asserts the range","Summary":""},{"Date":"Nov. 4, 2018 at 3:00 p.m. ET","Headline":"CVS, Cardinal Health, Walt Disney, Midterm Elections: The Week Ahead","Summary":""},{"Date":"Nov. 7, 2018 at 11:47 a.m. ET","Headline":"Charting November follow-through, S&P 500 ventures atop 200-day average","Summary":"Eli Lilly & Co. LLY on Tuesday raised its adjusted earnings per share guidance as it reported a more than doubled third-quarter profit. The Indianapolis, Ind.-based drugmaker earned a quarterly profit of $1.15 billion, or ..."},{"Date":"Nov. 6, 2018 at 4:49 p.m. ET","Headline":"Dow rises 173 points before investors turn attention to midterm election returns","Summary":"Eli Lilly & Co. LLY on Tuesday raised its adjusted earnings per share guidance as it reported a more than doubled third-quarter profit. The Indianapolis, Ind.-based drugmaker earned a quarterly profit of $1.15 billion, or ..."},{"Date":"Nov. 6, 2018 at 12:33 p.m. ET","Headline":"Charting the S&P 500\u2019s November bounce ahead of U.S. midterms","Summary":"Eli Lilly & Co. LLY on Tuesday raised its adjusted earnings per share guidance as it reported a more than doubled third-quarter profit. The Indianapolis, Ind.-based drugmaker earned a quarterly profit of $1.15 billion, or ..."},{"Date":"Nov. 6, 2018 at 12:03 p.m. ET","Headline":"Charting the S&P 500\u2019s November bounce ahead of U.S. midterms","Summary":"Eli Lilly & Co. LLY on Tuesday raised its adjusted earnings per share guidance as it reported a more than doubled third-quarter profit. The Indianapolis, Ind.-based drugmaker earned a quarterly profit of $1.15 billion, or ..."},{"Date":"Nov. 6, 2018 at 9:53 a.m. ET","Headline":"After midterm election, focus on the \u2018healthy\u2019 30%-plus correction headed for stocks","Summary":"Eli Lilly & Co. LLY on Tuesday raised its adjusted earnings per share guidance as it reported a more than doubled third-quarter profit. The Indianapolis, Ind.-based drugmaker earned a quarterly profit of $1.15 billion, or ..."},{"Date":"Nov. 6, 2018 at 8:35 a.m. ET","Headline":"How Trump could rescue Apple\u2019s fast-sinking stock","Summary":"Eli Lilly & Co. LLY on Tuesday raised its adjusted earnings per share guidance as it reported a more than doubled third-quarter profit. The Indianapolis, Ind.-based drugmaker earned a quarterly profit of $1.15 billion, or ..."},{"Date":"Nov. 6, 2018 at 7:16 a.m. ET","Headline":"Eli Lilly raises guidance after Q3 beat","Summary":"Eli Lilly & Co. LLY on Tuesday raised its adjusted earnings per share guidance as it reported a more than doubled third-quarter profit. The Indianapolis, Ind.-based drugmaker earned a quarterly profit of $1.15 billion, or ..."},{"Date":"Nov. 6, 2018 at 6:41 a.m. ET","Headline":"Eli Lilly beats earnings expectations, raises guidance","Summary":"Eli Lilly & Co.  reported Tuesday third-quarter earnings and revenue that topped expectations and raised its full-year guidance. The stock was still inactive in premarket trade. Net income rose to $1.15 billion, or $1.12 a..."},{"Date":"Nov. 9, 2018 at 11:52 a.m. ET","Headline":"S&P 500 nails the range top (2,817), stalls at well-defined resistance","Summary":""},{"Date":"Nov. 8, 2018 at 12:09 p.m. ET","Headline":"Bull case strengthens:  S&P 500, Nasdaq knife atop 200-day average","Summary":""},{"Date":"Nov. 8, 2018 at 9:23 a.m. ET","Headline":"Rudy Giuliani, Pam Bondi, Alex Azar among candidates to replace Jeff Sessions as attorney general","Summary":""},{"Date":"Nov. 13, 2018 at 1:07 p.m. ET","Headline":"Charting a post-election downdraft, S&P 500 returns to mini-crash range","Summary":""},{"Date":"Nov. 13, 2018 at 12:38 p.m. ET","Headline":"Charting a post-election downdraft, S&P 500 returns to mini-crash range","Summary":""},{"Date":"Nov. 12, 2018 at 11:57 a.m. ET","Headline":"Charting a failed technical test:  S&P 500, Nasdaq violate 200-day average","Summary":""},{"Date":"Nov. 14, 2018 at 12:23 p.m. ET","Headline":"Charting persistent November volatility, Dow industrials challenge 200-day average","Summary":"Eli Lilly & Co.  announced early Wednesday that it has made progress on two migraine therapies, including submitting an application for one medication -- intended for in-the-moment pain relief for migraines -- to the U.S. ..."},{"Date":"Nov. 14, 2018 at 7:52 a.m. ET","Headline":"Eli Lilly announces progress on new headache medications","Summary":"Eli Lilly & Co.  announced early Wednesday that it has made progress on two migraine therapies, including submitting an application for one medication -- intended for in-the-moment pain relief for migraines -- to the U.S. ..."},{"Date":"Nov. 19, 2018 at 12:00 p.m. ET","Headline":"Bearish momentum persists:  S&P 500, Nasdaq stall at well-defined resistance","Summary":""},{"Date":"Nov. 21, 2018 at 12:21 p.m. ET","Headline":"S&P 500 tags negative YTD territory, back for initial crack at the breakdown point","Summary":""},{"Date":"Nov. 20, 2018 at 12:46 p.m. ET","Headline":"Bearish momentum accelerates, S&P 500 ventures under major support","Summary":""},{"Date":"Nov. 20, 2018 at 12:06 p.m. ET","Headline":"Bearish momentum accelerates, S&P 500 ventures under major support","Summary":""},{"Date":"Nov. 27, 2018 at 12:36 p.m. ET","Headline":"S&P 500 nails the breakdown point (2,673), pulling-teeth retest underway","Summary":""},{"Date":"Nov. 27, 2018 at 12:07 p.m. ET","Headline":"S&P 500 nails the breakdown point (2,673), pulling-teeth retest underway","Summary":""},{"Date":"Nov. 26, 2018 at 11:46 a.m. ET","Headline":"Charting a bull-bear technical test:  S&P 500 nails the breakdown point (2,673)","Summary":""},{"Date":"Nov. 29, 2018 at 12:16 p.m. ET","Headline":"Charting a Fed-fueled nearly 8-to-1 up day, S&P 500 spikes to major resistance","Summary":""},{"Date":"Nov. 28, 2018 at 11:52 a.m. ET","Headline":"S&P 500 extends bounce ahead of the Fed, reclaims first resistance","Summary":""},{"Date":"Nov. 30, 2018 at 11:57 a.m. ET","Headline":"S&P 500 nails major resistance (2,742), sustains initial Fed-fueled gains","Summary":""},{"Date":"Dec. 3, 2018 at 11:58 a.m. ET","Headline":"Charting a trade-fueled rally attempt, S&P 500 reclaims 200-day average","Summary":""},{"Date":"Dec. 4, 2018 at 1:21 p.m. ET","Headline":"Market bears resurface:  S&P 500 nails major resistance amid flattening yield curve","Summary":""},{"Date":"Dec. 4, 2018 at 12:51 p.m. ET","Headline":"Market bears resurface:  S&P 500 nails major resistance amid flattening yield curve","Summary":""},{"Date":"Dec. 4, 2018 at 7:00 a.m. ET","Headline":"Bayer Is Just the Latest Pharma Giant to Get Back to Basics","Summary":""},{"Date":"Dec. 7, 2018 at 12:02 p.m. ET","Headline":"Charting a bearish market whipsaw, S&P 500 asserts wide December range","Summary":""},{"Date":"Dec. 7, 2018 at 9:12 a.m. ET","Headline":"Moderna: 5 things to know about the largest biotech to IPO","Summary":""},{"Date":"Dec. 6, 2018 at 12:00 p.m. ET","Headline":"Charting an aggressive December downdraft amid S&P 500\u2019s pending death cross","Summary":""},{"Date":"Dec. 11, 2018 at 12:44 p.m. ET","Headline":"Charting a December bounce:  S&P 500 nails major support","Summary":""},{"Date":"Dec. 11, 2018 at 12:09 p.m. ET","Headline":"Charting a December bounce:  S&P 500 nails major support","Summary":""},{"Date":"Dec. 10, 2018 at 11:31 a.m. ET","Headline":"Bearish momentum accelerates:  S&P 500 ventures under major support","Summary":""},{"Date":"Dec. 13, 2018 at 11:36 a.m. ET","Headline":"S&P 500 balks at major resistance as December bounce fades","Summary":""},{"Date":"Dec. 12, 2018 at 11:15 a.m. ET","Headline":"S&P 500 extends corrective bounce, major resistance (2,673) under siege","Summary":""},{"Date":"Dec. 14, 2018 at 11:17 a.m. ET","Headline":"Charting a failed technical test, S&P 500 traverses negative YTD territory","Summary":""},{"Date":"Dec. 17, 2018 at 11:42 a.m. ET","Headline":"S&P 500 reaches less-charted territory, second test of major support (2,581) underway","Summary":""},{"Date":"Dec. 19, 2018 at 4:18 p.m. ET","Headline":"Stocks tumble after Fed raises rates again, lowers expectations for hikes next year","Summary":"Shares of Eli Lilly & Co.  rallied 1.0% in premarket trade Wednesday, after the drug giant provided 2019 profit and revenue guidance that was above expectations, and raised its dividend by 15%. The company said it expects ..."},{"Date":"Dec. 19, 2018 at 2:59 p.m. ET","Headline":"Eli Lilly Forecast Points to a Strong Year","Summary":"Shares of Eli Lilly & Co.  rallied 1.0% in premarket trade Wednesday, after the drug giant provided 2019 profit and revenue guidance that was above expectations, and raised its dividend by 15%. The company said it expects ..."},{"Date":"Dec. 19, 2018 at 11:40 a.m. ET","Headline":"S&P 500 establishes near-term floor, bounces modestly ahead of Fed","Summary":"Shares of Eli Lilly & Co.  rallied 1.0% in premarket trade Wednesday, after the drug giant provided 2019 profit and revenue guidance that was above expectations, and raised its dividend by 15%. The company said it expects ..."},{"Date":"Dec. 19, 2018 at 9:31 a.m. ET","Headline":"Brace for a sudden, sharp rally for the S&P 500 in 2019, says strategist David Bianco","Summary":"Shares of Eli Lilly & Co.  rallied 1.0% in premarket trade Wednesday, after the drug giant provided 2019 profit and revenue guidance that was above expectations, and raised its dividend by 15%. The company said it expects ..."},{"Date":"Dec. 19, 2018 at 9:14 a.m. ET","Headline":"Eli Lilly Leaps, General Mills Jumps, and 6 More Wednesday Morning Movers","Summary":"Shares of Eli Lilly & Co.  rallied 1.0% in premarket trade Wednesday, after the drug giant provided 2019 profit and revenue guidance that was above expectations, and raised its dividend by 15%. The company said it expects ..."},{"Date":"Dec. 19, 2018 at 6:48 a.m. ET","Headline":"Eli Lilly's stock gains after upbeat profit and revenue outlook, raised dividend","Summary":"Shares of Eli Lilly & Co.  rallied 1.0% in premarket trade Wednesday, after the drug giant provided 2019 profit and revenue guidance that was above expectations, and raised its dividend by 15%. The company said it expects ..."},{"Date":"Dec. 18, 2018 at 12:42 p.m. ET","Headline":"Charting a falling-knife backdrop, S&P 500 confirms primary downtrend","Summary":""},{"Date":"Dec. 18, 2018 at 12:07 p.m. ET","Headline":"Charting a falling-knife backdrop, S&P 500 confirms primary downtrend","Summary":""},{"Date":"Dec. 21, 2018 at 12:05 p.m. ET","Headline":"Charting the December carnage, S&P 500 tags the 2,450 target","Summary":""},{"Date":"Dec. 20, 2018 at 11:57 a.m. ET","Headline":"Falling-knife backdrop persists, S&P 500 extends to less-charted territory","Summary":""},{"Date":"Dec. 20, 2018 at 9:55 a.m. ET","Headline":"Eli Lilly and Pfizer Are Boosting Dividends","Summary":""},{"Date":"Jan. 2, 2019 at 12:07 p.m. ET","Headline":"Charting a \u2018near-term\u2019 rally attempt, S&P 500 rises amid major technical damage","Summary":""},{"Date":"Jan. 4, 2019 at 11:37 a.m. ET","Headline":"S&P 500 back for second crack at resistance (2,520) amid Fed-fueled rally attempt","Summary":""},{"Date":"Jan. 3, 2019 at 1:10 p.m. ET","Headline":"The Celgene Deal Shows How the Lines Between Biotech and Big Pharma Have Blurred","Summary":""},{"Date":"Jan. 3, 2019 at 11:56 a.m. ET","Headline":"S&P 500 nails resistance (2,520), pulls in amid Apple-fueled volatility","Summary":""},{"Date":"Jan. 8, 2019 at 12:23 p.m. ET","Headline":"Charting a bull-bear battleground:  S&P 500, Nasdaq nail major resistance","Summary":"Most U.S. stock indexes traded lower Monday morning as investors watched developments in trade, following upbeat news on Friday from the labor market and the Federal Reserve. The Dow Jones Industrial Average  shed 37 point..."},{"Date":"Jan. 8, 2019 at 11:57 a.m. ET","Headline":"Charting a bull-bear battleground:  S&P 500, Nasdaq nail major resistance","Summary":"Most U.S. stock indexes traded lower Monday morning as investors watched developments in trade, following upbeat news on Friday from the labor market and the Federal Reserve. The Dow Jones Industrial Average  shed 37 point..."},{"Date":"Jan. 8, 2019 at 8:25 a.m. ET","Headline":"Samsung Warns on Revenue, but Trade Hopes Lift Global Stocks","Summary":"Most U.S. stock indexes traded lower Monday morning as investors watched developments in trade, following upbeat news on Friday from the labor market and the Federal Reserve. The Dow Jones Industrial Average  shed 37 point..."},{"Date":"Jan. 8, 2019 at 7:00 a.m. ET","Headline":"Debt Buybacks Could Be The New Stock Buybacks","Summary":"Most U.S. stock indexes traded lower Monday morning as investors watched developments in trade, following upbeat news on Friday from the labor market and the Federal Reserve. The Dow Jones Industrial Average  shed 37 point..."},{"Date":"Jan. 7, 2019 at 4:18 p.m. ET","Headline":"Stocks close higher for second session as U.S.-China trade talks resume","Summary":"Most U.S. stock indexes traded lower Monday morning as investors watched developments in trade, following upbeat news on Friday from the labor market and the Federal Reserve. The Dow Jones Industrial Average  shed 37 point..."},{"Date":"Jan. 7, 2019 at 3:06 p.m. ET","Headline":"Cancer stocks heat up after third big merger in the past month","Summary":"Most U.S. stock indexes traded lower Monday morning as investors watched developments in trade, following upbeat news on Friday from the labor market and the Federal Reserve. The Dow Jones Industrial Average  shed 37 point..."},{"Date":"Jan. 7, 2019 at 11:39 a.m. ET","Headline":"Second 20-to-1 up day strengthens S&P 500\u2019s \u2018near-term\u2019 recovery attempt","Summary":"Most U.S. stock indexes traded lower Monday morning as investors watched developments in trade, following upbeat news on Friday from the labor market and the Federal Reserve. The Dow Jones Industrial Average  shed 37 point..."},{"Date":"Jan. 7, 2019 at 9:40 a.m. ET","Headline":"U.S. stocks struggle for direction in early trade, following powerful Friday rally","Summary":"Most U.S. stock indexes traded lower Monday morning as investors watched developments in trade, following upbeat news on Friday from the labor market and the Federal Reserve. The Dow Jones Industrial Average  shed 37 point..."},{"Date":"Jan. 7, 2019 at 9:25 a.m. ET","Headline":"Eli Lilly Is Buying Loxo Oncology \u2014 and Paying a Big Premium for It","Summary":"Shares of Loxo Onocology Inc.  were indicated up about 33% in premarket trade Monday, after the biopharmaceutical company agreed to be acquired by Eli Lilly & Co.  in a deal valued at $8.0 billion. Lilly's stock fell 2.7% ..."},{"Date":"Jan. 7, 2019 at 9:01 a.m. ET","Headline":"Exact Sciences Stock Soars, General Motors Gains and 5 More Monday Morning Movers","Summary":"Shares of Loxo Onocology Inc.  were indicated up about 33% in premarket trade Monday, after the biopharmaceutical company agreed to be acquired by Eli Lilly & Co.  in a deal valued at $8.0 billion. Lilly's stock fell 2.7% ..."},{"Date":"Jan. 7, 2019 at 8:03 a.m. ET","Headline":"Slow Start for Dow Despite  Merger News, Gain for Oil","Summary":"Shares of Loxo Onocology Inc.  were indicated up about 33% in premarket trade Monday, after the biopharmaceutical company agreed to be acquired by Eli Lilly & Co.  in a deal valued at $8.0 billion. Lilly's stock fell 2.7% ..."},{"Date":"Jan. 7, 2019 at 6:42 a.m. ET","Headline":"Lilly to buy Loxo Oncology in a $8 billion deal, for a 68% premium","Summary":"Shares of Loxo Onocology Inc.  were indicated up about 33% in premarket trade Monday, after the biopharmaceutical company agreed to be acquired by Eli Lilly & Co.  in a deal valued at $8.0 billion. Lilly's stock fell 2.7% ..."},{"Date":"Jan. 10, 2019 at 11:58 a.m. ET","Headline":"Charting a bullish divergence:  Nasdaq reclaims the breakdown point","Summary":""},{"Date":"Jan. 9, 2019 at 11:29 a.m. ET","Headline":"Charting a bull-bear stalemate:  S&P 500 hesitates at major resistance (2,581)","Summary":""},{"Date":"Jan. 9, 2019 at 7:00 a.m. ET","Headline":"A Pension Fund Bought Apple Stock at the Wrong Time","Summary":""},{"Date":"Jan. 11, 2019 at 11:51 a.m. ET","Headline":"S&P 500 edges atop major resistance (2,581) amid persistent January rally attempt","Summary":""},{"Date":"Jan. 14, 2019 at 12:55 p.m. ET","Headline":"House Democrats launch probe into drug prices","Summary":""},{"Date":"Jan. 14, 2019 at 11:19 a.m. ET","Headline":"Charting a near-term holding pattern, S&P 500 digests January gains","Summary":""},{"Date":"Jan. 16, 2019 at 11:51 a.m. ET","Headline":"Bull case strengthens, Nasdaq reclaims the 50-day average","Summary":""},{"Date":"Jan. 15, 2019 at 4:48 p.m. ET","Headline":"Here\u2019s your guide to the upcoming biotechnology takeover wave","Summary":""},{"Date":"Jan. 15, 2019 at 12:18 p.m. ET","Headline":"Charting a bull flag:  S&P 500, Nasdaq maintain major support","Summary":""},{"Date":"Jan. 15, 2019 at 11:46 a.m. ET","Headline":"Charting a bull flag:  S&P 500, Nasdaq maintain major support","Summary":""},{"Date":"Jan. 18, 2019 at 4:24 p.m. ET","Headline":"Stocks close higher for fourth day as optimism mounts over U.S.-China trade","Summary":"U.S. stocks rose on Friday, putting benchmarks on pace for a fourth straight win, as investors hung on to optimism over a report that Washington might ease tariffs on Chinese goods. The Dow Jones Industrial Average  rose 1..."},{"Date":"Jan. 18, 2019 at 11:50 a.m. ET","Headline":"Bull case strengthens (again), S&P 500 signals intermediate-term \u2018trend\u2019 shift","Summary":"U.S. stocks rose on Friday, putting benchmarks on pace for a fourth straight win, as investors hung on to optimism over a report that Washington might ease tariffs on Chinese goods. The Dow Jones Industrial Average  rose 1..."},{"Date":"Jan. 18, 2019 at 9:36 a.m. ET","Headline":"Dow jumps 160 points as stock market set to end week with solid gains on China-trade optimism","Summary":"U.S. stocks rose on Friday, putting benchmarks on pace for a fourth straight win, as investors hung on to optimism over a report that Washington might ease tariffs on Chinese goods. The Dow Jones Industrial Average  rose 1..."},{"Date":"Jan. 18, 2019 at 6:59 a.m. ET","Headline":"Eli Lilly shares slide premarket on news of failed trial for sarcoma treatment","Summary":"Eli Lilly and Co. shares  fell as much as 5% in premarket trde Friday before paring those losses, after the company said a late-stage trial of a treatment for sarcoma failed to meet its main goals. The phase 3 trial of Lar..."},{"Date":"Jan. 17, 2019 at 11:44 a.m. ET","Headline":"Charting a persistent rally attempt, S&P 500 nails major resistance","Summary":""},{"Date":"Jan. 17, 2019 at 8:18 a.m. ET","Headline":"Ligand Pharmaceuticals stock down after extremely critical Citron report","Summary":""},{"Date":"Jan. 22, 2019 at 1:05 p.m. ET","Headline":"S&P 500 reaches firmer technical ground, pulls in from major resistance","Summary":""},{"Date":"Jan. 22, 2019 at 12:32 p.m. ET","Headline":"S&P 500 reaches firmer technical ground, pulls in from major resistance","Summary":""},{"Date":"Jan. 24, 2019 at 11:11 a.m. ET","Headline":"Charting a successful technical test, S&P 500 maintains major support","Summary":""},{"Date":"Jan. 23, 2019 at 12:01 p.m. ET","Headline":"S&P 500 retests major support (2,631) as first January selling pressure surfaces","Summary":""},{"Date":"Jan. 25, 2019 at 11:27 a.m. ET","Headline":"Bull \u2019trend\u2019 persists, S&P 500 back for second crack at major resistance (2,673)","Summary":""},{"Date":"Jan. 28, 2019 at 11:30 a.m. ET","Headline":"Charting a market whipsaw, S&P 500 pulls in to major support (2,631)","Summary":""},{"Date":"Jan. 30, 2019 at 11:12 a.m. ET","Headline":"Charting a breakout attempt:  Dow industrials rattle cage on major resistance (24,876)","Summary":""},{"Date":"Jan. 30, 2019 at 11:08 a.m. ET","Headline":"Biotech Giants Amgen and Biogen Fall on Earnings, Alzheimer\u2019s News","Summary":""},{"Date":"Jan. 29, 2019 at 3:43 p.m. ET","Headline":"Cummings, Grassley vow to combat rising drug prices in dueling hearings","Summary":""},{"Date":"Jan. 29, 2019 at 12:16 p.m. ET","Headline":"Charting a garden-variety pullback, S&P 500 asserts near-term range","Summary":""},{"Date":"Jan. 29, 2019 at 11:47 a.m. ET","Headline":"Charting a garden-variety pullback, S&P 500 asserts near-term range","Summary":""},{"Date":"Feb. 1, 2019 at 12:00 p.m. ET","Headline":"S&P 500 confirms bull trend, rises to nail next resistance (2,710)","Summary":""},{"Date":"Jan. 31, 2019 at 7:20 p.m. ET","Headline":"Patients would get prescription drug discounts directly under new plan","Summary":""},{"Date":"Jan. 31, 2019 at 11:57 a.m. ET","Headline":"Bull trend accelerates, S&P 500 reclaims major resistance (2,673) after the Fed","Summary":""},{"Date":"Jan. 31, 2019 at 11:27 a.m. ET","Headline":"Pfizer Stock\u2019s \u2018Dark Period\u2019 Might Finally Be Over","Summary":""},{"Date":"Feb. 5, 2019 at 12:59 p.m. ET","Headline":"Bull trend strengthens, S&P 500 approaches 200-day average","Summary":""},{"Date":"Feb. 5, 2019 at 12:16 p.m. ET","Headline":"Bull trend strengthens, S&P 500 approaches 200-day average","Summary":""},{"Date":"Feb. 4, 2019 at 11:34 a.m. ET","Headline":"Charting a bullish February start, Dow industrials sustain slight break atop 200-day average","Summary":""},{"Date":"Feb. 4, 2019 at 6:21 a.m. ET","Headline":"Does Fed\u2019s dovish turn signal further gains for stocks? Bond investors have doubts","Summary":""},{"Date":"Feb. 7, 2019 at 12:21 p.m. ET","Headline":"Charting a failed technical test: S&P 500 balks at 200-day average amid trade concerns","Summary":"Shares of Eli Lilly & Co.  dropped 2.7% in premarket trade Wednesday, after the drug giant reported a fourth-quarter profit that missed expectations and cut its full-year outlook. Lilly swung to net income of $1.13 billion..."},{"Date":"Feb. 6, 2019 at 4:23 p.m. ET","Headline":"Stocks close lower as Trump\u2019s State of the Union offers few details on economic agenda","Summary":"Shares of Eli Lilly & Co.  dropped 2.7% in premarket trade Wednesday, after the drug giant reported a fourth-quarter profit that missed expectations and cut its full-year outlook. Lilly swung to net income of $1.13 billion..."},{"Date":"Feb. 6, 2019 at 1:48 p.m. ET","Headline":"Eli Lilly Stock Falls Because 2019 Isn\u2019t 2018","Summary":"Shares of Eli Lilly & Co.  dropped 2.7% in premarket trade Wednesday, after the drug giant reported a fourth-quarter profit that missed expectations and cut its full-year outlook. Lilly swung to net income of $1.13 billion..."},{"Date":"Feb. 6, 2019 at 12:16 p.m. ET","Headline":"The Dow Slips 38 Points, Because It\u2019s Time for a Pause","Summary":"Shares of Eli Lilly & Co.  dropped 2.7% in premarket trade Wednesday, after the drug giant reported a fourth-quarter profit that missed expectations and cut its full-year outlook. Lilly swung to net income of $1.13 billion..."},{"Date":"Feb. 6, 2019 at 11:33 a.m. ET","Headline":"Charting a slow-motion breakout attempt, S&P 500 hesitates at 200-day average","Summary":"Shares of Eli Lilly & Co.  dropped 2.7% in premarket trade Wednesday, after the drug giant reported a fourth-quarter profit that missed expectations and cut its full-year outlook. Lilly swung to net income of $1.13 billion..."},{"Date":"Feb. 6, 2019 at 11:31 a.m. ET","Headline":"Spotify moves beyond music, and GoPro also aims to change its tune","Summary":"Shares of Eli Lilly & Co.  dropped 2.7% in premarket trade Wednesday, after the drug giant reported a fourth-quarter profit that missed expectations and cut its full-year outlook. Lilly swung to net income of $1.13 billion..."},{"Date":"Feb. 6, 2019 at 9:31 a.m. ET","Headline":"How hard is it to be a stock-market bear right now? This chart drives it home","Summary":"Shares of Eli Lilly & Co.  dropped 2.7% in premarket trade Wednesday, after the drug giant reported a fourth-quarter profit that missed expectations and cut its full-year outlook. Lilly swung to net income of $1.13 billion..."},{"Date":"Feb. 6, 2019 at 6:41 a.m. ET","Headline":"Eli Lilly's stock falls after profit miss, lowered outoook","Summary":"Shares of Eli Lilly & Co.  dropped 2.7% in premarket trade Wednesday, after the drug giant reported a fourth-quarter profit that missed expectations and cut its full-year outlook. Lilly swung to net income of $1.13 billion..."},{"Date":"Feb. 8, 2019 at 12:14 p.m. ET","Headline":"Charting limited technical damage (so far), S&P 500 extends pullback from resistance","Summary":"Eli Lilly and Co.  said Friday it will divest its remaining stake in Elanco Animal Health  via an exchange offer. Lilly shareholders will be able to exchange all, some of none of their shares of Lilly common stock for Elan..."},{"Date":"Feb. 8, 2019 at 11:20 a.m. ET","Headline":"Eli Lilly to Unload Its Remaining Stock in Elanco Animal Health","Summary":"Eli Lilly and Co.  said Friday it will divest its remaining stake in Elanco Animal Health  via an exchange offer. Lilly shareholders will be able to exchange all, some of none of their shares of Lilly common stock for Elan..."},{"Date":"Feb. 8, 2019 at 6:57 a.m. ET","Headline":"Eli Lilly to divest remaining stake in Elanco via an exchange offer","Summary":"Eli Lilly and Co.  said Friday it will divest its remaining stake in Elanco Animal Health  via an exchange offer. Lilly shareholders will be able to exchange all, some of none of their shares of Lilly common stock for Elan..."},{"Date":"Feb. 11, 2019 at 11:43 a.m. ET","Headline":"Bull trend intact, S&P 500 absorbs downturn from 200-day average","Summary":""},{"Date":"Feb. 11, 2019 at 6:00 a.m. ET","Headline":"Big Pharma Wants to Borrow Cash for M&A, but Could Run Into Credit Downgrades","Summary":""},{"Date":"Feb. 13, 2019 at 11:50 a.m. ET","Headline":"Nasdaq nails 200-day average, S&P 500 extends break atop major resistance","Summary":""},{"Date":"Feb. 12, 2019 at 12:32 p.m. ET","Headline":"Bull trend strengthens, S&P 500 rattles cage on 200-day average","Summary":""},{"Date":"Feb. 12, 2019 at 11:57 a.m. ET","Headline":"Bull trend strengthens, S&P 500 rattles cage on 200-day average","Summary":""},{"Date":"Feb. 15, 2019 at 11:47 a.m. ET","Headline":"S&P 500 extends break atop 200-day average, rises to nail next resistance (2,773)","Summary":""},{"Date":"Feb. 14, 2019 at 1:08 p.m. ET","Headline":"Zoetis Stock Gains Because People Keep Spending on Their Pets","Summary":""},{"Date":"Feb. 14, 2019 at 11:58 a.m. ET","Headline":"Charting a jagged breakout attempt:  S&P 500 whipsaws at major resistance","Summary":""},{"Date":"Feb. 19, 2019 at 12:36 p.m. ET","Headline":"Charting a primary trend shift:  S&P 500, Nasdaq reclaim 200-day average","Summary":""},{"Date":"Feb. 19, 2019 at 12:04 p.m. ET","Headline":"Charting a primary trend shift:  S&P 500, Nasdaq reclaim 200-day average","Summary":""},{"Date":"Feb. 18, 2019 at 6:00 a.m. ET","Headline":"Big Pharma Can\u2019t Resist Big Mergers. Here\u2019s Why.","Summary":""},{"Date":"Feb. 21, 2019 at 12:08 p.m. ET","Headline":"Charting a bull-trend pullback: Nasdaq, Dow industrials hesitate at major resistance","Summary":""},{"Date":"Feb. 20, 2019 at 11:50 a.m. ET","Headline":"Nasdaq nails major resistance, slow-motion breakout attempt underway","Summary":""},{"Date":"Feb. 22, 2019 at 11:37 a.m. ET","Headline":"Charting a tandem breakout attempt:  Nasdaq, Dow industrials clear major resistance","Summary":""},{"Date":"Feb. 25, 2019 at 11:58 a.m. ET","Headline":"Bull trend strengthens, S&P 500 ventures atop major resistance (2,802)","Summary":""},{"Date":"Feb. 27, 2019 at 12:08 p.m. ET","Headline":"Charting a garden-variety pullback, Nasdaq nails major support (7,486)","Summary":""},{"Date":"Feb. 26, 2019 at 12:46 p.m. ET","Headline":"Charting a V-shaped reversal, S&P 500 hesitates at major resistance","Summary":""},{"Date":"Feb. 26, 2019 at 12:17 p.m. ET","Headline":"Charting a V-shaped reversal, S&P 500 hesitates at major resistance","Summary":""},{"Date":"Mar. 1, 2019 at 11:24 a.m. ET","Headline":"S&P 500 rallies toward major resistance, pulling-teeth retest underway","Summary":""},{"Date":"Feb. 28, 2019 at 11:58 a.m. ET","Headline":"Bull trend pauses:  Nasdaq, Dow industrials maintain major support","Summary":""},{"Date":"Mar. 5, 2019 at 12:59 p.m. ET","Headline":"Charting a bull-trend pullback:  S&P 500 absorbs March shot across the bow","Summary":"Eli Lilly & Co.  said Monday it will introduce a generic version of Humalog insulin in the U.S., at a price that's half the current list price. The lower priced version, called insulin Lispro, has the same molecule as Huma..."},{"Date":"Mar. 5, 2019 at 12:27 p.m. ET","Headline":"Charting a bull-trend pullback:  S&P 500 weathers March shot across the bow","Summary":"Eli Lilly & Co.  said Monday it will introduce a generic version of Humalog insulin in the U.S., at a price that's half the current list price. The lower priced version, called insulin Lispro, has the same molecule as Huma..."},{"Date":"Mar. 5, 2019 at 7:11 a.m. ET","Headline":"Eli Lilly will offer a half-off version of its popular insulin drug Humalog","Summary":"Eli Lilly & Co.  said Monday it will introduce a generic version of Humalog insulin in the U.S., at a price that's half the current list price. The lower priced version, called insulin Lispro, has the same molecule as Huma..."},{"Date":"Mar. 4, 2019 at 12:50 p.m. ET","Headline":"Eli Lilly Is Cutting the Price of a Key Drug By 50%","Summary":"Eli Lilly & Co.  said Monday it will introduce a generic version of Humalog insulin in the U.S., at a price that's half the current list price. The lower priced version, called insulin Lispro, has the same molecule as Huma..."},{"Date":"Mar. 4, 2019 at 11:43 a.m. ET","Headline":"S&P 500 nails the range top (2,817), modest selling pressure resurfaces","Summary":"Eli Lilly & Co.  said Monday it will introduce a generic version of Humalog insulin in the U.S., at a price that's half the current list price. The lower priced version, called insulin Lispro, has the same molecule as Huma..."},{"Date":"Mar. 4, 2019 at 6:54 a.m. ET","Headline":"Eli Lilly to make generic insulin available at half of Humalog's current price","Summary":"Eli Lilly & Co.  said Monday it will introduce a generic version of Humalog insulin in the U.S., at a price that's half the current list price. The lower priced version, called insulin Lispro, has the same molecule as Huma..."},{"Date":"Mar. 7, 2019 at 11:59 a.m. ET","Headline":"S&P 500 ventures under 200-day average, pulls in to nail major support (2,742)","Summary":""},{"Date":"Mar. 6, 2019 at 12:08 p.m. ET","Headline":"Bull-bear stalemate persists, S&P 500 extends pullback from major resistance","Summary":""},{"Date":"Mar. 9, 2019 at 7:09 a.m. ET","Headline":"The best strategy to recover from a stock-market bottom is one you already know","Summary":""},{"Date":"Mar. 8, 2019 at 12:16 p.m. ET","Headline":"Charting near-term technical damage:  S&P 500 and Nasdaq violate 200-day average","Summary":""},{"Date":"Mar. 11, 2019 at 12:04 p.m. ET","Headline":"S&P 500 pulls rabbit from hat, rallies after barely holding major support (2,742)","Summary":""},{"Date":"Mar. 13, 2019 at 11:30 a.m. ET","Headline":"Charting a headline breakout attempt, S&P 500 challenges major resistance (2,817)","Summary":""},{"Date":"Mar. 12, 2019 at 12:52 p.m. ET","Headline":"Charting a bullish reversal, S&P 500 spikes from major support (2,742)","Summary":""},{"Date":"Mar. 12, 2019 at 12:49 p.m. ET","Headline":"Prescription drug prices aren\u2019t rising \u2014 they\u2019re falling for the first time in 47 years","Summary":""},{"Date":"Mar. 12, 2019 at 12:16 p.m. ET","Headline":"Charting a bullish reversal, S&P 500 spikes from major support (2,742)","Summary":""},{"Date":"Mar. 12, 2019 at 7:53 a.m. ET","Headline":"Here are Monday\u2019s stock-market winners after five-day losing streak is broken","Summary":""},{"Date":"Mar. 15, 2019 at 11:30 a.m. ET","Headline":"S&P 500 nails the range top, Nasdaq ventures atop major resistance (7,670)","Summary":""},{"Date":"Mar. 14, 2019 at 11:59 a.m. ET","Headline":"Charting an extended breakout attempt, S&P 500 nails resistance amid Boeing headwind","Summary":""},{"Date":"Mar. 19, 2019 at 12:36 p.m. ET","Headline":"Charting a break to \u2018clear skies\u2019 territory:  S&P 500, Nasdaq reclaim major resistance","Summary":""},{"Date":"Mar. 19, 2019 at 12:07 p.m. ET","Headline":"Charting a break to \u2018clear skies\u2019 territory:  S&P 500, Nasdaq reclaim major resistance","Summary":""},{"Date":"Mar. 18, 2019 at 11:43 a.m. ET","Headline":"Slow-motion breakout underway:  S&P 500, Nasdaq venture atop major resistance","Summary":""},{"Date":"Mar. 21, 2019 at 11:59 a.m. ET","Headline":"S&P 500, Nasdaq nail the breakout point, sustain break to \u2018clear skies\u2019 territory","Summary":""},{"Date":"Mar. 20, 2019 at 4:32 p.m. ET","Headline":"Eli Lilly Stock Is Up Because UBS Sees Reasons to Be Bullish","Summary":""},{"Date":"Mar. 20, 2019 at 11:36 a.m. ET","Headline":"S&P 500 pulls in to the breakout point (2,817) ahead of the Fed","Summary":""},{"Date":"Mar. 22, 2019 at 11:56 a.m. ET","Headline":"Market bears resurface:  S&P 500, Nasdaq venture under major support","Summary":""},{"Date":"Mar. 25, 2019 at 12:17 p.m. ET","Headline":"Charting a 7-to-1 down day:  S&P 500 ventures under support amid yield-curve headwind","Summary":""},{"Date":"Mar. 27, 2019 at 11:48 a.m. ET","Headline":"Charting a bull-bear stalemate:  S&P 500 whipsaws at the breakout point","Summary":""},{"Date":"Mar. 26, 2019 at 1:37 p.m. ET","Headline":"Wall Street is ditching amyloid-based Alzheimer\u2019s drugs \u2014 it shouldn't, scientists say","Summary":""},{"Date":"Mar. 26, 2019 at 12:40 p.m. ET","Headline":"Bull trend survives shot across bow, S&P 500 narrowly holds major support","Summary":""},{"Date":"Mar. 26, 2019 at 12:03 p.m. ET","Headline":"Bull trend survives shot across bow, S&P 500 narrowly holds major support","Summary":""},{"Date":"Mar. 29, 2019 at 3:23 p.m. ET","Headline":"Wall Street is buzzing about Gilead\u2019s rheumatoid arthritis drug. Here\u2019s why","Summary":""},{"Date":"Mar. 29, 2019 at 11:36 a.m. ET","Headline":"Closing the first quarter on a bullish note, S&P 500 rallies from the breakout point","Summary":""},{"Date":"Mar. 28, 2019 at 11:53 a.m. ET","Headline":"Bull-bear stalemate persists:  S&P 500, Nasdaq press major support","Summary":""},{"Date":"Mar. 29, 2019 at 8:34 p.m. ET","Headline":"There Are Animal Spirits in This Health-Care Business","Summary":""},{"Date":"Apr. 2, 2019 at 12:38 p.m. ET","Headline":"Charting a bullish second-quarter start, S&P 500 nails major resistance (2,873)","Summary":""},{"Date":"Apr. 2, 2019 at 12:07 p.m. ET","Headline":"Charting a bullish second-quarter start, S&P 500 nails major resistance (2,873)","Summary":""},{"Date":"Apr. 1, 2019 at 11:45 a.m. ET","Headline":"S&P 500 spikes from the breakout point, rises to challenge next resistance (2,860)","Summary":""},{"Date":"Apr. 4, 2019 at 11:48 a.m. ET","Headline":"Charting a belated breakout attempt, Dow industrials clear five-month range top","Summary":""},{"Date":"Apr. 3, 2019 at 11:42 a.m. ET","Headline":"Bull trend strengthens:  S&P 500, Nasdaq extend April breakout","Summary":""},{"Date":"Apr. 5, 2019 at 11:47 a.m. ET","Headline":"Charting the escape from mini-crash territory:  S&P 500 approaches 2,900 mark","Summary":""},{"Date":"Apr. 8, 2019 at 11:32 a.m. ET","Headline":"Bull trend pauses, S&P 500 digests decisive April breakout","Summary":""},{"Date":"Apr. 8, 2019 at 7:48 a.m. ET","Headline":"Lawsuit over migraine deal could be good for Amgen, analysts say","Summary":""},{"Date":"Apr. 10, 2019 at 11:22 a.m. ET","Headline":"Charting a garden-variety pullback, S&P 500 nails first support (2,873)","Summary":""},{"Date":"Apr. 9, 2019 at 12:28 p.m. ET","Headline":"Charting the S&P 500\u2019s approach of the 2,900 mark","Summary":""},{"Date":"Apr. 9, 2019 at 12:00 p.m. ET","Headline":"Charting the S&P 500\u2019s approach of the 2,900 mark","Summary":""},{"Date":"Apr. 12, 2019 at 11:38 a.m. ET","Headline":"S&P 500 extends April breakout, Nasdaq approaches 8,000 mark","Summary":""},{"Date":"Apr. 11, 2019 at 11:57 a.m. ET","Headline":"The Dow Loses 56 Points Because Trade Talk Isn\u2019t a Trade Deal","Summary":""},{"Date":"Apr. 11, 2019 at 11:38 a.m. ET","Headline":"Charting a bull flag, S&P 500 digests rally to six-month highs","Summary":""},{"Date":"Apr. 11, 2019 at 11:13 a.m. ET","Headline":"Eli Lilly Stock Was Downgraded Because Everyone Already Knows It\u2019s Good","Summary":""},{"Date":"Apr. 16, 2019 at 12:38 p.m. ET","Headline":"Charting the S&P 500\u2019s slow-motion approach of record territory","Summary":""},{"Date":"Apr. 16, 2019 at 11:58 a.m. ET","Headline":"Charting the S&P 500\u2019s slow-motion approach of record territory","Summary":""},{"Date":"Apr. 15, 2019 at 11:37 a.m. ET","Headline":"Charting a bull-flag breakout, S&P 500 (almost) tags next target","Summary":""},{"Date":"Apr. 18, 2019 at 6:37 p.m. ET","Headline":"Pfizer, Lilly shares decline as osteoarthritis drug misses goals in study","Summary":"Shares of drug makers Pfizer Inc.  and Eli Lilly & Co.  declined in the extended session Thursday after the companies said a clinical study of an osteoarthritis drug didn't meet certain goals. Pfizer shares declined 1% aft..."},{"Date":"Apr. 22, 2019 at 8:00 a.m. ET","Headline":"Eli Lilly stock down 3.4% despite positive Phase 3 findings for Taltz","Summary":"Shares of Eli Lilly and Co.  were down 3.4% in premarket trade Monday despite the company's announcement that a Phase 3 study of its drug Taltz had met both primary and secondary endpoints in treating a subset of patients ..."},{"Date":"Apr. 25, 2019 at 7:19 a.m. ET","Headline":"Eli Lilly's Lartruvo is being pulled from the market, but patients who are already taking the drug will still have access under new program","Summary":"Eli Lilly and Co.  said Thursday it is working with doctors to ensure patients who are currently receiving Lartruvo, a soft-tissue sarcoma therapy being pulled from the market following the failure of a late-stage trial, w..."},{"Date":"Apr. 30, 2019 at 4:22 p.m. ET","Headline":"S&P 500 ekes out third straight record close; Nasdaq retreats after Google revenue miss","Summary":"Shares of Eli Lilly & Co.  dropped 3.0% in premarket trade Tuesday, after the drug giant reported first-quarter earnings that topped expectations, but revenue that missed, as key drugs Trulicity and Alimta fell short of fo..."},{"Date":"Apr. 30, 2019 at 12:00 p.m. ET","Headline":"The Dow Loses 33 Points and Google\u2019s \u2018Shocking\u2019 Sales Miss Drags Down the Nasdaq","Summary":"Shares of Eli Lilly & Co.  dropped 3.0% in premarket trade Tuesday, after the drug giant reported first-quarter earnings that topped expectations, but revenue that missed, as key drugs Trulicity and Alimta fell short of fo..."},{"Date":"Apr. 30, 2019 at 10:20 a.m. ET","Headline":"Merck and Pfizer Stock Rise but Eli Lilly Slips as Big Pharma Earnings Roll in","Summary":"Shares of Eli Lilly & Co.  dropped 3.0% in premarket trade Tuesday, after the drug giant reported first-quarter earnings that topped expectations, but revenue that missed, as key drugs Trulicity and Alimta fell short of fo..."},{"Date":"Apr. 30, 2019 at 9:52 a.m. ET","Headline":"Fed and tech stocks could crack the market rally, warns Wall Street strategist","Summary":"Shares of Eli Lilly & Co.  dropped 3.0% in premarket trade Tuesday, after the drug giant reported first-quarter earnings that topped expectations, but revenue that missed, as key drugs Trulicity and Alimta fell short of fo..."},{"Date":"Apr. 30, 2019 at 6:59 a.m. ET","Headline":"Eli Lilly's stock sinks after earnings beat but revenue comes up short, hurt by Trulicity and Alimta misses","Summary":"Shares of Eli Lilly & Co.  dropped 3.0% in premarket trade Tuesday, after the drug giant reported first-quarter earnings that topped expectations, but revenue that missed, as key drugs Trulicity and Alimta fell short of fo..."},{"Date":"Apr. 30, 2019 at 5:32 a.m. ET","Headline":"Today Is Earnings Day for Big Pharma. Here\u2019s What to Watch.","Summary":""},{"Date":"Apr. 29, 2019 at 4:45 p.m. ET","Headline":"Insulin-maker Eli Lilly is scheduled to report earnings Tuesday. Here\u2019s what to expect","Summary":""},{"Date":"Apr. 29, 2019 at 1:42 p.m. ET","Headline":"Beaten-down health-care companies join Apple and Google in earnings parade","Summary":""},{"Date":"Apr. 29, 2019 at 1:41 p.m. ET","Headline":"Merck is reporting earnings on Tuesday. Here\u2019s what to expect","Summary":""},{"Date":"Apr. 29, 2019 at 6:35 a.m. ET","Headline":"Apple, Google, GE, and More Stocks to Watch This Week","Summary":""},{"Date":"May. 1, 2019 at 7:29 a.m. ET","Headline":"Eli Lilly misses on revenue in face of pricing pressures and growing generic competition","Summary":""},{"Date":"May. 3, 2019 at 5:57 p.m. ET","Headline":"Beyond Meat Is Now Worth More Than All the Peas in America","Summary":""},{"Date":"May. 6, 2019 at 6:23 a.m. ET","Headline":"Disney, Electronic Arts, and More Stocks to Watch This Week","Summary":""},{"Date":"May. 7, 2019 at 4:15 p.m. ET","Headline":"Allergan stock slips despite revenue beat, a sign of investors\u2019 worries over company\u2019s future","Summary":""},{"Date":"May. 13, 2019 at 2:29 p.m. ET","Headline":"Most of the profit in the health-care industry is going to drug companies \u2014 here\u2019s why you should care","Summary":""},{"Date":"May. 22, 2019 at 6:53 a.m. ET","Headline":"Eli Lilly's Insulin Lispro Injection available at half the list price of Humalog","Summary":"Eli Lilly & Co.  said its lower-priced Insulin Lispro Injection is now available for order in pharmacies, per vial or in a package of five KwikPens. The drug giant said Lispro Injection's list price is 50% lower than its i..."},{"Date":"May. 30, 2019 at 10:31 a.m. ET","Headline":"Will drug prices in TV ads really be transparent?","Summary":""},{"Date":"May. 29, 2019 at 9:52 a.m. ET","Headline":"Pro-choice groups lost in Alabama despite outspending the pro-life side by 100-to-1","Summary":""},{"Date":"May. 29, 2019 at 7:45 a.m. ET","Headline":"Pfizer, Eli Lilly, Bristol-Myer and J&J initiated with buy ratings by Goldman Sachs","Summary":""},{"Date":"Jun. 5, 2019 at 6:39 a.m. ET","Headline":"Eli Lilly's Emgality gets FDA approval for episodic cluster headaches","Summary":"Eli Lilly & Co.  said Wednesday Emgality injection was approved by the U.S. Food and Drug Administration for the treatment of episodic cluster headache in adults. Lilly said Emgality is the first and only treatment that re..."},{"Date":"Jun. 5, 2019 at 4:11 a.m. ET","Headline":"JAMA study: The cost of brand-name prescription drugs doubles every 7 to 8 years","Summary":""},{"Date":"Jun. 7, 2019 at 10:18 p.m. ET","Headline":"The \u2018Dividend Aristocrats\u2019 Stocks Are Shrugging Off Market Volatility","Summary":""},{"Date":"Jun. 10, 2019 at 11:55 a.m. ET","Headline":"The Dow Is Up Because There Won\u2019t Be a Trade War With Mexico","Summary":"Shares of Eli Lilly & Co.  fell 2.4% in premarket trade on Monday after a randomized control trial showed that diabetes drug Trulicity lowered the risk of major cardiovascular events in patients with type 2 diabetes by 12%..."},{"Date":"Jun. 10, 2019 at 10:48 a.m. ET","Headline":"H&R Block, Lululemon, Broadcom and More Stocks to Watch This Week","Summary":"Shares of Eli Lilly & Co.  fell 2.4% in premarket trade on Monday after a randomized control trial showed that diabetes drug Trulicity lowered the risk of major cardiovascular events in patients with type 2 diabetes by 12%..."},{"Date":"Jun. 10, 2019 at 9:13 a.m. ET","Headline":"Eli Lilly stock down 2.4% after Trulicity trial misses investors' expectations","Summary":"Shares of Eli Lilly & Co.  fell 2.4% in premarket trade on Monday after a randomized control trial showed that diabetes drug Trulicity lowered the risk of major cardiovascular events in patients with type 2 diabetes by 12%..."},{"Date":"Jun. 10, 2019 at 9:06 a.m. ET","Headline":"Eli Lilly Stock Is Falling and Novo Nordisk Is Rising on Diabetes-Drug Results","Summary":""},{"Date":"Jun. 13, 2019 at 4:12 p.m. ET","Headline":"Amgen, Biogen, Gilead and Novo Nordisk have \u2018very high\u2019 capacity for M&A, says Moody\u2019s","Summary":""},{"Date":"Jun. 14, 2019 at 6:11 p.m. ET","Headline":"Drugmakers file lawsuit to block rule requiring drug prices in TV ads","Summary":""},{"Date":"Jun. 17, 2019 at 3:20 p.m. ET","Headline":"Pfizer Is the Latest Drug Company to Put Its Credit Rating at Risk With M&A","Summary":""},{"Date":"Jun. 19, 2019 at 10:58 a.m. ET","Headline":"Allergan Stock Is Moving Up on Expectations of a Breakup","Summary":""},{"Date":"Jun. 18, 2019 at 7:09 a.m. ET","Headline":"Shares of cancer-therapy companies skyrocket after Pfizer acquisition news","Summary":""},{"Date":"Jun. 25, 2019 at 12:03 p.m. ET","Headline":"AbbVie Is Buying Allergan. Wall Street Has Doubts.","Summary":""},{"Date":"Jun. 26, 2019 at 7:37 a.m. ET","Headline":"Allergan acquisition is \u2018a major bailout\u2019 for shareholders, according to analysts","Summary":""},{"Date":"Jul. 5, 2019 at 8:53 p.m. ET","Headline":"The Stock Market May Be Pointing to Trump\u2019s Reelection","Summary":""},{"Date":"Jul. 9, 2019 at 11:15 a.m. ET","Headline":"Merck, Amgen, and Eli Lilly Get a Drug Pricing Win in Court","Summary":""},{"Date":"Jul. 11, 2019 at 1:35 p.m. ET","Headline":"Drug Stocks Are Falling Because Trump\u2019s Next Move on Pricing Could Be Trouble","Summary":""},{"Date":"Jul. 11, 2019 at 1:02 p.m. ET","Headline":"Weight Watchers Stock Is Soaring and the Dow Is Jumping","Summary":""},{"Date":"Jul. 11, 2019 at 10:42 a.m. ET","Headline":"Stocks of drug distributors and PBM-owners surge after Trump administration pulls rebate proposal","Summary":""},{"Date":"Jul. 12, 2019 at 9:11 p.m. ET","Headline":"The Economic Opportunity Washington Is Missing Right Now, According to Goldman Sachs\u2019 Abby Joseph Cohen","Summary":""},{"Date":"Jul. 12, 2019 at 9:04 p.m. ET","Headline":"2019 Midyear Roundtable: Where to Find Value Now","Summary":""},{"Date":"Jul. 26, 2019 at 10:56 p.m. ET","Headline":"Earnings Season So Far: Revenue Beats Meet Low Expectations","Summary":""},{"Date":"Jul. 29, 2019 at 8:14 a.m. ET","Headline":"The earnings menu: Beyond Meat, Apple and a big bag of chips","Summary":"3 numbers to help you navigate the market\u2014in just two minutes."},{"Date":"Jul. 29, 2019 at 6:00 a.m. ET","Headline":"Podcast: Beyond Meat\u2019s 720% Jump, and Two More Numbers to Know","Summary":"3 numbers to help you navigate the market\u2014in just two minutes."},{"Date":"Jul. 28, 2019 at 3:00 p.m. ET","Headline":"Apple, GE, Qualcomm and More Stocks to Watch This Week","Summary":""},{"Date":"Jul. 30, 2019 at 4:28 p.m. ET","Headline":"Stocks end lower as China trade deal hopes wane and corporate earnings come in mixed","Summary":"Shares of Eli Lilly & Co.  rallied 1.5% in premarket trading Tuesday, after the drug maker reported a second-quarter profit and revenue that beat expectations and raised its full-year outlook. Net income was $1.33 billion,..."},{"Date":"Jul. 30, 2019 at 1:52 p.m. ET","Headline":"Gilead and Amgen will report second-quarter earnings after the closing bell. Here\u2019s what to expect","Summary":"Shares of Eli Lilly & Co.  rallied 1.5% in premarket trading Tuesday, after the drug maker reported a second-quarter profit and revenue that beat expectations and raised its full-year outlook. Net income was $1.33 billion,..."},{"Date":"Jul. 30, 2019 at 9:44 a.m. ET","Headline":"There\u2019s a generational shift in the Fed\u2019s thinking, and here\u2019s what it means for stocks","Summary":"Shares of Eli Lilly & Co.  rallied 1.5% in premarket trading Tuesday, after the drug maker reported a second-quarter profit and revenue that beat expectations and raised its full-year outlook. Net income was $1.33 billion,..."},{"Date":"Jul. 30, 2019 at 9:06 a.m. ET","Headline":"Eli Lilly Stock Is Up as Earnings Edge Past Expectations","Summary":"Shares of Eli Lilly & Co.  rallied 1.5% in premarket trading Tuesday, after the drug maker reported a second-quarter profit and revenue that beat expectations and raised its full-year outlook. Net income was $1.33 billion,..."},{"Date":"Jul. 30, 2019 at 6:42 a.m. ET","Headline":"Eli Lilly's stock jumps after profit and revenue beats, raised guidance","Summary":"Shares of Eli Lilly & Co.  rallied 1.5% in premarket trading Tuesday, after the drug maker reported a second-quarter profit and revenue that beat expectations and raised its full-year outlook. Net income was $1.33 billion,..."},{"Date":"Aug. 13, 2019 at 8:48 a.m. ET","Headline":"Elanco Stock Jumps Because There\u2019s No Sign of Bayer Merger Yet","Summary":""},{"Date":"Aug. 20, 2019 at 10:59 a.m. ET","Headline":"Elanco Stock Tumbles After It Announces a Deal to Acquire Bayer\u2019s Animal-Health Business","Summary":""},{"Date":"Aug. 30, 2019 at 8:45 p.m. ET","Headline":"A Reckoning for Buybacks","Summary":""},{"Date":"Sep. 9, 2019 at 10:09 a.m. ET","Headline":"Eli Lilly Stock Shrugs Off Upbeat Drug Data","Summary":""},{"Date":"Sep. 19, 2019 at 9:10 a.m. ET","Headline":"Pfizer Is Spinning Off Upjohn. What\u2019s Left Will Be No Bargain, Analyst Says","Summary":""},{"Date":"Sep. 27, 2019 at 8:47 p.m. ET","Headline":"Buckle Up, Tesla Stockholders","Summary":""},{"Date":"Sep. 26, 2019 at 8:59 a.m. ET","Headline":"Five points every investor ought to consider about the Trump impeachment inquiry","Summary":""},{"Date":"Sep. 26, 2019 at 8:45 a.m. ET","Headline":"AbbVie Is Up After Another Analyst Reconsidered Its Allergan Acquisition and Upgraded the Stock","Summary":""},{"Date":"Sep. 29, 2019 at 3:00 p.m. ET","Headline":"McCormick, Costco, PepsiCo, and Other Stocks for Investors to Watch This Week","Summary":""},{"Date":"Sep. 30, 2019 at 4:51 p.m. ET","Headline":"Elanco announces layoff of 250 workers","Summary":"Elanco Animal Health Inc. , which  a year ago, on Monday said it plans to lay off 250 workers to save $12 million in 2020. The Greenfield, Ind.-based company previously announced job cuts and a $37 million restructuring ch..."},{"Date":"Sep. 30, 2019 at 2:07 p.m. ET","Headline":"Seattle Genetics, Merck, Bristol-Myers Unveil Upbeat Treatment Data at Cancer Conference","Summary":""},{"Date":"Sep. 30, 2019 at 6:00 a.m. ET","Headline":"The 3 Best Health-Care Stocks This Month. And the Worst","Summary":""},{"Date":"Sep. 26, 2019 at 10:46 a.m. ET","Headline":"A Big Cancer Conference Starts Tomorrow. Here\u2019s What It Means for Merck, Bristol-Myers and Other Drug Stocks.","Summary":""},{"Date":"Oct. 3, 2019 at 9:37 a.m. ET","Headline":"Eli Lilly to voluntarily delist from Euronext Paris exchange","Summary":"Eli Lilly and Co.  said Thursday it is voluntarily delisting from the Euronext Paris exchange, citing low trading volume, costs and administrative requirements. The stock will continue to trade on the New York Stock Exchan..."},{"Date":"Oct. 1, 2019 at 1:43 p.m. ET","Headline":"Biotech Roundtable: How to Invest in Medicine\u2019s Future","Summary":""},{"Date":"Oct. 14, 2019 at 9:03 a.m. ET","Headline":"Eli Lilly Stock Gets 2 Pieces of Good News","Summary":""},{"Date":"Oct. 17, 2019 at 10:41 a.m. ET","Headline":"4 Biotech Stocks That Are Set to Rally, Analyst Says","Summary":"Eli Lilly and Co.  said Wednesday a late-stage trail of a treatment for pancreatic cancer did not meet its main goal of overall survival. The company said detailed results of the phase 3 trial called Sequoia evaluating peg..."},{"Date":"Oct. 16, 2019 at 8:34 a.m. ET","Headline":"U.S. Stocks Set to Fall on Renewed China Concerns","Summary":"Eli Lilly and Co.  said Wednesday a late-stage trail of a treatment for pancreatic cancer did not meet its main goal of overall survival. The company said detailed results of the phase 3 trial called Sequoia evaluating peg..."},{"Date":"Oct. 16, 2019 at 6:57 a.m. ET","Headline":"Eli Lilly says late-stage trial of pancreatic cancer treatment failed to meet its main goal of overall survival","Summary":"Eli Lilly and Co.  said Wednesday a late-stage trail of a treatment for pancreatic cancer did not meet its main goal of overall survival. The company said detailed results of the phase 3 trial called Sequoia evaluating peg..."},{"Date":"Oct. 18, 2019 at 8:00 p.m. ET","Headline":"SmileDirectClub Is Battling With Dentists. Investors Are Caught in the Middle.","Summary":""},{"Date":"Oct. 23, 2019 at 1:02 p.m. ET","Headline":"Boeing, Caterpillar report disappointing earnings, but their shares bounce back","Summary":"Eli Lilly & Co.  said Wednesday it had net income of $1.254 billion, or $1.37 a share, in the third quarter, up from $1.149 billion, or $1.12 a share, in the year-earlier period. Adjusted per-share earnings came to $1.48, ..."},{"Date":"Oct. 23, 2019 at 8:37 a.m. ET","Headline":"Eli Lilly Earned More Than Expected. Here\u2019s Why the Stock Is Falling Anyway.","Summary":"Eli Lilly & Co.  said Wednesday it had net income of $1.254 billion, or $1.37 a share, in the third quarter, up from $1.149 billion, or $1.12 a share, in the year-earlier period. Adjusted per-share earnings came to $1.48, ..."},{"Date":"Oct. 23, 2019 at 6:58 a.m. ET","Headline":"Eli Lilly tops profit estimates in latest quarter as revenue falls short","Summary":"Eli Lilly & Co.  said Wednesday it had net income of $1.254 billion, or $1.37 a share, in the third quarter, up from $1.149 billion, or $1.12 a share, in the year-earlier period. Adjusted per-share earnings came to $1.48, ..."},{"Date":"Oct. 22, 2019 at 6:00 a.m. ET","Headline":"Eli Lilly Reports Earnings Tomorrow. Here\u2019s What to Expect.","Summary":""},{"Date":"Oct. 20, 2019 at 3:00 p.m. ET","Headline":"Chipotle, Microsoft, Caterpillar, and Other Stocks for Investors to Watch This Week","Summary":""},{"Date":"Oct. 28, 2019 at 2:26 p.m. ET","Headline":"China could quickly become the world\u2019s largest antidepressant market, but hurdles remain","Summary":""},{"Date":"Oct. 28, 2019 at 7:00 a.m. ET","Headline":"5 Dividend Stocks to Buy Even Though Investing Pros Are Really Gloomy","Summary":""},{"Date":"Nov. 3, 2019 at 7:30 a.m. ET","Headline":"Eli Lilly CEO David Ricks and Other Insiders Are Buying the Slumping Stock","Summary":""},{"Date":"Nov. 20, 2019 at 7:09 a.m. ET","Headline":"Eli Lilly to create 100 jobs in Indianapolis as it adds capacity to its technology center campus","Summary":"Eli Lilly & Co.  said Wednesday that it will create 100 new jobs in Indianapolis as it invests $400 million in its manufacturing facilities at its Lilly Technology Center campus. The drug maker said its plans are a result ..."},{"Date":"Nov. 29, 2019 at 12:27 p.m. ET","Headline":"The 10 most FIRE-friendly places to live if you want to retire early","Summary":""},{"Date":"Nov. 23, 2019 at 3:41 p.m. ET","Headline":"Pfizer Is the Dow\u2019s Worst Stock. A New Strategy Makes It Worth Another Look.","Summary":""},{"Date":"Dec. 6, 2019 at 1:53 p.m. ET","Headline":"Citigroup and 23 More Dividend Stocks That Offer Shelter in Today\u2019s Economy","Summary":""},{"Date":"Dec. 5, 2019 at 2:19 p.m. ET","Headline":"Biogen stock climbs as investors shrug off analyst skepticism about Alzheimer\u2019s drug","Summary":""},{"Date":"Dec. 9, 2019 at 4:44 p.m. ET","Headline":"Sanofi\u2019s New CEO Is Aiming for a Narrower Focus in Drug Development","Summary":""},{"Date":"Dec. 12, 2019 at 9:04 a.m. ET","Headline":"Big Pharma\u2019s Coming Back in 2020. Don\u2019t Hold Your Breath for Generic Drug Stocks","Summary":""},{"Date":"Dec. 13, 2019 at 8:05 p.m. ET","Headline":"Canada Turns to Cannabis 2.0: Edibles, Drinks, and Vapes","Summary":""},{"Date":"Dec. 16, 2019 at 4:57 p.m. ET","Headline":"Lilly board hikes dividend by 15%","Summary":"Eli Lilly & Co.  said late Monday that its board approved a 15% hike to the company's quarterly dividend. Lilly said it will pay a dividend of 74 cents a share, up from 64.5 cents a share, on March 10, 2020 to shareholders..."},{"Date":"Dec. 15, 2019 at 3:00 p.m. ET","Headline":"Nike, FedEx,\u00a0Micron and Other Stocks for Investors to Watch This Week","Summary":""},{"Date":"Dec. 18, 2019 at 11:34 a.m. ET","Headline":"Pharmaceutical Stocks Had a Rough Year. Here\u2019s Why 2020 Could Be Better.","Summary":"Shares of Eli Lilly & Co.  were indicated up nearly 1% in premarket trading Tuesday, after the drug maker provided an upbeat financial outlook for next year. The company said it expects 2020 net earnings per share of $6.38..."},{"Date":"Dec. 17, 2019 at 4:47 p.m. ET","Headline":"S&P 500, Dow and Nasdaq score fresh records at close","Summary":"Shares of Eli Lilly & Co.  were indicated up nearly 1% in premarket trading Tuesday, after the drug maker provided an upbeat financial outlook for next year. The company said it expects 2020 net earnings per share of $6.38..."},{"Date":"Dec. 17, 2019 at 1:10 p.m. ET","Headline":"The Dow Is Up, and Stocks Are on Track for 5 Straight Days of Gains","Summary":"Shares of Eli Lilly & Co.  were indicated up nearly 1% in premarket trading Tuesday, after the drug maker provided an upbeat financial outlook for next year. The company said it expects 2020 net earnings per share of $6.38..."},{"Date":"Dec. 17, 2019 at 8:28 a.m. ET","Headline":"Eli Lilly Stock Is Rising After It Delivered More Good News","Summary":"Shares of Eli Lilly & Co.  were indicated up nearly 1% in premarket trading Tuesday, after the drug maker provided an upbeat financial outlook for next year. The company said it expects 2020 net earnings per share of $6.38..."},{"Date":"Dec. 17, 2019 at 6:47 a.m. ET","Headline":"Eli Lilly's stock set to rally after upbeat profit, revenue guidance","Summary":"Shares of Eli Lilly & Co.  were indicated up nearly 1% in premarket trading Tuesday, after the drug maker provided an upbeat financial outlook for next year. The company said it expects 2020 net earnings per share of $6.38..."},{"Date":"Dec. 20, 2019 at 8:17 p.m. ET","Headline":"Research Reports","Summary":""},{"Date":"Dec. 23, 2019 at 3:05 p.m. ET","Headline":"Allergan's migraine drug approved by FDA","Summary":"Shares of Allergan  gained 0.5% after the Food and Drug Administration approved Ubrelvy, its migraine treatment. In two late-stage clinical trials, more patients who were taking the experimental therapy reported the pain e..."},{"Date":"Dec. 26, 2019 at 5:00 a.m. ET","Headline":"Pharma Companies Are Rushing to Treat a Little-Known Liver Disease. Investors Should Be Skeptical.","Summary":""},{"Date":"Dec. 27, 2019 at 5:30 a.m. ET","Headline":"The Biotech Sector Is Roaring Into 2020. Here\u2019s Why.","Summary":""},{"Date":"Jan. 7, 2020 at 3:18 p.m. ET","Headline":"Facing criticism over insulin prices, drugmakers launch affordability options","Summary":""},{"Date":"Jan. 7, 2020 at 9:17 a.m. ET","Headline":"It\u2019s Time to Buy Bristol-Myers Stock, According to 1 Analyst. Here\u2019s Why.","Summary":""},{"Date":"Jan. 8, 2020 at 9:54 a.m. ET","Headline":"January Is Often a Big Month for Biotech Mergers and Acquisitions","Summary":""},{"Date":"Jan. 10, 2020 at 4:33 p.m. ET","Headline":"Eli Lilly Made a Deal for Dermira. The Biotech\u2019s Stock Price Shows Investors Expect More.","Summary":"Eli Lilly & Co.  announced Friday a deal to buy medical dermatology company Dermira Inc.  in a deal valued at $1.1 billion. Under terms of the deal, Lilly will pay $18.75 in cash for each Dermira share outstanding, a 2.2% ..."},{"Date":"Jan. 10, 2020 at 4:29 p.m. ET","Headline":"Stocks close lower after Dow briefly tops 29,000 milestone for first time","Summary":"Eli Lilly & Co.  announced Friday a deal to buy medical dermatology company Dermira Inc.  in a deal valued at $1.1 billion. Under terms of the deal, Lilly will pay $18.75 in cash for each Dermira share outstanding, a 2.2% ..."},{"Date":"Jan. 10, 2020 at 9:50 a.m. ET","Headline":"Lilly Says It\u2019s Buying a Biotech With a Dermatitis Drug. Investors Have Other Ideas.","Summary":"Eli Lilly & Co.  announced Friday a deal to buy medical dermatology company Dermira Inc.  in a deal valued at $1.1 billion. Under terms of the deal, Lilly will pay $18.75 in cash for each Dermira share outstanding, a 2.2% ..."},{"Date":"Jan. 10, 2020 at 6:42 a.m. ET","Headline":"Eli Lilly to buy Dermira in a deal valued at $1.1 billion","Summary":"Eli Lilly & Co.  announced Friday a deal to buy medical dermatology company Dermira Inc.  in a deal valued at $1.1 billion. Under terms of the deal, Lilly will pay $18.75 in cash for each Dermira share outstanding, a 2.2% ..."},{"Date":"Jan. 9, 2020 at 6:45 a.m. ET","Headline":"For Dividend Growth, Consider Health-Care and Tech Stocks","Summary":""},{"Date":"Jan. 15, 2020 at 10:24 a.m. ET","Headline":"Democrats Called for Cuts to Drug Prices at the Debate. The Pharma Industry Says It\u2019s Trying.","Summary":"Eli Lilly and Co.  said Tuesday it is planning to add two more cheaper versions of its insulin product Humalog starting in mid-April. The drug company said its Humalog Mix75\/25 KwikPen and Humalog Junior KwikPen will have ..."},{"Date":"Jan. 14, 2020 at 11:13 a.m. ET","Headline":"Big Merger Deals Are Missing at Health Conference. Here\u2019s Why.","Summary":"Eli Lilly and Co.  said Tuesday it is planning to add two more cheaper versions of its insulin product Humalog starting in mid-April. The drug company said its Humalog Mix75\/25 KwikPen and Humalog Junior KwikPen will have ..."},{"Date":"Jan. 14, 2020 at 7:01 a.m. ET","Headline":"Eli Lilly to make two more cheaper insulin products available from mid-April","Summary":"Eli Lilly and Co.  said Tuesday it is planning to add two more cheaper versions of its insulin product Humalog starting in mid-April. The drug company said its Humalog Mix75\/25 KwikPen and Humalog Junior KwikPen will have ..."},{"Date":"Jan. 17, 2020 at 11:51 a.m. ET","Headline":"Comcast announces Peacock streaming service with free, subscription options","Summary":""},{"Date":"Jan. 16, 2020 at 5:19 p.m. ET","Headline":"NBC Unveils Spending Plans and More for Its Peacock Streaming Service","Summary":""},{"Date":"Jan. 25, 2020 at 4:41 p.m. ET","Headline":"This basket of dividend growth stocks can help your portfolio stand out in 2020","Summary":""},{"Date":"Jan. 25, 2020 at 8:50 a.m. ET","Headline":"Value stocks are making a comeback, and here\u2019s how to get in early","Summary":""},{"Date":"Jan. 24, 2020 at 9:32 p.m. ET","Headline":"Grocer Albertsons Has Tried Twice to Go Public and Failed. Now It\u2019s Mulling a Third Try.","Summary":""},{"Date":"Jan. 27, 2020 at 4:35 p.m. ET","Headline":"Tesla, Apple, Boeing, Amazon, and Other Stocks for Investors to Watch This Week","Summary":""},{"Date":"Jan. 26, 2020 at 11:59 a.m. ET","Headline":"The Dow is about to face its stiffest test in years","Summary":""},{"Date":"Jan. 29, 2020 at 8:00 a.m. ET","Headline":"Eli Lilly Reports Earnings Tomorrow. Here\u2019s What to Expect.","Summary":""},{"Date":"Jan. 30, 2020 at 8:52 a.m. ET","Headline":"Eli Lilly Stock Is Climbing After a Glowing Earnings Report","Summary":"Shares of Eli Lilly & Co.  rose 1.3% in premarket trading Thursday, after the drug maker reported fourth-quarter earnings and revenue that rose above expectations. Net income grew to $1.50 billion, or $1.64 a share, from $..."},{"Date":"Jan. 30, 2020 at 6:38 a.m. ET","Headline":"Eli Lilly's stock gains after earnings, revenue rise above expectations","Summary":"Shares of Eli Lilly & Co.  rose 1.3% in premarket trading Thursday, after the drug maker reported fourth-quarter earnings and revenue that rose above expectations. Net income grew to $1.50 billion, or $1.64 a share, from $..."},{"Date":"Feb. 10, 2020 at 9:19 a.m. ET","Headline":"Lilly and Biogen Stocks Get Hit as Another Alzheimer\u2019s Treatment Fails a Trial","Summary":"Shares of Eli Lilly and Co.  fell 4% in premarket trading on Monday after solanezumab, the experimental therapy it was testing in people with a form of Alzheimer's disease caused by a rare gene mutation, failed in a Phase ..."},{"Date":"Feb. 10, 2020 at 8:01 a.m. ET","Headline":"Lilly's stock falls on failed Alzheimer's study","Summary":"Shares of Eli Lilly and Co.  fell 4% in premarket trading on Monday after solanezumab, the experimental therapy it was testing in people with a form of Alzheimer's disease caused by a rare gene mutation, failed in a Phase ..."},{"Date":"Feb. 10, 2020 at 7:45 a.m. ET","Headline":"Tesla Stock is Surging Again, Lilly Falls on Alzheimer\u2019s Results, and the Dow Is Flat","Summary":""},{"Date":"Feb. 11, 2020 at 7:15 a.m. ET","Headline":"Teva Reports Earnings Tomorrow. Here\u2019s What to Expect.","Summary":""},{"Date":"Feb. 14, 2020 at 4:23 p.m. ET","Headline":"When Dividend Aristocrats Lose Their Status, Their Returns Often Improve","Summary":""},{"Date":"Mar. 3, 2020 at 7:10 a.m. ET","Headline":"Eli Lilly says it does not expect any shortages of medicines, including insulin, due to coronavirus","Summary":"Eli Lilly and Co.  said Tuesday it does not expect any shortages of medicine, including insulin, as a result of the coronavirus. The company has been monitoring its supply chain for potential impact, and does not source ac..."},{"Date":"Mar. 2, 2020 at 10:32 a.m. ET","Headline":"There\u2019s no guarantee that a coronavirus vaccine will be affordable","Summary":""},{"Date":"Mar. 5, 2020 at 6:36 a.m. ET","Headline":"These stocks soared the most after Biden burned Bernie on Super Tuesday","Summary":""},{"Date":"Mar. 9, 2020 at 3:19 p.m. ET","Headline":"Eli Lilly and 2 More Drug Stocks That Could Ride Out the Coronavirus Crisis, According to J.P. Morgan","Summary":""},{"Date":"Mar. 9, 2020 at 2:48 p.m. ET","Headline":"Two Companies Are Making Progress on Coronavirus Treatments. The Stocks Aren\u2019t Responding.","Summary":""},{"Date":"Mar. 21, 2020 at 11:19 a.m. ET","Headline":"Market Experts Say the Coronavirus Selloff Is \u2018Worse Than Anything We\u2019ve Seen Since 1929.\u2019 Here\u2019s How Bad It Could Get.","Summary":""},{"Date":"Mar. 23, 2020 at 10:11 a.m. ET","Headline":"Lilly to halt enrollment in clinical trials as a result of COVID-19","Summary":"Shares of Eli Lilly and Co.  were down 2% in trading on Monday. The drugmaker has announced Monday morning that it will delay the start of most new clinical studies and is pausing enrollment of participants in ongoing tria..."},{"Date":"Mar. 22, 2020 at 10:15 a.m. ET","Headline":"What Apple, Microsoft, GE and other U.S. companies are saying about the coronavirus outbreak","Summary":""},{"Date":"Mar. 29, 2020 at 11:49 a.m. ET","Headline":"Drug makers on shaky ground as clinical trials are postponed and drug launches delayed amid pandemic","Summary":""},{"Date":"Mar. 27, 2020 at 11:00 a.m. ET","Headline":"Big Pharma and Biotech Need to Do More in the Fight Against Covid-19","Summary":""},{"Date":"Apr. 1, 2020 at 6:37 a.m. ET","Headline":"These 30 S&P 500 stocks actually rose during the disastrous first quarter","Summary":""},{"Date":"Apr. 6, 2020 at 7:00 a.m. ET","Headline":"Nike, Signet Jewelers See Significant Insider Stock Purchases","Summary":""},{"Date":"Apr. 5, 2020 at 4:56 p.m. ET","Headline":"U.K. Prime Minister Boris Johnson Admitted to Hospital with \u2018Persistent\u2019 Coronavirus Symptoms","Summary":""},{"Date":"Apr. 7, 2020 at 6:38 a.m. ET","Headline":"Eli Lilly offers new $35 co-pay insulin value program during coronavirus pandemic","Summary":"Eli Lilly & Co.  said Tuesday it is introducing a Lilly Insulin Value Pogram, allowing anyone with insurance and those without insurance to fill their monthly insulin prescription for $35. The program has been launched wit..."},{"Date":"Apr. 10, 2020 at 5:33 p.m. ET","Headline":"Eli Lilly to study use of arthritis drug to treat COVID-19","Summary":"Eli Lilly and Co.  said late Friday it has reached an agreement with the National Institutes of Health to study one of its drugs as a COVID-19 treatment. Baricitinib, marketed as Olumiant, is approved in more than 65 count..."},{"Date":"Apr. 13, 2020 at 3:34 p.m. ET","Headline":"Johnson & Johnson has coronavirus vaccine candidate in works, but medical devices are likely to take a hit","Summary":""},{"Date":"Apr. 13, 2020 at 1:04 p.m. ET","Headline":"Eli Lilly Arthritis Drug Will Be Tested in Seriously Ill Covid-19 Patients","Summary":""},{"Date":"Apr. 16, 2020 at 7:30 a.m. ET","Headline":"China\u2019s Small Companies Are Beating Almost Every Market. Here Are The Best Sectors.","Summary":""},{"Date":"Apr. 17, 2020 at 9:28 p.m. ET","Headline":"Big Steel Has Many Woes, And Only One Is Covid-19","Summary":""},{"Date":"Apr. 17, 2020 at 12:19 p.m. ET","Headline":"These experimental drugs may help keep COVID-19 patients off ventilators","Summary":""},{"Date":"Apr. 20, 2020 at 11:17 a.m. ET","Headline":"Alexion Will Test Rare Disease Drug in Covid-19 Patients","Summary":""},{"Date":"Apr. 19, 2020 at 3:00 p.m. ET","Headline":"Netflix, Delta, AT&T and Other Stocks for Investors to Watch This Week","Summary":""},{"Date":"Apr. 17, 2020 at 7:20 p.m. ET","Headline":"In a Pandemic, Pharma\u2019s Strengths Emerge: Pipelines With Essential Drugs","Summary":""},{"Date":"Apr. 22, 2020 at 6:30 a.m. ET","Headline":"Eli Lilly Reports Earnings Tomorrow. Here\u2019s What to Expect.","Summary":""},{"Date":"Apr. 21, 2020 at 11:35 a.m. ET","Headline":"Eli Lilly Stock Has Gone as High as It Can Go for Now, Analyst Says","Summary":""},{"Date":"Apr. 24, 2020 at 10:43 a.m. ET","Headline":"Biotech and Pharmaceutical Stocks Beat the Market in Recessions","Summary":"Shares of Eli Lilly & Co.  rallied 1.5% in premarket trading Thursday, after the drug maker reported better-than-expected first-quarter profit and revenue, and actually provided a full-year outlook, which was in line with ..."},{"Date":"Apr. 23, 2020 at 4:58 p.m. ET","Headline":"The Dow Rose 39 Points Because the Gilead Leak Left the Market Flat","Summary":"Shares of Eli Lilly & Co.  rallied 1.5% in premarket trading Thursday, after the drug maker reported better-than-expected first-quarter profit and revenue, and actually provided a full-year outlook, which was in line with ..."},{"Date":"Apr. 23, 2020 at 4:49 p.m. ET","Headline":"Stocks Give Up Gains After Negative Report on Coronavirus Drug","Summary":"Shares of Eli Lilly & Co.  rallied 1.5% in premarket trading Thursday, after the drug maker reported better-than-expected first-quarter profit and revenue, and actually provided a full-year outlook, which was in line with ..."},{"Date":"Apr. 23, 2020 at 4:27 p.m. ET","Headline":"Dow books meager gain as report on Gilead\u2019s experimental coronavirus drug quashes stock-market rally","Summary":"Shares of Eli Lilly & Co.  rallied 1.5% in premarket trading Thursday, after the drug maker reported better-than-expected first-quarter profit and revenue, and actually provided a full-year outlook, which was in line with ..."},{"Date":"Apr. 23, 2020 at 11:46 a.m. ET","Headline":"Intel and Citrix may benefit from coronavirus, but face same fate as Netflix","Summary":"Shares of Eli Lilly & Co.  rallied 1.5% in premarket trading Thursday, after the drug maker reported better-than-expected first-quarter profit and revenue, and actually provided a full-year outlook, which was in line with ..."},{"Date":"Apr. 23, 2020 at 10:26 a.m. ET","Headline":"Big investors haven\u2019t capitulated yet, so be wary of this market, warns SocGen strategist","Summary":"Shares of Eli Lilly & Co.  rallied 1.5% in premarket trading Thursday, after the drug maker reported better-than-expected first-quarter profit and revenue, and actually provided a full-year outlook, which was in line with ..."},{"Date":"Apr. 23, 2020 at 9:18 a.m. ET","Headline":"Eli Lilly\u2019s Earnings Raise Hopes for Pharmaceutical Stocks","Summary":"Shares of Eli Lilly & Co.  rallied 1.5% in premarket trading Thursday, after the drug maker reported better-than-expected first-quarter profit and revenue, and actually provided a full-year outlook, which was in line with ..."},{"Date":"Apr. 23, 2020 at 6:39 a.m. ET","Headline":"Eli Lilly's stock gains after earnings beat, as COVID-19-related buying boosts revenue by $250 million","Summary":"Shares of Eli Lilly & Co.  rallied 1.5% in premarket trading Thursday, after the drug maker reported better-than-expected first-quarter profit and revenue, and actually provided a full-year outlook, which was in line with ..."},{"Date":"Apr. 22, 2020 at 7:30 a.m. ET","Headline":"How a Low-Volatility Fund Lives Up to Its Name Amid Stock Market Turmoil","Summary":""},{"Date":"Apr. 27, 2020 at 5:52 p.m. ET","Headline":"The Latest Updates on 9 Experimental Coronavirus Treatments","Summary":""},{"Date":"Apr. 30, 2020 at 5:31 p.m. ET","Headline":"Amgen Stock Jumps on Earnings, Covid-19 Trial Announcement","Summary":""},{"Date":"May. 1, 2020 at 8:52 p.m. ET","Headline":"Banks and Corporations Pull Back From Buybacks. Big Tech Feels Differently.","Summary":""},{"Date":"May. 1, 2020 at 11:56 a.m. ET","Headline":"Charting an early-May downdraft to start worst six months seasonally","Summary":""},{"Date":"May. 4, 2020 at 12:07 p.m. ET","Headline":"Charting a bearish pulse to start May, S&P 500 extends downturn from key resistance","Summary":""},{"Date":"May. 6, 2020 at 12:10 p.m. ET","Headline":"Charting a May trading range, U.S. benchmarks hold near-term support","Summary":""},{"Date":"May. 5, 2020 at 1:02 p.m. ET","Headline":"Charting a May whipsaw, S&P 500 holds key support to start worst six months seasonally","Summary":""},{"Date":"May. 5, 2020 at 12:27 p.m. ET","Headline":"Charting a May whipsaw, S&P 500 holds key support to start worst six months seasonally","Summary":""},{"Date":"May. 8, 2020 at 2:46 p.m. ET","Headline":"Government to test remdesivir with Lilly drug in COVID-19 patients","Summary":"The National Institute of Allergy and Infectious Diseases (NIAID) said Friday it is testing Gilead Sciences Inc.'s  remdesivir in combination with Eli Lilly & Co.'s  rheumatoid arthritis drug Olumiant in COVID-19 patients ..."},{"Date":"May. 8, 2020 at 12:04 p.m. ET","Headline":"Bullish divergence persists, Nasdaq extends break atop 9,000 mark","Summary":""},{"Date":"May. 7, 2020 at 12:06 p.m. ET","Headline":"Charting a bullish divergence, Nasdaq \u2018goes green\u2019 for 2020","Summary":""},{"Date":"May. 12, 2020 at 12:40 p.m. ET","Headline":"Charting a grinding-higher May rally, S&P 500 approaches major resistance","Summary":""},{"Date":"May. 12, 2020 at 12:02 p.m. ET","Headline":"Charting a grinding-higher May rally, S&P 500 approaches major resistance","Summary":""},{"Date":"May. 11, 2020 at 11:53 a.m. ET","Headline":"S&P 500 holds 2,900 mark, Nasdaq tags 10-week peak","Summary":""},{"Date":"May. 14, 2020 at 12:07 p.m. ET","Headline":"S&P 500 whipsaws at key retracement (2,793), Nasdaq nails major support (8,705)","Summary":""},{"Date":"May. 14, 2020 at 9:11 a.m. ET","Headline":"Abivax Stock Soars as French Regulator Approves Testing of a Drug to Treat Covid-19","Summary":""},{"Date":"May. 13, 2020 at 12:24 p.m. ET","Headline":"Charting a potential double top, S&P 500 pulls in from key resistance (2,954)","Summary":""},{"Date":"May. 15, 2020 at 12:15 p.m. ET","Headline":"Charting a \u2018rabbit from hat\u2019 reversal, S&P 500 maintains the May range","Summary":""},{"Date":"May. 18, 2020 at 11:54 a.m. ET","Headline":"S&P 500 extends bullish reversal, spikes to challenge major resistance (2,954)","Summary":""},{"Date":"May. 20, 2020 at 11:36 a.m. ET","Headline":"Charting a pulling-teeth breakout attempt, S&P ventures atop major resistance","Summary":""},{"Date":"May. 19, 2020 at 1:02 p.m. ET","Headline":"Charting a headline breakout attempt, S&P 500 nails major resistance (2,954)","Summary":""},{"Date":"May. 19, 2020 at 12:06 p.m. ET","Headline":"Charting a headline breakout attempt, S&P 500 nails major resistance (2,954)","Summary":""},{"Date":"May. 21, 2020 at 12:08 p.m. ET","Headline":"S&P 500 edges atop key resistance (2,954), Nasdaq digests break to 3-month high","Summary":""},{"Date":"May. 26, 2020 at 12:54 p.m. ET","Headline":"Charting a bull-flag breakout, S&P 500 ventures atop 200-day average","Summary":""},{"Date":"May. 26, 2020 at 12:07 p.m. ET","Headline":"Charting a bull-flag breakout, S&P 500 ventures atop 200-day average","Summary":""},{"Date":"May. 28, 2020 at 12:08 p.m. ET","Headline":"Charting a primary trend shift, S&P 500 breaks decisively atop 200-day average","Summary":""},{"Date":"May. 27, 2020 at 12:19 p.m. ET","Headline":"Charting bullish market rotation, S&P 500 hesitates at 200-day average","Summary":""},{"Date":"May. 27, 2020 at 8:13 a.m. ET","Headline":"White House announces plan for Medicare enrollees to get insulin for $35 a month","Summary":""},{"Date":"May. 29, 2020 at 11:56 a.m. ET","Headline":"Market rotation persists:  S&P 500 and Dow industrials digest late-May breakouts","Summary":"Shares of Eli Lilly & Co.  gained 0.8% in premarket trading on Friday, the day after the Food and Drug Administration (FDA) approved Tauvid, a drug used to help diagnose tau neurofibrillary tangles in people suspected of h..."},{"Date":"May. 29, 2020 at 8:17 a.m. ET","Headline":"Lilly gets FDA approval for Alzheimer's diagnostic agent","Summary":"Shares of Eli Lilly & Co.  gained 0.8% in premarket trading on Friday, the day after the Food and Drug Administration (FDA) approved Tauvid, a drug used to help diagnose tau neurofibrillary tangles in people suspected of h..."},{"Date":"Jun. 1, 2020 at 2:05 p.m. ET","Headline":"Coronavirus update: Global case tally tops 6 million as weekend protests spark concerns they will lead to an increase in infections","Summary":"Shares of Eli Lilly & Co.  gained 0.3% in premarket trading on Monday after the drugmaker said it had started a Phase 1 trial for its experimental COVID-19 antibody treatment. The therapy, LY-CoV555, was developed by Lilly..."},{"Date":"Jun. 1, 2020 at 11:52 a.m. ET","Headline":"Charting a sustained breakout, S&P 500 maintains 200-day average","Summary":"Shares of Eli Lilly & Co.  gained 0.3% in premarket trading on Monday after the drugmaker said it had started a Phase 1 trial for its experimental COVID-19 antibody treatment. The therapy, LY-CoV555, was developed by Lilly..."},{"Date":"Jun. 1, 2020 at 7:26 a.m. ET","Headline":"Lilly initiates Phase 1 clinical trial for a COVID-19 antibody treatment","Summary":"Shares of Eli Lilly & Co.  gained 0.3% in premarket trading on Monday after the drugmaker said it had started a Phase 1 trial for its experimental COVID-19 antibody treatment. The therapy, LY-CoV555, was developed by Lilly..."},{"Date":"Jun. 3, 2020 at 11:54 a.m. ET","Headline":"Charting bullish follow-through, S&P 500 spikes to next target (3,115)","Summary":""},{"Date":"Jun. 2, 2020 at 12:32 p.m. ET","Headline":"S&P 500 sustains key technical breakout amid bullish market rotation","Summary":""},{"Date":"Jun. 2, 2020 at 12:27 p.m. ET","Headline":"These 2 charts show why record-high stock valuations shouldn\u2019t worry investors","Summary":""},{"Date":"Jun. 2, 2020 at 12:02 p.m. ET","Headline":"S&P 500 sustains key technical breakout amid bullish market rotation","Summary":""},{"Date":"Jun. 2, 2020 at 9:16 a.m. ET","Headline":"Buy Lilly, AbbVie and Merck Stocks, J.P. Morgan Says, but Pfizer Is Still Expensive","Summary":""},{"Date":"Jun. 2, 2020 at 6:18 a.m. ET","Headline":"A new batch of data for Gilead Sciences\u2019 remdesivir points to efficacy but it\u2019s no \u2018silver bullet\u2019","Summary":""},{"Date":"Jun. 5, 2020 at 12:12 p.m. ET","Headline":"Charting a break to \u2018clearer skies\u2019 territory:  Nasdaq rattles cage on record highs","Summary":""},{"Date":"Jun. 4, 2020 at 11:45 a.m. ET","Headline":"Dow industrials challenge 200-day average as market rotation persists","Summary":""},{"Date":"Jun. 5, 2020 at 1:22 p.m. ET","Headline":"Antibody Drugs Could Help Curb the Pandemic. What Investors Need to Know.","Summary":""},{"Date":"Jun. 9, 2020 at 12:40 p.m. ET","Headline":"Charting a break to \u2018clear skies\u2019 territory, Nasdaq approaches 10,000 mark","Summary":""},{"Date":"Jun. 9, 2020 at 12:10 p.m. ET","Headline":"Charting a break to \u2018clear skies\u2019 territory, Nasdaq approaches 10,000 mark","Summary":""},{"Date":"Jun. 8, 2020 at 2:45 p.m. ET","Headline":"Coronavirus update: Global death tally tops 400,000; health experts urge police to stop using tear gas on anti-racism protesters","Summary":""},{"Date":"Jun. 8, 2020 at 11:52 a.m. ET","Headline":"Charting an unusually strong June start, S&P 500 challenges major resistance (3,215)","Summary":""},{"Date":"Jun. 11, 2020 at 12:21 p.m. ET","Headline":"Charting a bearish reversal, U.S. benchmarks venture (way) under key support","Summary":""},{"Date":"Jun. 11, 2020 at 10:46 a.m. ET","Headline":"Regeneron\u2019s Antibody Cocktail Against Covid Starts Human Trials, With Encouraging Data","Summary":""},{"Date":"Jun. 10, 2020 at 11:56 a.m. ET","Headline":"Market rotation persists, Nasdaq rattles cage on 10,000 mark","Summary":""},{"Date":"Jun. 15, 2020 at 3:18 p.m. ET","Headline":"Coronavirus update: U.S. death toll tops 115,000 amid growing worry about uptick in cases in Florida, Texas among others","Summary":"Shares of Eli Lilly & Co.  were down 1.1% in premarket trading on Monday after the drugmaker said the first patient had been enrolled in a late-stage  assessing rheumatoid arthritis drug Olumiant as a treatment for COVID-1..."},{"Date":"Jun. 15, 2020 at 8:40 a.m. ET","Headline":"Lilly Is Testing Its Arthritis Drug as a Coronavirus Treatment","Summary":"Shares of Eli Lilly & Co.  were down 1.1% in premarket trading on Monday after the drugmaker said the first patient had been enrolled in a late-stage  assessing rheumatoid arthritis drug Olumiant as a treatment for COVID-1..."},{"Date":"Jun. 15, 2020 at 7:36 a.m. ET","Headline":"Lilly's shares drop as it enrolls first patient in COVID-19 study for arthritis drug","Summary":"Shares of Eli Lilly & Co.  were down 1.1% in premarket trading on Monday after the drugmaker said the first patient had been enrolled in a late-stage  assessing rheumatoid arthritis drug Olumiant as a treatment for COVID-1..."},{"Date":"Jun. 17, 2020 at 10:11 a.m. ET","Headline":"Lilly Stock Has a 10% Upside, Guggenheim Says","Summary":"Shares of Eli Lilly & Co.  gained 7.4% in premarket trading on Tuesday after the drugmaker said its breast-cancer drug Verzenio decreased recurrence and death in certain breast-cancer patients when prescribed in combinatio..."},{"Date":"Jun. 16, 2020 at 10:49 a.m. ET","Headline":"Eli Lilly\u2019s Cancer Drug Succeeded Where Pfizer Failed. What It Means for Their Stocks.","Summary":"Shares of Eli Lilly & Co.  gained 7.4% in premarket trading on Tuesday after the drugmaker said its breast-cancer drug Verzenio decreased recurrence and death in certain breast-cancer patients when prescribed in combinatio..."},{"Date":"Jun. 16, 2020 at 7:17 a.m. ET","Headline":"Lilly's shares jump on promising data from study for breast-cancer drug","Summary":"Shares of Eli Lilly & Co.  gained 7.4% in premarket trading on Tuesday after the drugmaker said its breast-cancer drug Verzenio decreased recurrence and death in certain breast-cancer patients when prescribed in combinatio..."},{"Date":"Jun. 18, 2020 at 4:12 p.m. ET","Headline":"A Stockpicker on the Reshaping of Health Care","Summary":""},{"Date":"Jun. 22, 2020 at 9:34 a.m. ET","Headline":"Gilead's stock falls as it announces clinical trial for inhaled remdesivir","Summary":"Shares of Gilead Sciences Inc.  were down 1.2% in trading on Monday after the drugmaker said it plans to start Phase 1 clinical trials for an inhaled version of remdesivir, its treatment for severely ill COVID-19 patients...."},{"Date":"Jun. 20, 2020 at 9:48 a.m. ET","Headline":"Biotech Stocks Are Getting Ready to Run. How to Play It.","Summary":""},{"Date":"Jun. 29, 2020 at 7:47 a.m. ET","Headline":"These 6 health-care stocks are \u2018buys\u2019 because they can thrive under either Trump or Biden","Summary":""},{"Date":"Jul. 2, 2020 at 4:37 p.m. ET","Headline":"The Number of Covid-19 Cases Is Rising. What Comes Next.","Summary":""},{"Date":"Jul. 2, 2020 at 8:30 a.m. ET","Headline":"These 5 Dividend Funds Offer the Flexibility to Weather the Pandemic","Summary":""},{"Date":"Jul. 6, 2020 at 10:43 a.m. ET","Headline":"Regeneron Stock Is Rising as Covid-19 Antibody Moves Into Phase 3 Tests","Summary":""},{"Date":"Jul. 14, 2020 at 12:00 p.m. ET","Headline":"Will Stocks Survive Earnings Season Uncertainty? Almost Probably.","Summary":""},{"Date":"Jul. 21, 2020 at 2:24 p.m. ET","Headline":"You should invest in big banks now for their rich dividends","Summary":""},{"Date":"Jul. 20, 2020 at 7:00 a.m. ET","Headline":"A Big Contrarian Investor Sold Walmart, Merck and Pfizer Stock. Here\u2019s What It Bought.","Summary":""},{"Date":"Jul. 24, 2020 at 8:07 p.m. ET","Headline":"Even as Indy Goes Autonomous, the Race to True Self-Driving Has Been Long","Summary":""},{"Date":"Jul. 26, 2020 at 6:27 p.m. ET","Headline":"Amazon, Apple,\u00a0Boeing, Starbucks, Visa and Other Stocks to Watch This Week","Summary":""},{"Date":"Jul. 30, 2020 at 4:17 p.m. ET","Headline":"Dow, S&P 500 finish lower but Nasdaq books a gain ahead of parade of earnings from megacap tech-related firms","Summary":"Shares of Eli Lilly & Co.  rallied 2.6% in premarket trading Thursday, after the drug maker beat profit expectations and raised its full-year outlook, while revenue fell shy. Net income rose to $1.41 billion, or $1.55 a sh..."},{"Date":"Jul. 30, 2020 at 4:04 p.m. ET","Headline":"Coronavirus update: U.S. death toll tops 150,000 as Florida, California, North Carolina and Idaho set one-day records","Summary":"Shares of Eli Lilly & Co.  rallied 2.6% in premarket trading Thursday, after the drug maker beat profit expectations and raised its full-year outlook, while revenue fell shy. Net income rose to $1.41 billion, or $1.55 a sh..."},{"Date":"Jul. 30, 2020 at 12:40 p.m. ET","Headline":"Stocks Are Falling as Investors Digest Pandemic\u2019s Economic Toll","Summary":"Shares of Eli Lilly & Co.  rallied 2.6% in premarket trading Thursday, after the drug maker beat profit expectations and raised its full-year outlook, while revenue fell shy. Net income rose to $1.41 billion, or $1.55 a sh..."},{"Date":"Jul. 30, 2020 at 10:45 a.m. ET","Headline":"Eli Lilly Stock Falls as Sales Disappoint. Analyst Welcomes Data on Diabetes Drug.","Summary":"Shares of Eli Lilly & Co.  rallied 2.6% in premarket trading Thursday, after the drug maker beat profit expectations and raised its full-year outlook, while revenue fell shy. Net income rose to $1.41 billion, or $1.55 a sh..."},{"Date":"Jul. 30, 2020 at 6:39 a.m. ET","Headline":"Eli Lilly's stock rallies after a profit beat and raised outlook, although revenue fell short","Summary":"Shares of Eli Lilly & Co.  rallied 2.6% in premarket trading Thursday, after the drug maker beat profit expectations and raised its full-year outlook, while revenue fell shy. Net income rose to $1.41 billion, or $1.55 a sh..."},{"Date":"Aug. 4, 2020 at 11:24 a.m. ET","Headline":"Regeneron\u2019s Covid-19 Antibody Looks Promising in Animal Test","Summary":"Shares of Eli Lilly & Co.  gained 1.1% in premarket trading on Monday after the drugmaker said it started a Phase 3 trial for a treatment that aims to prevent COVID-19 infections in residents and workers in nursing homes. ..."},{"Date":"Aug. 4, 2020 at 6:30 a.m. ET","Headline":"Regeneron Pharmaceuticals Reports Earnings Tomorrow. Here\u2019s What to Expect.","Summary":"Shares of Eli Lilly & Co.  gained 1.1% in premarket trading on Monday after the drugmaker said it started a Phase 3 trial for a treatment that aims to prevent COVID-19 infections in residents and workers in nursing homes. ..."},{"Date":"Aug. 3, 2020 at 3:31 p.m. ET","Headline":"Coronavirus update: U.S. death toll climbs to 155,000, as COVID-19 enters \u2018dangerous new phase\u2019","Summary":"Shares of Eli Lilly & Co.  gained 1.1% in premarket trading on Monday after the drugmaker said it started a Phase 3 trial for a treatment that aims to prevent COVID-19 infections in residents and workers in nursing homes. ..."},{"Date":"Aug. 3, 2020 at 1:16 p.m. ET","Headline":"Stocks Climb to Start the Month as New Virus Cases Fall","Summary":"Shares of Eli Lilly & Co.  gained 1.1% in premarket trading on Monday after the drugmaker said it started a Phase 3 trial for a treatment that aims to prevent COVID-19 infections in residents and workers in nursing homes. ..."},{"Date":"Aug. 3, 2020 at 12:46 p.m. ET","Headline":"Gilead Stock Is Rising Because Covid-Treatment Sales Could Top $3 Billion","Summary":"Shares of Eli Lilly & Co.  gained 1.1% in premarket trading on Monday after the drugmaker said it started a Phase 3 trial for a treatment that aims to prevent COVID-19 infections in residents and workers in nursing homes. ..."},{"Date":"Aug. 3, 2020 at 9:16 a.m. ET","Headline":"Eli Lilly Stock Is Rising as the Company Tests a Covid-19 Antibody Drug In Nursing Homes","Summary":"Shares of Eli Lilly & Co.  gained 1.1% in premarket trading on Monday after the drugmaker said it started a Phase 3 trial for a treatment that aims to prevent COVID-19 infections in residents and workers in nursing homes. ..."},{"Date":"Aug. 3, 2020 at 7:32 a.m. ET","Headline":"Lilly's stock rises as it announces late-stage trial for COVID-19 drug in nursing homes","Summary":"Shares of Eli Lilly & Co.  gained 1.1% in premarket trading on Monday after the drugmaker said it started a Phase 3 trial for a treatment that aims to prevent COVID-19 infections in residents and workers in nursing homes. ..."},{"Date":"Aug. 5, 2020 at 1:56 p.m. ET","Headline":"Coronavirus update: Global death toll tops 700,000 with 18.5 million confirmed cases and U.S. accounts for more than a quarter","Summary":"Shares of Eli Lilly & Co.  gained 0.6% in premarket trading on Wednesday, the day after the National Institutes of Health said it plans to study whether several experimental monoclonal antibodies can treat hospitalized COV..."},{"Date":"Aug. 5, 2020 at 11:18 a.m. ET","Headline":"The stock market will be flying high in a year \u2014 for 2 simple reasons","Summary":"Shares of Eli Lilly & Co.  gained 0.6% in premarket trading on Wednesday, the day after the National Institutes of Health said it plans to study whether several experimental monoclonal antibodies can treat hospitalized COV..."},{"Date":"Aug. 5, 2020 at 7:58 a.m. ET","Headline":"NIH to test Lilly's experimental monoclonal antibody treatment in mild and moderate COVID-19 cases","Summary":"Shares of Eli Lilly & Co.  gained 0.6% in premarket trading on Wednesday, the day after the National Institutes of Health said it plans to study whether several experimental monoclonal antibodies can treat hospitalized COV..."},{"Date":"Aug. 7, 2020 at 1:14 p.m. ET","Headline":"Coronavirus update: Global case tally climbs above 19 million; U.S. death toll moves above 160,000 after 11 straight days with 1,000-plus fatalities","Summary":"The National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.'s  remdesivir with Merck KGaA's  interferon beta-1a as a treatment for COVID-19 p..."},{"Date":"Aug. 7, 2020 at 9:11 a.m. ET","Headline":"NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment","Summary":"The National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.'s  remdesivir with Merck KGaA's  interferon beta-1a as a treatment for COVID-19 p..."},{"Date":"Aug. 14, 2020 at 7:59 a.m. ET","Headline":"Here Are the Covid-19 Vaccines and Antivirals Being Worked on Right Now","Summary":""},{"Date":"Sep. 3, 2020 at 10:15 a.m. ET","Headline":"The Blockbuster Drug That Could Pay Off Big for Eli Lilly","Summary":""},{"Date":"Sep. 4, 2020 at 8:04 p.m. ET","Headline":"Research Reports","Summary":""},{"Date":"Sep. 11, 2020 at 2:18 p.m. ET","Headline":"Animal Spirits for Elanco? Pet-Care Company\u2019s Stock Is Well Positioned for Gains.","Summary":""},{"Date":"Sep. 11, 2020 at 10:20 a.m. ET","Headline":"U.S. Drug Stocks Look Cheap. Here\u2019s Why, According to One Analyst.","Summary":""},{"Date":"Sep. 11, 2020 at 10:00 a.m. ET","Headline":"It\u2019s Likely Too Late for Regeneron\u2019s Virus Treatment","Summary":""},{"Date":"Sep. 15, 2020 at 8:19 a.m. ET","Headline":"Steve Cohen Finally Buys the Mets. You Can Buy the Braves.","Summary":"Eli Lily & Co.  and Incyte Corp.  said Monday that their rheumatoid arthritis drug Olumiant helped reduce recovery time in hospitalized COVID-19 patients when it was used in combination with Gilead Sciences Inc.'s  remdesi..."},{"Date":"Sep. 14, 2020 at 3:15 p.m. ET","Headline":"Balloons at Macy\u2019s Thanksgiving Day Parade Will Be Rigged to Special Vehicles","Summary":"Eli Lily & Co.  and Incyte Corp.  said Monday that their rheumatoid arthritis drug Olumiant helped reduce recovery time in hospitalized COVID-19 patients when it was used in combination with Gilead Sciences Inc.'s  remdesi..."},{"Date":"Sep. 14, 2020 at 1:31 p.m. ET","Headline":"Coronavirus update: WHO says record number of new cases \u2014 307,930 \u2014 counted worldwide on Sunday","Summary":"Eli Lily & Co.  and Incyte Corp.  said Monday that their rheumatoid arthritis drug Olumiant helped reduce recovery time in hospitalized COVID-19 patients when it was used in combination with Gilead Sciences Inc.'s  remdesi..."},{"Date":"Sep. 14, 2020 at 7:48 a.m. ET","Headline":"Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time","Summary":"Eli Lily & Co.  and Incyte Corp.  said Monday that their rheumatoid arthritis drug Olumiant helped reduce recovery time in hospitalized COVID-19 patients when it was used in combination with Gilead Sciences Inc.'s  remdesi..."},{"Date":"Sep. 17, 2020 at 3:05 p.m. ET","Headline":"Coronavirus update: Global cases near 30 million; Trump contradicts CDC head on vaccine timetable and again derides face masks","Summary":"Eli Lilly and Co.  and Amgen Inc.  said Thursday they will collaborate on COVID-19 antibody treatments as a way to significantly boost global supply capacity. The announcement comes a day after Lilly said interim data from..."},{"Date":"Sep. 17, 2020 at 6:41 a.m. ET","Headline":"Eli Lilly and Amgen to collaborate on COVID-19 antibody therapies","Summary":"Eli Lilly and Co.  and Amgen Inc.  said Thursday they will collaborate on COVID-19 antibody treatments as a way to significantly boost global supply capacity. The announcement comes a day after Lilly said interim data from..."},{"Date":"Sep. 16, 2020 at 1:57 p.m. ET","Headline":"Lilly and Pfizer Are Testing Treatments for Hospitalized Covid Patients","Summary":"Shares of Eli Lilly & Co.  gained 2.6% in premarket trading on Wednesday after the drug maker said interim data from a mid-stage clinical trial assessing its experimental antibody treatment reduced the rate of hospitalizat..."},{"Date":"Sep. 16, 2020 at 1:19 p.m. ET","Headline":"Coronavirus update: Global cases edge toward 30 million; Trump denies playing down crisis, says U.S. will have \u2018herd mentality\u2019","Summary":"Shares of Eli Lilly & Co.  gained 2.6% in premarket trading on Wednesday after the drug maker said interim data from a mid-stage clinical trial assessing its experimental antibody treatment reduced the rate of hospitalizat..."},{"Date":"Sep. 16, 2020 at 7:46 a.m. ET","Headline":"Shares of Lilly gain as it discloses promising interim findings for COVID-19 antibody treatment","Summary":"Shares of Eli Lilly & Co.  gained 2.6% in premarket trading on Wednesday after the drug maker said interim data from a mid-stage clinical trial assessing its experimental antibody treatment reduced the rate of hospitalizat..."},{"Date":"Sep. 18, 2020 at 3:29 p.m. ET","Headline":"Coronavirus update: Global case tally tops 30 million, and controversial CDC testing guideline changes were reportedly not made by CDC scientists","Summary":"Shares of Roche Holding AG  gained 1.9% in premarket trading on Friday after the drug maker said hospitalized COVID-19 patients taking rheumatoid arthritis drug Actemra were less likely to need mechanical ventilation than ..."},{"Date":"Sep. 18, 2020 at 1:16 p.m. ET","Headline":"How this Nasdaq-U.K.-listed Chinese biotech is revolutionizing cancer treatment","Summary":"Shares of Roche Holding AG  gained 1.9% in premarket trading on Friday after the drug maker said hospitalized COVID-19 patients taking rheumatoid arthritis drug Actemra were less likely to need mechanical ventilation than ..."},{"Date":"Sep. 18, 2020 at 7:42 a.m. ET","Headline":"Shares of Roche gain as it says arthritis drug can lessen need for ventilators in COVID-19 patients","Summary":"Shares of Roche Holding AG  gained 1.9% in premarket trading on Friday after the drug maker said hospitalized COVID-19 patients taking rheumatoid arthritis drug Actemra were less likely to need mechanical ventilation than ..."},{"Date":"Sep. 18, 2020 at 4:55 a.m. ET","Headline":"How This Nasdaq-U.K.-Listed Chinese Biotech Is Revolutionizing Cancer Treatment","Summary":""},{"Date":"Sep. 21, 2020 at 3:22 p.m. ET","Headline":"Coronavirus update: Global death tally approaches 1 million, U.S. deaths near 200,000","Summary":""},{"Date":"Sep. 21, 2020 at 10:42 a.m. ET","Headline":"Anticancer Drug Team-Ups Show Promise. 4 Stocks That Stand to Gain.","Summary":""},{"Date":"Sep. 21, 2020 at 7:30 a.m. ET","Headline":"Initial data from a pair of clinical trials may revive interest in arthritis drugs as COVID-19 treatments","Summary":""},{"Date":"Sep. 29, 2020 at 6:08 p.m. ET","Headline":"Regeneron Says Antibodies Helped Covid Patients Recover Faster. Here Are the Next Steps.","Summary":""},{"Date":"Sep. 30, 2020 at 9:13 a.m. ET","Headline":"Regeneron\u2019s Good News on Covid Antibodies Is Positive for Vaccines, Too","Summary":""},{"Date":"Oct. 2, 2020 at 10:23 a.m. ET","Headline":"Trump\u2019s Covid Case Brings New Urgency to Treatments and Vaccines","Summary":""},{"Date":"Oct. 5, 2020 at 12:10 p.m. ET","Headline":"Trump\u2019s Use of Regeneron Antibodies Will Help It Become a Big Seller, Say Analysts","Summary":""},{"Date":"Oct. 4, 2020 at 1:19 p.m. ET","Headline":"President Trump is prescribed a third drug to combat his COVID-19 infection","Summary":""},{"Date":"Oct. 4, 2020 at 11:16 a.m. ET","Headline":"An experimental antibody treatment reduced viral load in some COVID-19 patients. That may also be a positive sign for vaccines","Summary":""},{"Date":"Oct. 7, 2020 at 3:09 p.m. ET","Headline":"Coronavirus update: U.S. death toll tops 211,000 as doctors caution that Trump is entering a key phase in his diagnosis","Summary":"Shares of Eli Lilly & Co.  rallied 3.2% in premarket trading on Wednesday after the drug maker said it submitted its experimental COVID-19 monoclonal antibody treatment to the Food and Drug Administration for an emergency ..."},{"Date":"Oct. 7, 2020 at 1:44 p.m. ET","Headline":"Lilly Serves Up an Anti-Covid Cocktail, Like Regeneron\u2019s. The Stock Is Rising.","Summary":"Shares of Eli Lilly & Co.  rallied 3.2% in premarket trading on Wednesday after the drug maker said it submitted its experimental COVID-19 monoclonal antibody treatment to the Food and Drug Administration for an emergency ..."},{"Date":"Oct. 7, 2020 at 9:16 a.m. ET","Headline":"Lilly submits authorization request to FDA for antibody-based COVID-19 therapy","Summary":"Shares of Eli Lilly & Co.  rallied 3.2% in premarket trading on Wednesday after the drug maker said it submitted its experimental COVID-19 monoclonal antibody treatment to the Food and Drug Administration for an emergency ..."},{"Date":"Sep. 28, 2020 at 8:56 a.m. ET","Headline":"10 Stocks to Buy as the Health-Care Revolution Races Ahead, According to Experts","Summary":""},{"Date":"Oct. 9, 2020 at 10:12 a.m. ET","Headline":"Need More Proof That Gilead\u2019s Treatment Helps Covid Patients? You Just Got It.","Summary":"Shares of Regeneron Pharmaceuticals Inc.  were up 4.7% in premarket trading on Thursday, the day after the company said it had submitted a request for emergency authorization to the Food and Drug Administration for its exp..."},{"Date":"Oct. 8, 2020 at 3:05 p.m. ET","Headline":"Coronavirus update: New England Journal of Medicine says Trump should be voted out over pandemic management as U.S. death toll tops 212,000","Summary":"Shares of Regeneron Pharmaceuticals Inc.  were up 4.7% in premarket trading on Thursday, the day after the company said it had submitted a request for emergency authorization to the Food and Drug Administration for its exp..."},{"Date":"Oct. 8, 2020 at 10:06 a.m. ET","Headline":"Regeneron Wants FDA Approval for Trump\u2019s Covid-19 Treatment. What Could Come Next.","Summary":"Shares of Regeneron Pharmaceuticals Inc.  were up 4.7% in premarket trading on Thursday, the day after the company said it had submitted a request for emergency authorization to the Food and Drug Administration for its exp..."},{"Date":"Oct. 8, 2020 at 8:31 a.m. ET","Headline":"Regeneron's stock rallies after it announces EUA request for antibody treatment","Summary":"Shares of Regeneron Pharmaceuticals Inc.  were up 4.7% in premarket trading on Thursday, the day after the company said it had submitted a request for emergency authorization to the Food and Drug Administration for its exp..."},{"Date":"Oct. 8, 2020 at 7:00 a.m. ET","Headline":"Eli Lilly to work with Bill & Melinda Gates Foundatin to get COVID antibody therapy to poorer countries","Summary":"Eli Lilly and Co.  said Thursday it has entered an agreement with the Bill & Melinda Gates Foundation to ensure access to Lilly's COVID-19 antibody therapy for low- and middle-income countries. The agreement is part of the..."},{"Date":"Oct. 11, 2020 at 6:10 p.m. ET","Headline":"This Is What\u2019s Causing the Stock Market to Rise","Summary":""},{"Date":"Oct. 10, 2020 at 7:00 a.m. ET","Headline":"Alaska Bought Up Gilead, Lilly, and Wells Fargo Stock. Here\u2019s What It Sold.","Summary":""},{"Date":"Oct. 9, 2020 at 7:46 p.m. ET","Headline":"Brown\u2019s Returns Beat the Big Boys of the Ivy League","Summary":""},{"Date":"Oct. 13, 2020 at 8:25 p.m. ET","Headline":"First Confirmed U.S. Patient Reinfected With Covid-19","Summary":"Stocks ended lower Tuesday, snapping a four-day winning streak for major indexes, as investors weighed separate setbacks in trials for a COVID-19 vaccine and a treatment and sifted through earnings for big Wall Street bank..."},{"Date":"Oct. 13, 2020 at 6:05 p.m. ET","Headline":"Supreme Court Rules That Census Count Can End Early","Summary":"Stocks ended lower Tuesday, snapping a four-day winning streak for major indexes, as investors weighed separate setbacks in trials for a COVID-19 vaccine and a treatment and sifted through earnings for big Wall Street bank..."},{"Date":"Oct. 13, 2020 at 5:37 p.m. ET","Headline":"It\u2019s \u2018Reality Check Tuesday.\u2019 Here\u2019s How the Dow Jones Industrial Average Did.","Summary":"Stocks ended lower Tuesday, snapping a four-day winning streak for major indexes, as investors weighed separate setbacks in trials for a COVID-19 vaccine and a treatment and sifted through earnings for big Wall Street bank..."},{"Date":"Oct. 13, 2020 at 4:23 p.m. ET","Headline":"The Dow Closed Lower After Disappointing Coronavirus Drug News","Summary":"Stocks ended lower Tuesday, snapping a four-day winning streak for major indexes, as investors weighed separate setbacks in trials for a COVID-19 vaccine and a treatment and sifted through earnings for big Wall Street bank..."},{"Date":"Oct. 13, 2020 at 4:22 p.m. ET","Headline":"Dow, S&P 500 breaks four-day win streak as J&J and Eli Lilly pause COVID-19 drug trials","Summary":"Stocks ended lower Tuesday, snapping a four-day winning streak for major indexes, as investors weighed separate setbacks in trials for a COVID-19 vaccine and a treatment and sifted through earnings for big Wall Street bank..."},{"Date":"Oct. 13, 2020 at 4:08 p.m. ET","Headline":"Stocks snap 4-day winning streak as coronavirus vaccine, treatment hit snags","Summary":"Stocks ended lower Tuesday, snapping a four-day winning streak for major indexes, as investors weighed separate setbacks in trials for a COVID-19 vaccine and a treatment and sifted through earnings for big Wall Street bank..."},{"Date":"Oct. 13, 2020 at 3:39 p.m. ET","Headline":"10-year Treasury yield sees biggest drop in 4 months on pause to drugmakers\u2019 clinical trials","Summary":"U.S. Treasury yields fell Tuesday after U.S. drugmakers reported setbacks to their efforts to develop of a remedy for the deadly COVID-19 disease."},{"Date":"Oct. 13, 2020 at 3:24 p.m. ET","Headline":"A study testing Lilly's antibody treatment and remdesivir is paused","Summary":"Shares of Eli Lilly & Co.  tumbled 3.1% in trading on Tuesday after the drug maker confirmed a data safety monitoring board had paused enrollment in a clinical study testing its experimental COVID-19 monoclonal antibody tr..."},{"Date":"Oct. 13, 2020 at 2:55 p.m. ET","Headline":"Dow trades near Tuesday's low as Eli Lilly says it halted a coronavirus antibody trial","Summary":"U.S. stocks took a dip lower Tuesday afternoon after drugmaker Eli Lilly  said that it paused a drug treatment trial for the illness caused by the novel strain of coroavirus that causes COVID-19. A pause in such clinical t..."},{"Date":"Oct. 12, 2020 at 7:20 a.m. ET","Headline":"LabCorp Has Been Tested by Covid-19. But It\u2019s Now on a Roll.","Summary":""},{"Date":"Oct. 11, 2020 at 2:20 p.m. ET","Headline":"Why This Value Fund Likes UPS, Walmart, and Home Depot Stock","Summary":""},{"Date":"Oct. 14, 2020 at 5:38 p.m. ET","Headline":"Dow slips for second day as hope for fiscal stimulus before election fades","Summary":"Shares of Eli Lilly & Co.  were down 0.5% in premarket trading on Wednesday, the day after the drug maker confirmed that a clinical trial for its COVID-19 antibody treatment in combination with remdesivir had been paused. ..."},{"Date":"Oct. 14, 2020 at 4:39 p.m. ET","Headline":"Stocks Close Lower as Banks Report Earnings, Stimulus Hopes Fade","Summary":"Shares of Eli Lilly & Co.  were down 0.5% in premarket trading on Wednesday, the day after the drug maker confirmed that a clinical trial for its COVID-19 antibody treatment in combination with remdesivir had been paused. ..."},{"Date":"Oct. 14, 2020 at 2:45 p.m. ET","Headline":"Coronavirus update: U.S. death toll tops 216,000 as Midwest and Mountain West cases start to stretch hospital capacity","Summary":"Shares of Eli Lilly & Co.  were down 0.5% in premarket trading on Wednesday, the day after the drug maker confirmed that a clinical trial for its COVID-19 antibody treatment in combination with remdesivir had been paused. ..."},{"Date":"Oct. 14, 2020 at 11:14 a.m. ET","Headline":"How to Invest In Covid-19 Vaccines and Treatments When Trials Keep Getting Paused","Summary":"Shares of Eli Lilly & Co.  were down 0.5% in premarket trading on Wednesday, the day after the drug maker confirmed that a clinical trial for its COVID-19 antibody treatment in combination with remdesivir had been paused. ..."},{"Date":"Oct. 14, 2020 at 8:43 a.m. ET","Headline":"Here\u2019s why it\u2019s time to start shorting overextended markets, says one research firm","Summary":"Shares of Eli Lilly & Co.  were down 0.5% in premarket trading on Wednesday, the day after the drug maker confirmed that a clinical trial for its COVID-19 antibody treatment in combination with remdesivir had been paused. ..."},{"Date":"Oct. 14, 2020 at 8:26 a.m. ET","Headline":"Covid Is Making a Comeback. The Stock Market Is Watching.","Summary":"Shares of Eli Lilly & Co.  were down 0.5% in premarket trading on Wednesday, the day after the drug maker confirmed that a clinical trial for its COVID-19 antibody treatment in combination with remdesivir had been paused. ..."},{"Date":"Oct. 14, 2020 at 7:32 a.m. ET","Headline":"NIH confirms trial for Lilly antibody treatment is paused","Summary":"Shares of Eli Lilly & Co.  were down 0.5% in premarket trading on Wednesday, the day after the drug maker confirmed that a clinical trial for its COVID-19 antibody treatment in combination with remdesivir had been paused. ..."},{"Date":"Oct. 16, 2020 at 8:26 p.m. ET","Headline":"Make Up Your Mind, Already: Inside the Stock Market\u2019s Indecisive Week","Summary":""},{"Date":"Oct. 16, 2020 at 7:38 p.m. ET","Headline":"Airbus Is Struggling. And a Contract to Build a Mars Spacecraft Can\u2019t Lift the Earthbound Gloom.","Summary":""},{"Date":"Oct. 16, 2020 at 4:30 p.m. ET","Headline":"The Dow Gains as Retail Sales Come in Strong","Summary":""},{"Date":"Oct. 16, 2020 at 11:03 a.m. ET","Headline":"Autos and apparel makers boost European stocks","Summary":""},{"Date":"Oct. 21, 2020 at 12:00 p.m. ET","Headline":"Fauci Tells Doctors Covid is Worse in the U.S. Because of a Failure to Avoid Crowds","Summary":""},{"Date":"Oct. 23, 2020 at 7:17 p.m. ET","Headline":"Remdesivir Gets FDA Approval. What It Means for Gilead Stock and Vaccine Makers.","Summary":""},{"Date":"Oct. 23, 2020 at 5:51 p.m. ET","Headline":"Why Snap\u2019s Surge Is Good News for Social Media","Summary":""},{"Date":"Oct. 24, 2020 at 1:22 p.m. ET","Headline":"Wanted: Stock investors with time and money to support profitable, well-run companies","Summary":""},{"Date":"Oct. 24, 2020 at 9:38 a.m. ET","Headline":"S&P 500 corporate boards lack diversity, but these top companies are leading change \u2014 and the stock market rewards them","Summary":""},{"Date":"Oct. 24, 2020 at 6:00 a.m. ET","Headline":"Cancer Meeting Could Ignite These Biotech Stocks","Summary":""},{"Date":"Oct. 27, 2020 at 4:31 p.m. ET","Headline":"Dow books back-to-back loss as Wall Street struggles to rebound from Monday selloff","Summary":"Eli Lilly & Co. shares  fell 4% in premarket trade Tuesday, after the drug maker posted weaker-than-expected earnings for the third quarter. Indianapolis-based Eli Lilly said it had net income of $1.208 billion, or $1.33 a..."},{"Date":"Oct. 27, 2020 at 4:16 p.m. ET","Headline":"Stocks Close Mixed After Monday\u2019s Selloff","Summary":"Eli Lilly & Co. shares  fell 4% in premarket trade Tuesday, after the drug maker posted weaker-than-expected earnings for the third quarter. Indianapolis-based Eli Lilly said it had net income of $1.208 billion, or $1.33 a..."},{"Date":"Oct. 27, 2020 at 10:09 a.m. ET","Headline":"The Dow Isn\u2019t Bouncing Back From Monday\u2019s Selloff. Here\u2019s Why.","Summary":"Eli Lilly & Co. shares  fell 4% in premarket trade Tuesday, after the drug maker posted weaker-than-expected earnings for the third quarter. Indianapolis-based Eli Lilly said it had net income of $1.208 billion, or $1.33 a..."},{"Date":"Oct. 27, 2020 at 8:16 a.m. ET","Headline":"Why Eli Lilly\u2019s September Earnings Disappointed Wall Street","Summary":"Eli Lilly & Co. shares  fell 4% in premarket trade Tuesday, after the drug maker posted weaker-than-expected earnings for the third quarter. Indianapolis-based Eli Lilly said it had net income of $1.208 billion, or $1.33 a..."},{"Date":"Oct. 27, 2020 at 7:29 a.m. ET","Headline":"As markets gyrate over second-wave fears, here are 2 consumer staple stocks to ride for the long run, from Barclays","Summary":"Eli Lilly & Co. shares  fell 4% in premarket trade Tuesday, after the drug maker posted weaker-than-expected earnings for the third quarter. Indianapolis-based Eli Lilly said it had net income of $1.208 billion, or $1.33 a..."},{"Date":"Oct. 27, 2020 at 6:53 a.m. ET","Headline":"Eli Lilly shares slump premarket after earnings miss","Summary":"Eli Lilly & Co. shares  fell 4% in premarket trade Tuesday, after the drug maker posted weaker-than-expected earnings for the third quarter. Indianapolis-based Eli Lilly said it had net income of $1.208 billion, or $1.33 a..."},{"Date":"Oct. 26, 2020 at 7:15 p.m. ET","Headline":"Eli Lilly antibody drug fails in a COVID-19 study; other studies go on","Summary":""},{"Date":"Oct. 26, 2020 at 7:31 a.m. ET","Headline":"Apple, Amazon, Boeing, Visa, Pfizer, and Other Stocks to Watch This Week","Summary":""},{"Date":"Oct. 29, 2020 at 11:46 a.m. ET","Headline":"Coronavirus update: U.S. continues to set new case records as Trump remains insistent that U.S. has \u2018rounded the corner\u2019","Summary":"Shares of Eli Lilly & Co.  were up 0.8% in after-hours trading on Wednesday after an analysis published in thefound that the drug maker's experimental antibody treatment led to fewer hospitalizations and \"symptom burden\" c..."},{"Date":"Oct. 29, 2020 at 7:27 a.m. ET","Headline":"Coronavirus update: Pandemic sets record case numbers across the U.S. as White House suggests the crisis is over","Summary":"Shares of Eli Lilly & Co.  were up 0.8% in after-hours trading on Wednesday after an analysis published in thefound that the drug maker's experimental antibody treatment led to fewer hospitalizations and \"symptom burden\" c..."},{"Date":"Oct. 28, 2020 at 5:51 p.m. ET","Headline":"Study: Lilly's experimental COVID-19 drug may reduce hospitalizations","Summary":"Shares of Eli Lilly & Co.  were up 0.8% in after-hours trading on Wednesday after an analysis published in thefound that the drug maker's experimental antibody treatment led to fewer hospitalizations and \"symptom burden\" c..."},{"Date":"Oct. 28, 2020 at 7:34 a.m. ET","Headline":"Lilly signs deal with U.S. government for still-investigational COVID-19 antibody drug","Summary":"Shares of Eli Lilly & Co.  were down 0.7% in premarket trading on Wednesday after the drug maker said the U.S. government signed a deal to acquire 300,000 doses of its experimental neutralizing antibody COVID-19 treatment ..."},{"Date":"Oct. 28, 2020 at 6:17 a.m. ET","Headline":"Coronavirus update: U.S. case tally tops 8.7 million and marks seven-day record, with more than 20 states seeing most new cases since start of the outbreak","Summary":""},{"Date":"Oct. 30, 2020 at 8:13 p.m. ET","Headline":"George Floyd\u2019s Death Leads to a Surge of New Black Board Members","Summary":"It\u2019s the latest setback for antibody-drug trials in patients with the most advanced disease."},{"Date":"Oct. 30, 2020 at 3:04 p.m. ET","Headline":"Trial of Regeneron\u2019s Covid-19 Antibody Drug Is Halted in Sickest Hospital Patients","Summary":"It\u2019s the latest setback for antibody-drug trials in patients with the most advanced disease."},{"Date":"Nov. 2, 2020 at 8:36 a.m. ET","Headline":"Gilead unexpectedly cashes in with nearly $900 million in sales of COVID-19 drug","Summary":""},{"Date":"Nov. 4, 2020 at 5:18 p.m. ET","Headline":"These stocks rose the most Wednesday as investors cheered a divided government following the elections","Summary":"Shares of UnitedHealth Group Inc.  soared 10.2% in morning trading, enough to pace the Dow Jones Industrial Average's  gainers, as the . The stock's price gain of $32.65 was adding about 215 points to the Dow's price, whil..."},{"Date":"Nov. 4, 2020 at 11:23 a.m. ET","Headline":"Health care stocks soar, add more than 350 points to the Dow's price","Summary":"Shares of UnitedHealth Group Inc.  soared 10.2% in morning trading, enough to pace the Dow Jones Industrial Average's  gainers, as the . The stock's price gain of $32.65 was adding about 215 points to the Dow's price, whil..."},{"Date":"Nov. 6, 2020 at 2:39 p.m. ET","Headline":"Former Vanguard Group CEO Bill McNabb Bought Up IBM Stock","Summary":""},{"Date":"Nov. 6, 2020 at 1:39 p.m. ET","Headline":"Elanco Animal Health Stock Stumbles After Earnings Report","Summary":""},{"Date":"Nov. 6, 2020 at 6:56 a.m. ET","Headline":"Signs point to FDA approval for Biogen\u2019s experimental Alzheimer\u2019s disease treatment, though there are skeptics","Summary":""},{"Date":"Nov. 10, 2020 at 4:48 p.m. ET","Headline":"Microsoft and Other Tech Stocks Got Crushed. Why the Dow Jones Industrial Average Rose Today.","Summary":""},{"Date":"Nov. 10, 2020 at 4:22 p.m. ET","Headline":"Dow gains 260 points, while Nasdaq slides as vaccine hopes spark rotation away from tech highfliers","Summary":""},{"Date":"Nov. 10, 2020 at 2:22 p.m. ET","Headline":"Coronavirus update: U.S. adds another 130,000 cases in a day: \u2018This is what exponential math looks like,\u2019 says expert","Summary":""},{"Date":"Nov. 10, 2020 at 1:07 p.m. ET","Headline":"Investors need to brace for a \u2018violent rotation into\u2019 cyclicals, value stocks, says Lee","Summary":""},{"Date":"Nov. 10, 2020 at 11:34 a.m. ET","Headline":"Stocks Take a Pause as Investors Realize a Vaccine Is Still Months Away","Summary":""},{"Date":"Nov. 10, 2020 at 9:46 a.m. ET","Headline":"The FDA Authorizes Eli Lilly\u2019s Covid Antibody Drug. What That Means for Revenue.","Summary":""},{"Date":"Nov. 10, 2020 at 8:12 a.m. ET","Headline":"Some States Announce New Restrictions as U.S. Passes 10 Million Covid Cases","Summary":""},{"Date":"Nov. 9, 2020 at 7:32 p.m. ET","Headline":"Lilly\u2019s COVID-19 treatment receives emergency-use approval from FDA, stock jumps 3%","Summary":""},{"Date":"Nov. 9, 2020 at 8:30 a.m. ET","Headline":"Trump\u2019s vaccine czar says the first vaccine should be submitted for emergency authorization around Thanksgiving","Summary":""},{"Date":"Nov. 11, 2020 at 4:45 p.m. ET","Headline":"Dow snaps 2-day win streak, Nasdaq gains as rotation fades with surging coronavirus cases","Summary":""},{"Date":"Nov. 10, 2020 at 8:12 a.m. ET","Headline":"Beyond Meat\u2019s Bad Day Shows How Hard It Is to Be the Next Big Thing","Summary":""},{"Date":"Nov. 13, 2020 at 8:39 p.m. ET","Headline":"Mary Barra on General Motors\u2019 All-Electric Future","Summary":""},{"Date":"Nov. 20, 2020 at 8:19 a.m. ET","Headline":"Lilly's arthritis drug and Gilead's Veklury receive FDA authorization as combination COVID-19 treatment","Summary":"Shares of Eli Lilly & Co.  gained 0.6% in premarket trading on Friday, the day after the Food and Drug Administration granted an emergency use authorization to the company's rheumatoid arthritis drug Olumiant as a COVID-19..."},{"Date":"Nov. 22, 2020 at 9:54 a.m. ET","Headline":"Regeneron antibody \u2018cocktail\u2019 wins emergency-use authorization from FDA","Summary":""},{"Date":"Nov. 21, 2020 at 11:32 a.m. ET","Headline":"U.S. moves closer to 200,000 daily COVID cases; Birx and Fauci urge Americans to follow safety measures over Thanksgiving","Summary":""},{"Date":"Nov. 23, 2020 at 12:58 p.m. ET","Headline":"Holiday Travel Season Is Starting. Will Thanksgiving Be the Next Superspreader Event?","Summary":""},{"Date":"Nov. 23, 2020 at 10:38 a.m. ET","Headline":"Regeneron Is Allowed to Sell the Covid Antibody It Served Trump and the Stock Is Rising","Summary":""},{"Date":"Nov. 23, 2020 at 9:56 a.m. ET","Headline":"Here\u2019s When the First Americans Could Get a Coronavirus Vaccine","Summary":""},{"Date":"Dec. 1, 2020 at 4:55 p.m. ET","Headline":"Activist Shareholders Press Pfizer, J&J, and Other Pharma Companies on Covid Vaccine Price and Access","Summary":""},{"Date":"Dec. 4, 2020 at 3:00 p.m. ET","Headline":"CDC forecasts up to 19,500 deaths from COVID-19 in week ending Dec. 26","Summary":"Eli Lilly & Co.  and UnitedHealth Group Inc.  said Friday they are joining forces for a study of Lilly's bamlanivimab in high-risk, COVID-19 infected patients. Bamlanivimab is an antibody treatment that recently won U.S. F..."},{"Date":"Dec. 4, 2020 at 10:11 a.m. ET","Headline":"Vaccines and Approved Antibodies Dim Vir Biotechnology\u2019s Covid Opportunity, Analyst Says","Summary":"Eli Lilly & Co.  and UnitedHealth Group Inc.  said Friday they are joining forces for a study of Lilly's bamlanivimab in high-risk, COVID-19 infected patients. Bamlanivimab is an antibody treatment that recently won U.S. F..."},{"Date":"Dec. 4, 2020 at 8:08 a.m. ET","Headline":"Eli Lilly and UnitedHealth to study Lilly's antibody treatment bamlanivimab in high-risk COVID patients","Summary":"Eli Lilly & Co.  and UnitedHealth Group Inc.  said Friday they are joining forces for a study of Lilly's bamlanivimab in high-risk, COVID-19 infected patients. Bamlanivimab is an antibody treatment that recently won U.S. F..."},{"Date":"Dec. 7, 2020 at 8:38 a.m. ET","Headline":"AbCellera Biologics sets terms of IPO, which could value the company at up to $4.5 billion","Summary":"AbCellera Biologics Inc.  said Monday that terms of its initial public offering have been set, which could value the artificial intelligence (AI)-powered drug discovery company at up to $4.52 billion. The Vancouver-based c..."},{"Date":"Dec. 10, 2020 at 7:21 a.m. ET","Headline":"What to expect from the FDA\u2019s important COVID-19 vaccine meeting Thursday","Summary":""},{"Date":"Dec. 9, 2020 at 8:48 a.m. ET","Headline":"DoorDash, Airbnb Lead Big IPO Week\u2014but Peter Thiel\u2019s AbCellera Could Be the Winner","Summary":""},{"Date":"Dec. 11, 2020 at 8:15 p.m. ET","Headline":"Iconic Rock Songs Are Suddenly Hot Commodities. One Reason: Streaming.","Summary":""},{"Date":"Dec. 14, 2020 at 4:12 p.m. ET","Headline":"Eli Lilly raises dividend by 15%","Summary":"Eli Lilly & Co.  said late Monday its board of directors approved a 15% increase in its quarterly dividend, to 85 cents a share. The dividend is payable March 10 to shareholders of record as of the close on Feb. 12, the co..."},{"Date":"Dec. 13, 2020 at 3:00 p.m. ET","Headline":"Nike, FedEx, Lennar, Eli Lilly, and Other Stocks for Investors to Watch This Week","Summary":""},{"Date":"Dec. 16, 2020 at 2:33 p.m. ET","Headline":"Focus Shifts to Europe as Gilead Backs Away From Arthritis-Drug Partnership","Summary":"Shares of Eli Lilly & Co.  rallied 1.6% in premarket trading Tuesday, after the drug maker raised its full-year profit outlook and provided an upbeat 2021 revenue forecast. The company said it now expects 2020 net earnings..."},{"Date":"Dec. 15, 2020 at 4:47 p.m. ET","Headline":"Dow ends sharply higher, \ntech and small caps hit fresh records on stimulus hopes","Summary":"Shares of Eli Lilly & Co.  rallied 1.6% in premarket trading Tuesday, after the drug maker raised its full-year profit outlook and provided an upbeat 2021 revenue forecast. The company said it now expects 2020 net earnings..."},{"Date":"Dec. 15, 2020 at 4:37 p.m. ET","Headline":"Stocks Close Higher on Vaccine Optimism Despite Surging Hospitalizations","Summary":"Shares of Eli Lilly & Co.  rallied 1.6% in premarket trading Tuesday, after the drug maker raised its full-year profit outlook and provided an upbeat 2021 revenue forecast. The company said it now expects 2020 net earnings..."},{"Date":"Dec. 15, 2020 at 9:48 a.m. ET","Headline":"Lilly Sees Gains from Fighting Covid and Buys into Gene Therapy","Summary":"Shares of Eli Lilly & Co.  rallied 1.6% in premarket trading Tuesday, after the drug maker raised its full-year profit outlook and provided an upbeat 2021 revenue forecast. The company said it now expects 2020 net earnings..."},{"Date":"Dec. 15, 2020 at 6:43 a.m. ET","Headline":"Eli Lilly's stock rallies after raising full-year profit outlook","Summary":"Shares of Eli Lilly & Co.  rallied 1.6% in premarket trading Tuesday, after the drug maker raised its full-year profit outlook and provided an upbeat 2021 revenue forecast. The company said it now expects 2020 net earnings..."},{"Date":"Dec. 19, 2020 at 7:00 a.m. ET","Headline":"Eli Lilly, Amgen, and 2 Other Companies That Raised Their Dividends This Week","Summary":""},{"Date":"Dec. 30, 2020 at 9:28 a.m. ET","Headline":"Regeneron\u2019s Antibodies Appear to Help Hospitalized Patients\u2014and Could Help 2021 Revenue","Summary":""},{"Date":"Jan. 5, 2021 at 6:00 a.m. ET","Headline":"Get Ready for Health-Care Stocks to Go Wild. How to Play Them.","Summary":""},{"Date":"Jan. 11, 2021 at 5:00 p.m. ET","Headline":"The Dow Fell 89 Points Because Stocks Are Way Overextended","Summary":"Shares of Biogen Inc.  gained 5.6% in trading on Monday after another drugmaker shared positive clinical data about an experimental Alzheimer's disease treatment that is similar to a Biogen therapy under review by the Food..."},{"Date":"Jan. 11, 2021 at 4:16 p.m. ET","Headline":"Stocks Close Down as Impeachment Momentum Picks Up","Summary":"Shares of Biogen Inc.  gained 5.6% in trading on Monday after another drugmaker shared positive clinical data about an experimental Alzheimer's disease treatment that is similar to a Biogen therapy under review by the Food..."},{"Date":"Jan. 11, 2021 at 3:08 p.m. ET","Headline":"Stock market exuberance is here to stay, Credit Suisse says. Here\u2019s why investors can be positive","Summary":"Shares of Biogen Inc.  gained 5.6% in trading on Monday after another drugmaker shared positive clinical data about an experimental Alzheimer's disease treatment that is similar to a Biogen therapy under review by the Food..."},{"Date":"Jan. 11, 2021 at 11:42 a.m. ET","Headline":"Biogen's stock is up 5% after Lilly reports positive data from an Alzheimer's study","Summary":"Shares of Biogen Inc.  gained 5.6% in trading on Monday after another drugmaker shared positive clinical data about an experimental Alzheimer's disease treatment that is similar to a Biogen therapy under review by the Food..."},{"Date":"Jan. 11, 2021 at 8:56 a.m. ET","Headline":"Eli Lilly Soars, Twitter Tumbles as Stock Market Slides to Start the Week","Summary":"Shares of Eli Lilly & Co.  gained 15.4% in premarket trading on Monday after the drugmaker said its experimental Alzheimer's disease drug helped slow the decline of cognition and daily function in patients with early forms..."},{"Date":"Jan. 11, 2021 at 8:55 a.m. ET","Headline":"Eli Lilly Stock Gains as Drug Slows Decline in Alzheimer\u2019s Patients","Summary":"Shares of Eli Lilly & Co.  gained 15.4% in premarket trading on Monday after the drugmaker said its experimental Alzheimer's disease drug helped slow the decline of cognition and daily function in patients with early forms..."},{"Date":"Jan. 11, 2021 at 7:22 a.m. ET","Headline":"Lilly's stock jumps 15% after experimental Alzheimer's drug shows it can slow cognitive decline","Summary":"Shares of Eli Lilly & Co.  gained 15.4% in premarket trading on Monday after the drugmaker said its experimental Alzheimer's disease drug helped slow the decline of cognition and daily function in patients with early forms..."},{"Date":"Jan. 13, 2021 at 12:06 p.m. ET","Headline":"Here are the 10 best places to work in 2021, according to employees","Summary":""},{"Date":"Jan. 12, 2021 at 3:10 p.m. ET","Headline":"Eli Lilly Has Good News About Its Alzheimer\u2019s Drug. Here\u2019s What It Means for Biogen.","Summary":""},{"Date":"Jan. 14, 2021 at 3:29 p.m. ET","Headline":"Biogen Stock Is Jumping Because There May Be Hope for Its Alzheimer\u2019s Drug Yet","Summary":""},{"Date":"Jan. 17, 2021 at 9:46 a.m. ET","Headline":"\u2018Manufacturers and middlemen have created a vicious cycle of price increases\u2019: Mark Cuban pledges to sell this $225 medication for $20","Summary":""},{"Date":"Jan. 19, 2021 at 3:33 p.m. ET","Headline":"High-tech British firms eye U.S. listings in blow to post-Brexit London stock market","Summary":""},{"Date":"Jan. 19, 2021 at 8:05 a.m. ET","Headline":"Eli Lilly Stock Is Still Pricey. Why It Might Be a Buy.","Summary":""},{"Date":"Jan. 21, 2021 at 9:29 a.m. ET","Headline":"Eli Lilly Says Its Antibody Prevented Covid-19 in Nursing Home Residents","Summary":"Shares of Eli Lilly & Co.  gained 0.8% in premarket trading on Wednesday, the day after the drugmaker announced a deal worth up to $1.6 billion with Merus  to develop three antibody therapies aimed at treating cancer. The ..."},{"Date":"Jan. 20, 2021 at 10:35 a.m. ET","Headline":"Eli Lilly Stock Is Surging on Hope for Alzheimer\u2019s Drug. Analyst Says It Won\u2019t Last.","Summary":"Shares of Eli Lilly & Co.  gained 0.8% in premarket trading on Wednesday, the day after the drugmaker announced a deal worth up to $1.6 billion with Merus  to develop three antibody therapies aimed at treating cancer. The ..."},{"Date":"Jan. 20, 2021 at 7:35 a.m. ET","Headline":"Lilly signs cancer drug deal worth up to $1.6 billion","Summary":"Shares of Eli Lilly & Co.  gained 0.8% in premarket trading on Wednesday, the day after the drugmaker announced a deal worth up to $1.6 billion with Merus  to develop three antibody therapies aimed at treating cancer. The ..."},{"Date":"Jan. 23, 2021 at 10:24 a.m. ET","Headline":"These \u2018lucky seven\u2019 ETFs have left the S&P 500 in the dust","Summary":""},{"Date":"Jan. 22, 2021 at 8:29 p.m. ET","Headline":"Shipping Costs Are Spiking. What That Means for Inflation.","Summary":""},{"Date":"Jan. 22, 2021 at 8:07 a.m. ET","Headline":"The Stock Market Is Falling Because Covid Fears Are Back","Summary":""},{"Date":"Jan. 22, 2021 at 8:06 a.m. ET","Headline":"New Covid-19 Strains May Make Vaccines Less Effective, Fauci Warns","Summary":""},{"Date":"Jan. 25, 2021 at 2:16 p.m. ET","Headline":"Tesla, Apple, AT&T, Microsoft, and Other Stocks for Investors to Watch This Week","Summary":""},{"Date":"Jan. 27, 2021 at 10:08 a.m. ET","Headline":"Vir Will Test Its Covid-19 Antibody With Eli Lilly\u2019s, Sending Shares Up Again","Summary":"Shares of Regeneron Pharmaceuticals Inc.  were up 1.8% in premarket trading on Tuesday after the company said its COVID-19 antibody cocktail can prevent people at high risk of a COVID-19 infection from contracting the viru..."},{"Date":"Jan. 26, 2021 at 2:54 p.m. ET","Headline":"U.S. COVID-19 death toll tops 423,000 as Biden prepares to boost daily vaccination targets","Summary":"Shares of Regeneron Pharmaceuticals Inc.  were up 1.8% in premarket trading on Tuesday after the company said its COVID-19 antibody cocktail can prevent people at high risk of a COVID-19 infection from contracting the viru..."},{"Date":"Jan. 26, 2021 at 10:10 a.m. ET","Headline":"Eli Lilly and Regeneron Report More Positive Data on Covid-19 Antibody Cocktails","Summary":"Shares of Regeneron Pharmaceuticals Inc.  were up 1.8% in premarket trading on Tuesday after the company said its COVID-19 antibody cocktail can prevent people at high risk of a COVID-19 infection from contracting the viru..."},{"Date":"Jan. 26, 2021 at 8:48 a.m. ET","Headline":"Regeneron says its COVID-19 antibody cocktail can prevent infections, based on late-stage study","Summary":"Shares of Regeneron Pharmaceuticals Inc.  were up 1.8% in premarket trading on Tuesday after the company said its COVID-19 antibody cocktail can prevent people at high risk of a COVID-19 infection from contracting the viru..."},{"Date":"Jan. 26, 2021 at 8:45 a.m. ET","Headline":"Lilly says late-stage study showed combo therapy can reduce deaths and hospitalizations in COVID-19 patients","Summary":"Shares of Eli Lilly & Co.  were up 0.3% in premarket trading on Tuesday after the drugmaker said combining two of its experimental COVID-19 antibody treatments can reduce hospitalizations and deaths in high-risk patients b..."},{"Date":"Jan. 29, 2021 at 4:49 p.m. ET","Headline":"U.S. stocks skid Friday to book worst week since October, as GameStop ruckus and vaccine news stress market","Summary":"Eli Lilly & Co.  reported Friday a big fourth-quarter profit beat and revenue that rose 22% to top forecasts, as it recognized $850 million in U.S. revenue for bamlanivimab, the drugmaker's treatment for mile to moderate C..."},{"Date":"Jan. 29, 2021 at 11:16 a.m. ET","Headline":"Lilly Reports Strong Sales, Boosted by Covid Antibodies","Summary":"Eli Lilly & Co.  reported Friday a big fourth-quarter profit beat and revenue that rose 22% to top forecasts, as it recognized $850 million in U.S. revenue for bamlanivimab, the drugmaker's treatment for mile to moderate C..."},{"Date":"Jan. 29, 2021 at 6:37 a.m. ET","Headline":"Eli Lilly beats profit and sales forecasts, to deliver 500,000 more COVID-19 treatment doses by end of March","Summary":"Eli Lilly & Co.  reported Friday a big fourth-quarter profit beat and revenue that rose 22% to top forecasts, as it recognized $850 million in U.S. revenue for bamlanivimab, the drugmaker's treatment for mile to moderate C..."},{"Date":"Feb. 4, 2021 at 6:09 p.m. ET","Headline":"The new South African strain is more infectious, and it\u2019s also making COVID-19 vaccines less effective","Summary":""},{"Date":"Feb. 4, 2021 at 8:42 a.m. ET","Headline":"We still know frustratingly little about Alzheimer\u2019s disease, but there are ways to minimize your risk","Summary":""},{"Date":"Feb. 5, 2021 at 11:05 a.m. ET","Headline":"FDA to issue guidance for vaccine developers about new variants","Summary":"The U.S. government plans to provide additional guidance about new strains of SARS-CoV-2 to companies that have developed or are developing new tests, treatments, and vaccines. The Food and Drug Administration said Thursda..."},{"Date":"Feb. 7, 2021 at 7:00 a.m. ET","Headline":"Big Pension Buys Up Alibaba, Lilly, and Cisco Stock. Here\u2019s What It Sold.","Summary":""},{"Date":"Feb. 10, 2021 at 1:32 p.m. ET","Headline":"WHO Recommends Use of AstraZeneca Vaccine Against Variants","Summary":"Shares of Eli Lilly & Co.  were up 1.1% in premarket trading on Wednesday, the day after the Food and Drug Administration granted emergency authorization to the company's COVID-19 antibody cocktail. The infusion pairs two ..."},{"Date":"Feb. 10, 2021 at 8:05 a.m. ET","Headline":"FDA grants authorization to Lilly's COVID-19 antibody treatment","Summary":"Shares of Eli Lilly & Co.  were up 1.1% in premarket trading on Wednesday, the day after the Food and Drug Administration granted emergency authorization to the company's COVID-19 antibody cocktail. The infusion pairs two ..."},{"Date":"Feb. 9, 2021 at 4:30 p.m. ET","Headline":"S&P 500, Dow miss out on new records and snap 6-day win streak","Summary":"The drugmaker appoints Anat Ashkenazi to succeed Smiley as finance chief."},{"Date":"Feb. 9, 2021 at 2:54 p.m. ET","Headline":"Lilly CFO Josh Smiley Resigns Following Allegations of Inappropriate Personal Relationship","Summary":"The drugmaker appoints Anat Ashkenazi to succeed Smiley as finance chief."},{"Date":"Feb. 9, 2021 at 7:18 a.m. ET","Headline":"Lilly promotes Anat Ashkenazi to CFO, says previous CFO had 'inappropriate' communication with employees","Summary":"Shares of Eli Lilly & Co.  were down 0.3% in premarket trading on Tuesday after the drugmaker said chief financial officer Josh Smiley will resign after engaging in inappropriate personal communications with some employees..."},{"Date":"Feb. 7, 2021 at 1:27 p.m. ET","Headline":"The Other Pandemic: What to Do About the Coming Alzheimer\u2019s Crisis","Summary":""},{"Date":"Feb. 12, 2021 at 10:00 a.m. ET","Headline":"Eli Lilly Executives Enthusiastic About Alzheimer\u2019s Drug, Analyst Says","Summary":""},{"Date":"Feb. 12, 2021 at 8:08 a.m. ET","Headline":"The SEC Finally Says Enough to One Social Media-Fueled Trade","Summary":""},{"Date":"Feb. 7, 2021 at 1:44 p.m. ET","Headline":"Biogen\u2019s Alzheimer\u2019s Drug Faces a Big Test. What to Know.","Summary":""},{"Date":"Feb. 18, 2021 at 4:20 p.m. ET","Headline":"U.S. stocks close lower for third day as investors weigh economic data, rising bond yields","Summary":"Rigel Pharmaceuticals Inc. shares  soared 39% in premarket trade Thursday, after the company said it has agreed to partner with Eli Lilly and Co.  in developing RIPK1 Inhibitors to treat immunological and neurodegenerative..."},{"Date":"Feb. 18, 2021 at 6:52 a.m. ET","Headline":"Rigel Pharma shares soar 39% premarket on news of deal with Eli Lilly","Summary":"Rigel Pharmaceuticals Inc. shares  soared 39% in premarket trade Thursday, after the company said it has agreed to partner with Eli Lilly and Co.  in developing RIPK1 Inhibitors to treat immunological and neurodegenerative..."},{"Date":"Feb. 17, 2021 at 12:06 p.m. ET","Headline":"5 Affordable Biopharma Stocks With Growth Potential","Summary":""},{"Date":"Feb. 17, 2021 at 9:29 a.m. ET","Headline":"Vir and GSK Will Collaborate on Flu Therapy","Summary":""},{"Date":"Feb. 26, 2021 at 12:45 p.m. ET","Headline":"Global COVID cases top 113 million as FDA committee meets to vote on J&J vaccine","Summary":"Eli Lilly & Co.  said Friday the U.S. government has agreed to purchase at least 100,000 doses of its COVID-19 antibody therapy, which was recently granted emergency use authorization for use in recently diagnosed, mild to..."},{"Date":"Feb. 26, 2021 at 9:25 a.m. ET","Headline":"Eli Lilly Signs $210 Million Deal With U.S. for Covid-19 Antibody Therapy","Summary":"Eli Lilly & Co.  said Friday the U.S. government has agreed to purchase at least 100,000 doses of its COVID-19 antibody therapy, which was recently granted emergency use authorization for use in recently diagnosed, mild to..."},{"Date":"Feb. 26, 2021 at 7:11 a.m. ET","Headline":"Eli Lilly says U.S. government has agreed to buy at least 100,000 doses of its COVID antibody therapy","Summary":"Eli Lilly & Co.  said Friday the U.S. government has agreed to purchase at least 100,000 doses of its COVID-19 antibody therapy, which was recently granted emergency use authorization for use in recently diagnosed, mild to..."},{"Date":"Mar. 4, 2021 at 3:03 p.m. ET","Headline":"NIH to study three experimental COVID-19 treatments","Summary":"The National Institutes of Health said Thursday that it is putting three more investigational COVID-19 treatments into Phase 2\/3 clinical trials. The experimental therapies are: an inhalable beta interferon developed by Sy..."},{"Date":"Mar. 3, 2021 at 2:57 p.m. ET","Headline":"Vir Shares Plummeted Today. What to Know.","Summary":""},{"Date":"Mar. 5, 2021 at 9:10 a.m. ET","Headline":"Eli Lilly Will Unveil Alzheimer\u2019s Drug Data Next Week. What to Watch.","Summary":""},{"Date":"Mar. 10, 2021 at 2:24 p.m. ET","Headline":"Biden to buy another 100 million doses of J&J vaccine as Alaska becomes first state to open eligibility to everyone aged 16 and over","Summary":"Shares of Eli Lilly & Co.  gained 0.7% in premarket trading on Wednesday after the drug maker said its COVID-19 antibody cocktail reduced hospitalizations and deaths in 769 high-risk patients who had recently tested positi..."},{"Date":"Mar. 10, 2021 at 9:29 a.m. ET","Headline":"Eli Lilly Has More Positive Data on Its Combination Covid-19 Antibody Therapy","Summary":"Shares of Eli Lilly & Co.  gained 0.7% in premarket trading on Wednesday after the drug maker said its COVID-19 antibody cocktail reduced hospitalizations and deaths in 769 high-risk patients who had recently tested positi..."},{"Date":"Mar. 10, 2021 at 7:27 a.m. ET","Headline":"Lilly shares more data that says its COVID-19 antibody cocktail can cut hospitalizations, deaths","Summary":"Shares of Eli Lilly & Co.  gained 0.7% in premarket trading on Wednesday after the drug maker said its COVID-19 antibody cocktail reduced hospitalizations and deaths in 769 high-risk patients who had recently tested positi..."},{"Date":"Mar. 9, 2021 at 3:00 p.m. ET","Headline":"What to Watch at the Alzheimer\u2019s Conference (Besides Lilly): Biogen and Prothena","Summary":""},{"Date":"Mar. 11, 2021 at 8:38 a.m. ET","Headline":"Vir\u2019s Covid-19 Antibody Works Well, Sending Shares Flying","Summary":""},{"Date":"Mar. 13, 2021 at 6:30 a.m. ET","Headline":"Eli Lilly Offers More Positive Data on Its Alzheimer\u2019s Drug","Summary":""},{"Date":"Mar. 16, 2021 at 4:02 p.m. ET","Headline":"AstraZeneca to Supply Extra 500,000 Doses of Covid-19 Antibody-Based Treatment to U.S.","Summary":"ShaShares of Eli Lilly & Co.  were down 5.2% in premarket trading on Monday, two days after the drug maker said additional clinical-trial data reinforced the role its experimental Alzheimer's disease drug can play in slowi..."},{"Date":"Mar. 16, 2021 at 9:30 a.m. ET","Headline":"Dip in Eli Lilly Stock Makes It a Buy, Mizuho Analyst Says","Summary":"ShaShares of Eli Lilly & Co.  were down 5.2% in premarket trading on Monday, two days after the drug maker said additional clinical-trial data reinforced the role its experimental Alzheimer's disease drug can play in slowi..."},{"Date":"Mar. 15, 2021 at 4:52 p.m. ET","Headline":"Eli Lilly Said Its Alzheimer\u2019s Data Were Positive. The Stock Market Says Otherwise.","Summary":"ShaShares of Eli Lilly & Co.  were down 5.2% in premarket trading on Monday, two days after the drug maker said additional clinical-trial data reinforced the role its experimental Alzheimer's disease drug can play in slowi..."},{"Date":"Mar. 15, 2021 at 4:46 p.m. ET","Headline":"S&P 500, Dow clinch another round of records as investors await Fed meeting","Summary":"ShaShares of Eli Lilly & Co.  were down 5.2% in premarket trading on Monday, two days after the drug maker said additional clinical-trial data reinforced the role its experimental Alzheimer's disease drug can play in slowi..."},{"Date":"Mar. 15, 2021 at 8:43 a.m. ET","Headline":"Big Pharma Battled the Pandemic. The Stocks Are Cheap.","Summary":"ShaShares of Eli Lilly & Co.  were down 5.2% in premarket trading on Monday, two days after the drug maker said additional clinical-trial data reinforced the role its experimental Alzheimer's disease drug can play in slowi..."},{"Date":"Mar. 15, 2021 at 8:32 a.m. ET","Headline":"Eli Lilly Shares Fall After Alzheimer\u2019s Drug Data Falls Short Of High Expectations","Summary":"ShaShares of Eli Lilly & Co.  were down 5.2% in premarket trading on Monday, two days after the drug maker said additional clinical-trial data reinforced the role its experimental Alzheimer's disease drug can play in slowi..."},{"Date":"Mar. 15, 2021 at 7:44 a.m. ET","Headline":"Lilly's stock is down after sharing additional clinical data about its Alzheimer's disease drug candidate","Summary":"ShaShares of Eli Lilly & Co.  were down 5.2% in premarket trading on Monday, two days after the drug maker said additional clinical-trial data reinforced the role its experimental Alzheimer's disease drug can play in slowi..."},{"Date":"Mar. 18, 2021 at 9:39 a.m. ET","Headline":"Don\u2019t Lose Sight of Biogen\u2019s Depression Drug. How It Could Send the Stock Much Higher.","Summary":"Shares of Eli Lilly & Co.  were up 0.2% in premarket trading on Thursday after the drug maker confirmed that the U.S. government is no longer allowing its monoclonal antibody bamlanivimab to be ordered in Arizona, Californ..."},{"Date":"Mar. 18, 2021 at 8:05 a.m. ET","Headline":"Lilly says its monoclonal antibody is no longer being ordered in 3 states due to variant concerns","Summary":"Shares of Eli Lilly & Co.  were up 0.2% in premarket trading on Thursday after the drug maker confirmed that the U.S. government is no longer allowing its monoclonal antibody bamlanivimab to be ordered in Arizona, Californ..."},{"Date":"Mar. 17, 2021 at 11:54 a.m. ET","Headline":"AstraZeneca to supply U.S. with extra 500,000 doses of COVID-19 antibody-based cocktail","Summary":""},{"Date":"Mar. 20, 2021 at 8:32 a.m. ET","Headline":"The age of the \u2018silver stoners\u2019 is nigh","Summary":""},{"Date":"Mar. 19, 2021 at 4:33 p.m. ET","Headline":"Lilly\u2019s and Biogen\u2019s Alzheimer\u2019s Drugs Have a Way to Go. There Are Still Reasons to Be Hopeful.","Summary":""},{"Date":"Mar. 24, 2021 at 8:28 a.m. ET","Headline":"Elon Musk Says You Can Buy a Tesla With Bitcoin Now. What That Means for Investors.","Summary":"Shares of Regeneron Pharmaceuticals Inc.  gained 1.1% in premarket trading on Tuesday after the drug maker said its COVID-19 antibody cocktail still reduced the risk of hospitalization and death by about 70% among COVID-19..."},{"Date":"Mar. 23, 2021 at 2:23 p.m. ET","Headline":"Global case tally for COVID-19 nears 124 million as U.S. health experts question AstraZeneca trial data","Summary":"Shares of Regeneron Pharmaceuticals Inc.  gained 1.1% in premarket trading on Tuesday after the drug maker said its COVID-19 antibody cocktail still reduced the risk of hospitalization and death by about 70% among COVID-19..."},{"Date":"Mar. 23, 2021 at 12:42 p.m. ET","Headline":"Pfizer Will Test a Pill to Kill the Covid-19 Virus","Summary":"Shares of Regeneron Pharmaceuticals Inc.  gained 1.1% in premarket trading on Tuesday after the drug maker said its COVID-19 antibody cocktail still reduced the risk of hospitalization and death by about 70% among COVID-19..."},{"Date":"Mar. 23, 2021 at 9:17 a.m. ET","Headline":"Regeneron Stock Climbs on Positive Covid-19 Antibody Data","Summary":"Shares of Regeneron Pharmaceuticals Inc.  gained 1.1% in premarket trading on Tuesday after the drug maker said its COVID-19 antibody cocktail still reduced the risk of hospitalization and death by about 70% among COVID-19..."},{"Date":"Mar. 23, 2021 at 8:27 a.m. ET","Headline":"Regeneron says its COVID-19 treatment still works even at a lower dose","Summary":"Shares of Regeneron Pharmaceuticals Inc.  gained 1.1% in premarket trading on Tuesday after the drug maker said its COVID-19 antibody cocktail still reduced the risk of hospitalization and death by about 70% among COVID-19..."},{"Date":"Mar. 26, 2021 at 9:49 a.m. ET","Headline":"GSK and Vir Submit Covid-19 Antibody for FDA Authorization","Summary":"Pfizer Inc.  and Eli Lilly and Co.  said Thursday that a joint advisory committee of the U.S. Food and Drug Administration has voted against  their investigational tanezumab drug for the treatment of certain types of arthr..."},{"Date":"Mar. 26, 2021 at 8:13 a.m. ET","Headline":"FDA Advisory Panel Says Risks Outweigh Benefits of Pfizer and Lilly\u2019s Pain Drug","Summary":"Pfizer Inc.  and Eli Lilly and Co.  said Thursday that a joint advisory committee of the U.S. Food and Drug Administration has voted against  their investigational tanezumab drug for the treatment of certain types of arthr..."},{"Date":"Mar. 25, 2021 at 4:12 p.m. ET","Headline":"Pfizer, Eli Lilly say experimental arthritis drug tanezumab hits FDA snag","Summary":"Pfizer Inc.  and Eli Lilly and Co.  said Thursday that a joint advisory committee of the U.S. Food and Drug Administration has voted against  their investigational tanezumab drug for the treatment of certain types of arthr..."},{"Date":"Mar. 25, 2021 at 8:01 a.m. ET","Headline":"Vaccines are here. That\u2019s no reason to call off the hunt for effective COVID-19 treatments.","Summary":""},{"Date":"Mar. 29, 2021 at 2:42 p.m. ET","Headline":"U.S. COVID death toll nears 550,000 as Dr. Birx says most could have been avoided","Summary":"Eli Lilly & Co. , Vir Biotechnology Inc.  and GlaxoSmithKline PLC  on Monday reported positive data from a Phase 2 trial evaluating the combination of two monoclonal antibodies in treating low-risk adult COVID-19 patients...."},{"Date":"Mar. 29, 2021 at 8:44 a.m. ET","Headline":"Eli Lilly, Vir and Glaxo say Phase 2 trial combining antibodies reduced viral load by 70% at day 7","Summary":"Eli Lilly & Co. , Vir Biotechnology Inc.  and GlaxoSmithKline PLC  on Monday reported positive data from a Phase 2 trial evaluating the combination of two monoclonal antibodies in treating low-risk adult COVID-19 patients...."},{"Date":"Apr. 7, 2021 at 10:14 a.m. ET","Headline":"Pfizer\u2019s Xeljanz Faces Canadian Review Amid More Scrutiny of JAK Inhibitors","Summary":""},{"Date":"Apr. 9, 2021 at 8:43 a.m. ET","Headline":"NIH recommends Lilly and Regeneron's combination antibody treatments to people with mild and moderate COVID-19","Summary":"The National Institutes of Health on Thursday  that patients with mild to moderate COVID-19 who are at high risk of worsening disease should be treated with monoclonal antibody cocktails. The recommendation was issued by t..."},{"Date":"Apr. 8, 2021 at 2:14 p.m. ET","Headline":"Global COVID-19 cases top 133 million as Brazil and India become flashpoints","Summary":"Eli Lilly & Co.  and Incyte Corp.  said Thursday a Phase 3 trial of rheumatoid arthritis treatment baricitinib plus standard of care (SoC) versus placebo plus SoC failed to meet its main goal. The trial's primary endpoint ..."},{"Date":"Apr. 8, 2021 at 7:01 a.m. ET","Headline":"Eli Lilly and Incyte say Phase 3 study of baricitinib in hospitalized COVID-19 patients failed to meet main goal","Summary":"Eli Lilly & Co.  and Incyte Corp.  said Thursday a Phase 3 trial of rheumatoid arthritis treatment baricitinib plus standard of care (SoC) versus placebo plus SoC failed to meet its main goal. The trial's primary endpoint ..."},{"Date":"Apr. 12, 2021 at 3:21 p.m. ET","Headline":"COVID-19 cases keep surging in some U.S. states, and Michigan governor continues plea for more vaccines as shots in arms hits daily record","Summary":"Shares of Eli Lilly & Co.  were up 0.3% in premarket trading on Monday after the company said the U.S. government modified purchase agreements for its COVID-19 antibody therapies. The agreement for bamlanivimab, which was ..."},{"Date":"Apr. 12, 2021 at 8:31 a.m. ET","Headline":"Lilly says U.S. government modified purchases of its COVID-19 antibody treatments","Summary":"Shares of Eli Lilly & Co.  were up 0.3% in premarket trading on Monday after the company said the U.S. government modified purchase agreements for its COVID-19 antibody therapies. The agreement for bamlanivimab, which was ..."},{"Date":"Apr. 17, 2021 at 9:34 a.m. ET","Headline":"More than 3 million people have died of COVID-19 and more than 140 million have been infected","Summary":"Eli Lilly and Co.  said Friday it is seeking a revocation of the emergency use authorization granted by U.S. regulators for its bamlanivimab antibody treatment for COVID-19 alone in order to complete the transition to baml..."},{"Date":"Apr. 16, 2021 at 5:33 p.m. ET","Headline":"Dow and S&P 500 finish at records, book 4 weeks of gains in a row","Summary":"Eli Lilly and Co.  said Friday it is seeking a revocation of the emergency use authorization granted by U.S. regulators for its bamlanivimab antibody treatment for COVID-19 alone in order to complete the transition to baml..."},{"Date":"Apr. 16, 2021 at 6:48 a.m. ET","Headline":"Eli Lilly asks FDA to revoke EUA for COVID antibody treatment alone to speed transition to combination therapy","Summary":"Eli Lilly and Co.  said Friday it is seeking a revocation of the emergency use authorization granted by U.S. regulators for its bamlanivimab antibody treatment for COVID-19 alone in order to complete the transition to baml..."},{"Date":"Apr. 19, 2021 at 10:03 a.m. ET","Headline":"Biogen Stock Could Rise 85%. Two Drugs Are Critical.","Summary":""},{"Date":"Apr. 23, 2021 at 7:10 p.m. ET","Headline":"Amid Chip Shortage Taiwan Semiconductor Invests for the Future","Summary":""},{"Date":"Apr. 25, 2021 at 6:30 p.m. ET","Headline":"Polls Say More Than Half of Americans Approve of Biden\u2019s Performance in First 100 Days","Summary":""},{"Date":"Apr. 27, 2021 at 4:18 p.m. ET","Headline":"Stocks Close Mostly Flat on Big Day for Earnings","Summary":"Eli Lilly & Co. shares  slid 5% in premarket trade Tuesday, after the drug company posted weaker-than-expected first-quarter earnings and offered guidance that is below consensus. The company posted net income of $1.355 bi..."},{"Date":"Apr. 27, 2021 at 4:16 p.m. ET","Headline":"Dow ekes out modest gain but Nasdaq slips as investors watch tech earnings","Summary":"Eli Lilly & Co. shares  slid 5% in premarket trade Tuesday, after the drug company posted weaker-than-expected first-quarter earnings and offered guidance that is below consensus. The company posted net income of $1.355 bi..."},{"Date":"Apr. 27, 2021 at 12:55 p.m. ET","Headline":"Don\u2019t bail on stocks now, says world\u2019s top fund manager BlackRock","Summary":"Eli Lilly & Co. shares  slid 5% in premarket trade Tuesday, after the drug company posted weaker-than-expected first-quarter earnings and offered guidance that is below consensus. The company posted net income of $1.355 bi..."},{"Date":"Apr. 27, 2021 at 8:11 a.m. ET","Headline":"Eli Lilly Cuts Earnings Forecast as Profits Fall Short","Summary":"Eli Lilly & Co. shares  slid 5% in premarket trade Tuesday, after the drug company posted weaker-than-expected first-quarter earnings and offered guidance that is below consensus. The company posted net income of $1.355 bi..."},{"Date":"Apr. 27, 2021 at 6:40 a.m. ET","Headline":"Eli Lilly shares slide 5% premarket as earnings fall short of estimates and guidance lags consensus","Summary":"Eli Lilly & Co. shares  slid 5% in premarket trade Tuesday, after the drug company posted weaker-than-expected first-quarter earnings and offered guidance that is below consensus. The company posted net income of $1.355 bi..."},{"Date":"Apr. 26, 2021 at 7:55 a.m. ET","Headline":"Tesla, Apple, Amazon, and Other Stocks to Watch This Week","Summary":""},{"Date":"Apr. 29, 2021 at 9:04 a.m. ET","Headline":"Bristol Myers Squibb Stock Fell After Earnings. Here\u2019s Why.","Summary":""},{"Date":"Apr. 29, 2021 at 7:44 a.m. ET","Headline":"Merck Earnings Fell Short of Expectations. Here\u2019s What Caused the Miss.","Summary":""},{"Date":"Apr. 28, 2021 at 7:09 a.m. ET","Headline":"Lilly\u2019s COVID-19 antibody drugs are a top seller this quarter, but investors aren\u2019t that excited","Summary":""},{"Date":"Apr. 25, 2021 at 8:28 p.m. ET","Headline":"The Big Tech Stocks Could Fall, if History Is Any Guide","Summary":""},{"Date":"May. 3, 2021 at 3:56 p.m. ET","Headline":"Lilly board authorizes $5 billion more in buybacks","Summary":""},{"Date":"May. 3, 2021 at 1:19 p.m. ET","Headline":"Pfizer\u2019s Earnings Are Tuesday. Here\u2019s What to Expect.","Summary":""},{"Date":"May. 3, 2021 at 9:35 a.m. ET","Headline":"Uber, Pfizer, ViacomCBS, General Motors, and Other Stocks to Watch This Week","Summary":""},{"Date":"May. 2, 2021 at 11:50 p.m. ET","Headline":"Asian markets pull back in light trading","Summary":""},{"Date":"Apr. 30, 2021 at 7:55 p.m. ET","Headline":"Spotify Has Big Growth Expectations. So Far It\u2019s Short of Proof.","Summary":""},{"Date":"May. 4, 2021 at 10:24 a.m. ET","Headline":"Pfizer\u2019s Vaccine Drove a Big Earnings Beat. What It Means for the Stock.","Summary":"Shares of Eli Lilly & Co.  gained 0.1% in premarket trading on Tuesday after the company said it will donate 400,000 doses of Olumiant, its rheumatoid arthritis drug  as a COVID-19 treatment for the severely ill in the U.S..."},{"Date":"May. 4, 2021 at 7:22 a.m. ET","Headline":"Lilly to donate experimental COVID-19 treatment Olumiant to India","Summary":"Shares of Eli Lilly & Co.  gained 0.1% in premarket trading on Tuesday after the company said it will donate 400,000 doses of Olumiant, its rheumatoid arthritis drug  as a COVID-19 treatment for the severely ill in the U.S..."},{"Date":"May. 6, 2021 at 8:55 p.m. ET","Headline":"Stock buybacks top $200 billion in April, the second-highest monthly total since Trump\u2019s tax cuts","Summary":"The biotech company reported financial results early Thursday. It was the details that seemed to matter."},{"Date":"May. 6, 2021 at 8:23 a.m. ET","Headline":"Pfizer\u2019s next play: A vaccine maker and pandemic \u2018partner\u2019 to governments","Summary":"The biotech company reported financial results early Thursday. It was the details that seemed to matter."},{"Date":"May. 6, 2021 at 7:34 a.m. ET","Headline":"Regeneron Earnings Lift Stock. Here\u2019s Why.","Summary":"The biotech company reported financial results early Thursday. It was the details that seemed to matter."},{"Date":"May. 5, 2021 at 4:44 p.m. ET","Headline":"Investing in the Covid-19 vaccine companies? Here\u2019s the great divide in the group","Summary":""},{"Date":"May. 11, 2021 at 5:07 p.m. ET","Headline":"Apple, Netflix, and 17 More Stocks Investors Are Selling That Wall Street Loves","Summary":""},{"Date":"May. 17, 2021 at 8:21 a.m. ET","Headline":"Bitcoin Won\u2019t Stop Dropping. Blame Elon Musk.","Summary":""},{"Date":"May. 20, 2021 at 7:00 a.m. ET","Headline":"5 Biopharma Stocks That Are Cheap and Growing","Summary":""},{"Date":"May. 24, 2021 at 10:48 a.m. ET","Headline":"Big Drug Stocks Have Rallied. Why an Analyst Says They Have More Room to Run.","Summary":""},{"Date":"May. 28, 2021 at 4:00 p.m. ET","Headline":"This Just-Approved Amgen Drug Is the First to Hit a Hard Target in Cancer","Summary":"The U.S. government said this week it is halting distribution of Eli Lilly & Co.'s  COVID-19 antibody treatment in six states due to the growing prevalence of the P.1 and B.1.351 variants there. Lilly's combination therapy..."},{"Date":"May. 28, 2021 at 10:44 a.m. ET","Headline":"U.S. stops distributing Lilly's COVID-19 antibody therapy in six states, instead recommends Regeneron's treatment","Summary":"The U.S. government said this week it is halting distribution of Eli Lilly & Co.'s  COVID-19 antibody treatment in six states due to the growing prevalence of the P.1 and B.1.351 variants there. Lilly's combination therapy..."},{"Date":"May. 28, 2021 at 10:17 a.m. ET","Headline":"Eli Lilly Receives DOJ Subpoena Related to Manufacturing Site","Summary":""},{"Date":"May. 31, 2021 at 8:05 a.m. ET","Headline":"The FDA authorized the third antibody infusion therapy. Here\u2019s why Vir and GSK say the U.S. still needs COVID-19 treatments","Summary":""},{"Date":"Jun. 2, 2021 at 10:58 a.m. ET","Headline":"J&J stock gains after Moody's says $2.5 billion payment for talc claims doesn't affect Aaa rating","Summary":"Shares of Johnson & Johnson  rose 0.4% in morning trading, in the wake of the a Missouri court verdict regarding various talc cases against the consumer products and drug maker. As a result of the Supreme Court decision, J..."},{"Date":"Jun. 2, 2021 at 8:25 a.m. ET","Headline":"Amazon Prime Day Is Good For Shoppers. Just Don\u2019t Expect It to Move the Stock.","Summary":""},{"Date":"Jun. 1, 2021 at 2:54 p.m. ET","Headline":"Alzheimer\u2019s Drug Decision Is a Big Deal for Biogen\u2014and the Entire Biotech Sector","Summary":""},{"Date":"Jun. 4, 2021 at 11:07 a.m. ET","Headline":"FDA Authorizes Lower Regeneron Covid-19 Antibody Dose. What That Means for the Stock.","Summary":""},{"Date":"Jun. 8, 2021 at 10:47 a.m. ET","Headline":"Eli Lilly May Be a Big Winner From the FDA\u2019s Alzheimer\u2019s Decision","Summary":""},{"Date":"Jun. 7, 2021 at 4:38 p.m. ET","Headline":"Dow books modest loss after touching record, Nasdaq Composite and small-cap Russell 2000 end higher","Summary":""},{"Date":"Jun. 7, 2021 at 11:58 a.m. ET","Headline":"Biogen\u2019s Alzheimer\u2019s Drug Is Approved by the FDA. The Price? $56,000 a Year.","Summary":""},{"Date":"Jun. 7, 2021 at 12:01 a.m. ET","Headline":"What to Know About the FDA\u2019s Approval of Biogen\u2019s Alzheimer\u2019s Drug","Summary":""},{"Date":"Jun. 4, 2021 at 7:37 a.m. ET","Headline":"FDA Has a Monday Deadline to Decide on Biogen\u2019s Alzheimer\u2019s Drug. What to Know.","Summary":""},{"Date":"Jun. 9, 2021 at 1:28 p.m. ET","Headline":"Merck Could See $1.2 Billion Covid-19 Antiviral Sale to U.S. Government","Summary":""},{"Date":"Jun. 14, 2021 at 9:31 a.m. ET","Headline":"Biogen\u2019s Alzheimer\u2019s Drug Opens Up a New Market. These Stocks Could Benefit if More Approvals Come.","Summary":""},{"Date":"Jun. 16, 2021 at 10:44 a.m. ET","Headline":"Elanco Strikes Deal to Better Compete With Rival Zoetis in Pet Dermatology","Summary":""},{"Date":"Jun. 18, 2021 at 8:45 a.m. ET","Headline":"Is it time for Americans to drop their infatuation with the PCR test? That\u2019s what this COVID-19 testing expert thinks","Summary":""},{"Date":"Jun. 24, 2021 at 7:26 p.m. ET","Headline":"Lilly to seek FDA approval for potential Alzheimer\u2019s drug later this year","Summary":""},{"Date":"Jun. 24, 2021 at 10:20 a.m. ET","Headline":"The Alzheimer\u2019s Drug Floodgates Are Opening. Eli Lilly Has Positive News.","Summary":""},{"Date":"Jun. 24, 2021 at 9:02 a.m. ET","Headline":"Eli Lilly Jumps, Dollar Tree Slips as Stock Market Chases Infrastructure Plan Higher","Summary":""},{"Date":"Jun. 25, 2021 at 4:45 p.m. ET","Headline":"Eli Lilly COVID-19 antibody drug shipments paused over variant concerns","Summary":""},{"Date":"Jun. 25, 2021 at 8:16 a.m. ET","Headline":"Eli Lilly Stock Soared on Alzheimer\u2019s Hopes. Now Wall Street Has Doubts.","Summary":""},{"Date":"Jun. 25, 2021 at 7:55 a.m. ET","Headline":"The Market\u2019s Not Paying Enough Attention to the Infrastructure Deal","Summary":""},{"Date":"Jun. 28, 2021 at 8:15 a.m. ET","Headline":"These 30 stocks are the best dividend income growers among the S&P 500","Summary":""},{"Date":"Jun. 28, 2021 at 8:06 a.m. ET","Headline":"The Covid-19 Booster Market Just Keeps Getting Bigger, Moderna\u2019s CEO Says","Summary":""},{"Date":"Jun. 30, 2021 at 11:32 a.m. ET","Headline":"Here Are the Best and Worst Biopharma Stock Performers So Far This Year","Summary":""},{"Date":"Jun. 29, 2021 at 1:06 p.m. ET","Headline":"Now on Sale at Walmart: Insulin That\u2019s Cheaper Than Brands from Lilly, Sanofi, or Novo Nordisk","Summary":""},{"Date":"Jul. 2, 2021 at 9:55 a.m. ET","Headline":"FDA made a mistake in approving a questionable Alzheimer\u2019s drug, but Medicare could act to reduce false hopes and unethical profits","Summary":""},{"Date":"Jul. 8, 2021 at 4:15 a.m. ET","Headline":"Vaccine Maker AstraZeneca\u2019s Strong Drug Pipeline Could Lift the Stock Higher for Years","Summary":""},{"Date":"Jul. 7, 2021 at 9:47 a.m. ET","Headline":"Analyst Raises Price Targets on 3 Smaller Alzheimer\u2019s Stocks","Summary":""},{"Date":"Jul. 7, 2021 at 12:40 p.m. ET","Headline":"When Big Tech Stumbles, the Market Can Fall Hard. These 5 Funds Can Help.","Summary":""},{"Date":"Jul. 14, 2021 at 4:22 p.m. ET","Headline":"Dow, S&P 500 end higher after Powell stresses time not right to pull back Fed support","Summary":"Eli Lilly & Co.  said Wednesday it is acquiring the shares of Protomer Technologies it does not already own, in a deal it says has a potential value of more than $1 billion based on future development and commercial milest..."},{"Date":"Jul. 14, 2021 at 11:22 a.m. ET","Headline":"Roche Stock Could Be an Alzheimer\u2019s Winner. It\u2019s a Buy, Jefferies Says","Summary":"Eli Lilly & Co.  said Wednesday it is acquiring the shares of Protomer Technologies it does not already own, in a deal it says has a potential value of more than $1 billion based on future development and commercial milest..."},{"Date":"Jul. 14, 2021 at 7:00 a.m. ET","Headline":"Eli Lilly buys remaining shares of Protomer Technologies in glucose-responsive insulin play","Summary":"Eli Lilly & Co.  said Wednesday it is acquiring the shares of Protomer Technologies it does not already own, in a deal it says has a potential value of more than $1 billion based on future development and commercial milest..."},{"Date":"Jul. 30, 2021 at 8:34 p.m. ET","Headline":"GE Has a No-Drama Earnings Beat, Powered by Its Free Cash Flow","Summary":"Shares of Eli Lilly & Co.  gained 0.6% in premarket trading on Thursday after the company announced a deal with Kumquat Biosciences to develop and commercialize small molecules that utilize Kumquat's immuno-oncology platfo..."},{"Date":"Jul. 30, 2021 at 3:08 p.m. ET","Headline":"How Contagious Is the Delta Variant? CDC Study Sheds Light.","Summary":"Shares of Eli Lilly & Co.  gained 0.6% in premarket trading on Thursday after the company announced a deal with Kumquat Biosciences to develop and commercialize small molecules that utilize Kumquat's immuno-oncology platfo..."},{"Date":"Jul. 29, 2021 at 7:28 a.m. ET","Headline":"Lilly signs deal with Kumquat Biosciences","Summary":"Shares of Eli Lilly & Co.  gained 0.6% in premarket trading on Thursday after the company announced a deal with Kumquat Biosciences to develop and commercialize small molecules that utilize Kumquat's immuno-oncology platfo..."},{"Date":"Aug. 1, 2021 at 6:00 a.m. ET","Headline":"A Huge Pension Bet Big on Moderna Stock. It Sold Starbucks, United, and Eli Lilly.","Summary":""},{"Date":"Aug. 3, 2021 at 4:42 p.m. ET","Headline":"S&P 500 closes at fresh peak, U.S. stocks end higher amid corporate earnings and COVID worries","Summary":"Shares of Eli Lilly & Co.  fell 1.4% in premarket trading Tuesday after the drug maker missed second-quarter profit expectations while revenue beat, as gross margin as a percentage of revenue fell due primarily to an exces..."},{"Date":"Aug. 3, 2021 at 1:28 p.m. ET","Headline":"Eli Lilly Earnings Missed Expectations. Why the Stock Is Soaring.","Summary":"Shares of Eli Lilly & Co.  fell 1.4% in premarket trading Tuesday after the drug maker missed second-quarter profit expectations while revenue beat, as gross margin as a percentage of revenue fell due primarily to an exces..."},{"Date":"Aug. 3, 2021 at 6:44 a.m. ET","Headline":"Eli Lilly's stock falls after profit comes up short of expectations, while revenue beat","Summary":"Shares of Eli Lilly & Co.  fell 1.4% in premarket trading Tuesday after the drug maker missed second-quarter profit expectations while revenue beat, as gross margin as a percentage of revenue fell due primarily to an exces..."},{"Date":"Aug. 2, 2021 at 9:09 a.m. ET","Headline":"Uber, DraftKings, GM, ViacomCBS, and Other Stocks to Watch This Week","Summary":""},{"Date":"Aug. 2, 2021 at 8:08 a.m. ET","Headline":"Buy This Drugmaker Stock Because Its Turnaround Could Be Accelerated","Summary":""},{"Date":"Aug. 17, 2021 at 6:58 a.m. ET","Headline":"Eli Lilly creates neuroscience and immunology business units","Summary":"Eli Lilly & Co.  announced Tuesday that it will split its Lilly Bio-Medicines division into two business units: Lilly Neuroscience and Lilly Immunology, effective September 5. Lilly Neuroscience will be led by Anne White, ..."},{"Date":"Aug. 16, 2021 at 4:15 a.m. ET","Headline":"These 10 Standout Stocks Could Be the Next Amazon","Summary":""},{"Date":"Aug. 19, 2021 at 6:37 a.m. ET","Headline":"Robinhood Enjoys Crypto Boom. Why the Stock Is Tumbling.","Summary":""},{"Date":"Aug. 23, 2021 at 7:00 a.m. ET","Headline":"A Top U.S. Pension Manager Bought Up Philip Morris Stock","Summary":""},{"Date":"Sep. 2, 2021 at 3:04 p.m. ET","Headline":"AbbVie Stock Dropped After FDA Warning. Analysts Say Selloff Is Overblown.","Summary":""},{"Date":"Sep. 3, 2021 at 7:39 p.m. ET","Headline":"Why Caterpillar Stock Is Likely to Keep Plowing Ahead","Summary":""},{"Date":"Sep. 9, 2021 at 9:55 a.m. ET","Headline":"White House to Announce Drug-Pricing Plan. Pharma Stocks Are Down.","Summary":""},{"Date":"Sep. 14, 2021 at 8:38 a.m. ET","Headline":"Merck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end","Summary":"Merck & Co. Inc.  said it expects the company's experimental oral antiviral treatment for COVID-19 could get emergency authorization by the end of the year. \"We expect to be able to see clinical data here in the back half ..."},{"Date":"Sep. 15, 2021 at 6:53 a.m. ET","Headline":"Eli Lilly to supply the U.S. government with doses of COVID-19 treatment etesevimab for $330 million","Summary":"Eli Lilly & Co.  announced Wednesday to sell 388,000 doses of etesevimab, which has been authorized for emergency use as a COVID-19 treatment for $330 million. As part of the deal, about 200,000 doses of etesevimab, which ..."},{"Date":"Sep. 17, 2021 at 9:57 a.m. ET","Headline":"FDA\u2019s Call on Lilly\u2019s Covid Drug Is Lifting a Partner\u2019s Beaten-Down Stock","Summary":""},{"Date":"Sep. 17, 2021 at 6:21 a.m. ET","Headline":"Alaska joins Idaho in rationing health care as hospitals are packed with COVID patients, and WHO says Africa is being left behind in vaccine push","Summary":""},{"Date":"Sep. 24, 2021 at 11:47 a.m. ET","Headline":"Biogen\u2019s Aduhelm Struggles Don\u2019t Hurt Lilly\u2019s Outlook, Says Analyst","Summary":""},{"Date":"Sep. 28, 2021 at 1:28 p.m. ET","Headline":"With Insulin Sales Shrinking in Importance, Lilly Cuts Price","Summary":"Eli Lilly & Co.  said Tuesday it is reducing the list price of Insulin Lispro Injection in the U.S. by another 40% effective Jan. 1, 2022, bringing the price down to 2008 levels. \"Lilly's Insulin Lispro Injection, 100 unit..."},{"Date":"Sep. 28, 2021 at 6:41 a.m. ET","Headline":"Eli Lilly to reduce list price of Insulin Lispro injection by an additional 40% from Jan. 1, restoring it to 2008 levels","Summary":"Eli Lilly & Co.  said Tuesday it is reducing the list price of Insulin Lispro Injection in the U.S. by another 40% effective Jan. 1, 2022, bringing the price down to 2008 levels. \"Lilly's Insulin Lispro Injection, 100 unit..."},{"Date":"Sep. 27, 2021 at 7:53 a.m. ET","Headline":"Medicine\u2019s Golden Age Is Dawning. 10 Stocks to Play the Latest Innovations.","Summary":""},{"Date":"Sep. 30, 2021 at 7:10 p.m. ET","Headline":"Merck CEO Sees \u2018Multibillion-Dollar\u2019 Opportunity With Acceleron","Summary":""},{"Date":"Sep. 29, 2021 at 1:05 p.m. ET","Headline":"After Lilly\u2019s Selloff, Citi Declares the Stock a Buy","Summary":""},{"Date":"Oct. 5, 2021 at 7:07 a.m. ET","Headline":"Location, location, location: Ohio is benefiting in tech growth as a major transportation hub","Summary":""},{"Date":"Oct. 7, 2021 at 4:00 a.m. ET","Headline":"Government Price Controls Will Kill Pharma Innovation, Lilly CEO Says","Summary":""},{"Date":"Oct. 14, 2021 at 10:39 a.m. ET","Headline":"FDA Will Consider Regeneron\u2019s Covid-19 Antibody for Full Approval","Summary":""},{"Date":"Oct. 15, 2021 at 11:04 a.m. ET","Headline":"Don\u2019t Count Out Covid-19 Monoclonal Antibody Treatments, Analyst Says. These Are the Stocks to Watch.","Summary":""},{"Date":"Oct. 15, 2021 at 7:45 a.m. ET","Headline":"Why a pill you take at home could change the direction of the pandemic","Summary":""},{"Date":"Oct. 15, 2021 at 4:00 a.m. ET","Headline":"The FDA Is About to Make Some Major Drug Decisions. What Investors Need to Know.","Summary":""},{"Date":"Oct. 20, 2021 at 1:23 p.m. ET","Headline":"4 Healthcare Stocks Selling for Way Less Than Analysts Think They\u2019re Worth","Summary":""},{"Date":"Oct. 22, 2021 at 6:00 p.m. ET","Headline":"Adobe on Holiday Shopping: Online Gains and Supply Chain Woes","Summary":""},{"Date":"Oct. 23, 2021 at 8:30 a.m. ET","Headline":"The Federal Reserve\u2019s next interest rate-hike cycle is coming but may not look like what officials have been projecting","Summary":""},{"Date":"Oct. 26, 2021 at 4:38 p.m. ET","Headline":"Dow, S&P 500 end at all-time records as U.S. stocks extend winning streak amid strong company earnings","Summary":"Shares of Eli Lilly & Co.  gained 0.8% in premarket trading on Tuesday after the company told investors as part of its third-quarter earnings that it has started the process to seek approval from the Food and Drug Administ..."},{"Date":"Oct. 26, 2021 at 2:09 p.m. ET","Headline":"Eli Lilly Earnings Disappointed. Why the Stock Is Rising.","Summary":"Shares of Eli Lilly & Co.  gained 0.8% in premarket trading on Tuesday after the company told investors as part of its third-quarter earnings that it has started the process to seek approval from the Food and Drug Administ..."},{"Date":"Oct. 26, 2021 at 11:47 a.m. ET","Headline":"Eli Lilly Is Asking the FDA to Approve Its Alzheimer\u2019s Therapy","Summary":"Shares of Eli Lilly & Co.  gained 0.8% in premarket trading on Tuesday after the company told investors as part of its third-quarter earnings that it has started the process to seek approval from the Food and Drug Administ..."},{"Date":"Oct. 26, 2021 at 8:02 a.m. ET","Headline":"Lilly plans to run clinical trial comparing its Alzheimer's drug candidate to Biogen's Aduhelm","Summary":"Shares of Eli Lilly & Co.  gained 0.8% in premarket trading on Tuesday after the company told investors as part of its third-quarter earnings that it has started the process to seek approval from the Food and Drug Administ..."},{"Date":"Oct. 26, 2021 at 6:50 a.m. ET","Headline":"Eli Lilly & Co. net income falls 8%, but adjusted profit rises","Summary":"Eli Lilly & Co.  said Tuesday its third-quarter net income fell 8% to $1.11 billion, or $1.22 a share, from $1.21 billion, or $1.33 a share in the year-ago period. Adjusted net income increased to $1.94 a share from $1.41 ..."},{"Date":"Oct. 25, 2021 at 8:27 a.m. ET","Headline":"Apple, Amazon, Comcast, Chevron, Boeing, and Other Stocks to Watch This Week","Summary":""},{"Date":"Nov. 2, 2021 at 6:22 p.m. ET","Headline":"Democrats Reach Deal on Drug Prices, Schumer Says. Pharma Stocks Are Steady.","Summary":""},{"Date":"Nov. 5, 2021 at 8:36 p.m. ET","Headline":"Gene Therapy Is a Huge Opportunity. It Pays to be Patient.","Summary":""},{"Date":"Nov. 4, 2021 at 9:53 a.m. ET","Headline":"Regeneron Earnings Blow Past Estimates on Strong Covid-19 Antibody Sales","Summary":""},{"Date":"Nov. 14, 2021 at 10:03 p.m. ET","Headline":"Pfizer\u2019s Big Gamble Is Paying Off. Its Stock Is a Good Long-Term Bet.","Summary":""},{"Date":"Nov. 17, 2021 at 12:07 p.m. ET","Headline":"Biogen Stock Slips After EU Regulator Has Doubts on Controversial Alzheimer\u2019s Therapy","Summary":""},{"Date":"Nov. 17, 2021 at 9:30 a.m. ET","Headline":"Glaxo and Vir Report $1 Billion Sale of Covid-19 Antibody. The U.S. Is Still Buying.","Summary":""},{"Date":"Nov. 16, 2021 at 10:31 a.m. ET","Headline":"Biogen Stock Is Dropping After a Key Executive Announced His Retirement Amid Alzheimer\u2019s Drug Stumbles","Summary":""},{"Date":"Nov. 19, 2021 at 6:34 a.m. ET","Headline":"Tech Stocks Are Carrying the S&P 500. Alibaba\u2019s Slump Offers a Warning.","Summary":""},{"Date":"Nov. 18, 2021 at 2:26 p.m. ET","Headline":"Pfizer CEO Talks About Covid Vaccines and What Comes Next: \u2018I Think We Are Undervalued.\u2019","Summary":""},{"Date":"Nov. 18, 2021 at 11:51 a.m. ET","Headline":"New \u2018Twitter Buzz\u2019 Index Launches. Tesla Didn\u2019t Make It.","Summary":""},{"Date":"Nov. 20, 2021 at 3:44 p.m. ET","Headline":"This fund company was an early believer in Tesla \u2014 it\u2019s now making these bets","Summary":""},{"Date":"Dec. 1, 2021 at 7:53 a.m. ET","Headline":"FDA advisers recommend Merck\u2019s COVID-19 pill in close vote","Summary":"Early tests suggest that the COVID-19 antibody treatment developed by Regeneron Pharmaceuticals Inc.loses effectiveness against the omicron variant of the coronavirus that causes COVID, but the full impact will only be kno..."},{"Date":"Dec. 1, 2021 at 6:46 a.m. ET","Headline":"WHO urges calm approach to omicron variant of COVID, warns travel restrictions may undermine surveillance and tracking","Summary":"Early tests suggest that the COVID-19 antibody treatment developed by Regeneron Pharmaceuticals Inc.loses effectiveness against the omicron variant of the coronavirus that causes COVID, but the full impact will only be kno..."},{"Date":"Nov. 30, 2021 at 9:57 a.m. ET","Headline":"Stock Market Jitters Continue Over Omicron. Why It\u2019s Too Early to Panic.","Summary":"Early tests suggest that the COVID-19 antibody treatment developed by Regeneron Pharmaceuticals Inc.loses effectiveness against the omicron variant of the coronavirus that causes COVID, but the full impact will only be kno..."},{"Date":"Nov. 30, 2021 at 8:59 a.m. ET","Headline":"Regeneron Stock Is Falling Because Its Covid Antibody Might Not Work as Well Against Omicron","Summary":"Early tests suggest that the COVID-19 antibody treatment developed by Regeneron Pharmaceuticals Inc.loses effectiveness against the omicron variant of the coronavirus that causes COVID, but the full impact will only be kno..."},{"Date":"Nov. 30, 2021 at 6:26 a.m. ET","Headline":"Tests suggest Regeneron antibody treatment for COVID loses effectiveness against omicron variant: WSJ","Summary":"Early tests suggest that the COVID-19 antibody treatment developed by Regeneron Pharmaceuticals Inc.loses effectiveness against the omicron variant of the coronavirus that causes COVID, but the full impact will only be kno..."},{"Date":"Dec. 3, 2021 at 5:22 p.m. ET","Headline":"Lilly\u2019s COVID-19 antibody drug authorized for use in children","Summary":"Eli Lilly & Co.  said Friday that the U.S. Food and Drug Administration has expanded the Emergency Use Authorization (EUA) for its bamlanivimab and etesevimab, taken together, to treat certain high-risk patients that are u..."},{"Date":"Dec. 3, 2021 at 3:03 p.m. ET","Headline":"Eli Lilly's COVID-19 treatment now authorized high-risk patients 'of any age'","Summary":"Eli Lilly & Co.  said Friday that the U.S. Food and Drug Administration has expanded the Emergency Use Authorization (EUA) for its bamlanivimab and etesevimab, taken together, to treat certain high-risk patients that are u..."},{"Date":"Dec. 3, 2021 at 2:59 p.m. ET","Headline":"Lilly's COVID-19 antibody treatment authorized for young children and infants","Summary":"Shares of Eli Lilly & Co.  were down 1.6% in trading on Friday after the company said the Food and Drug Administration has extended the emergency authorization for its COVID-19 antibody therapy to include children younger ..."},{"Date":"Dec. 9, 2021 at 8:08 a.m. ET","Headline":"Novartis CEO Vasant Narasimhan Sees Consistent Growth While Sitting on Cash","Summary":""},{"Date":"Dec. 8, 2021 at 8:04 a.m. ET","Headline":"Vir, GSK\u2019s COVID-19 antibody treatment works against omicron in a lab study, and WHO no longer recommends convalescent plasma","Summary":""},{"Date":"Dec. 13, 2021 at 7:55 p.m. ET","Headline":"Eli Lilly and Foghorn Partner Up. Foghorn Stock Soared.","Summary":""},{"Date":"Dec. 13, 2021 at 4:43 p.m. ET","Headline":"Dow and S&P 500 post biggest one-day declines in almost two weeks, with focus shifting to Fed and \u2018tidal wave\u2019 of omicron","Summary":""},{"Date":"Dec. 13, 2021 at 3:53 p.m. ET","Headline":"Eli Lilly hikes quarterly dividend 15%","Summary":""},{"Date":"Dec. 13, 2021 at 6:14 a.m. ET","Headline":"Foghorn Therapeutics shares soar 26% premarket on news of cancer collaboration with Eli Lilly","Summary":"Eli Lilly & Co.  said Monday it has entered a strategic collaboration with Foghorn Therapeutics Inc.  for novel oncology targets using Foghorn's proprietary gene traffic control platform, a move that sent Foghorn's shares ..."},{"Date":"Dec. 15, 2021 at 4:33 p.m. ET","Headline":"Dow, S&P 500 post best day in a week after Fed tapers bond buying aggressively, pencils in 3 rate hikes next year","Summary":"Eli Lilly & Co. shares  rose 5% in premarket trade Wednesday, after the company raised guidance as part of an update on its pipeline released ahead of an investor day. The company said it now expects 2021 adjusted per-shar..."},{"Date":"Dec. 15, 2021 at 2:32 p.m. ET","Headline":"Stocks Ended Today With a Nice Bounce. Certainty From the Fed Made a Big Difference.","Summary":"Eli Lilly & Co. shares  rose 5% in premarket trade Wednesday, after the company raised guidance as part of an update on its pipeline released ahead of an investor day. The company said it now expects 2021 adjusted per-shar..."},{"Date":"Dec. 15, 2021 at 12:23 p.m. ET","Headline":"Eli Lilly Stock Is Jumping Because Its Revenue Forecast Looks Strong","Summary":"Eli Lilly & Co. shares  rose 5% in premarket trade Wednesday, after the company raised guidance as part of an update on its pipeline released ahead of an investor day. The company said it now expects 2021 adjusted per-shar..."},{"Date":"Dec. 15, 2021 at 9:02 a.m. ET","Headline":"It\u2019s Fed day. Here are two big questions for markets from a trading veteran.","Summary":"Eli Lilly & Co. shares  rose 5% in premarket trade Wednesday, after the company raised guidance as part of an update on its pipeline released ahead of an investor day. The company said it now expects 2021 adjusted per-shar..."},{"Date":"Dec. 15, 2021 at 7:00 a.m. ET","Headline":"Eli Lilly shares jump 5% premarket after company raises guidance in update on pipeline","Summary":"Eli Lilly & Co. shares  rose 5% in premarket trade Wednesday, after the company raised guidance as part of an update on its pipeline released ahead of an investor day. The company said it now expects 2021 adjusted per-shar..."},{"Date":"Dec. 19, 2021 at 5:26 p.m. ET","Headline":"Omicron may sideline two leading drugs used to treat COVID-19","Summary":""},{"Date":"Dec. 18, 2021 at 9:59 a.m. ET","Headline":"After a dazzling 2021, Apple and Tesla stocks are expected to be duds in 2022","Summary":""},{"Date":"Dec. 21, 2021 at 8:39 a.m. ET","Headline":"Biogen\u2019s decision to halve price of Alzheimer\u2019s drug is \u2018a day late and a dollar short,\u2019 says Raymond James","Summary":"The global tally for the coronavirus-borne illness climbed above 274.7 million on Monday, while the death toll edged above 5.35 million, according to . The U.S. continues to lead the world with 50.8 million cases  and 806,..."},{"Date":"Dec. 20, 2021 at 7:33 a.m. ET","Headline":"Coronavirus tally: Global cases of COVID-19 near 275 million and research shows only Pfizer\/Moderna vaccines with booster stop omicron","Summary":"The global tally for the coronavirus-borne illness climbed above 274.7 million on Monday, while the death toll edged above 5.35 million, according to . The U.S. continues to lead the world with 50.8 million cases  and 806,..."},{"Date":"Dec. 25, 2021 at 9:30 a.m. ET","Headline":"Pfizer\u2019s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.","Summary":""},{"Date":"Dec. 24, 2021 at 8:00 a.m. ET","Headline":"U.S. Halts Distribution of Regeneron and Eli Lilly Covid Antibody Drugs Over Omicron Efficacy Concerns","Summary":""},{"Date":"Jan. 4, 2022 at 9:22 a.m. ET","Headline":"Tesla beat bitcoin over the past year \u2014 so did 124 other stocks in the S&P 500","Summary":""},{"Date":"Jan. 10, 2022 at 8:34 a.m. ET","Headline":"Lots of Deals, but No Blockbuster M&A, to Start Year\u2019s Biggest Healthcare Conference","Summary":""},{"Date":"Jan. 10, 2022 at 4:15 a.m. ET","Headline":"Biogen\u2019s Alzheimer\u2019s Drug Has a Shot at Redemption This Week. Will It Be Enough?","Summary":""},{"Date":"Jan. 8, 2022 at 1:18 p.m. ET","Headline":"Biogen\u2019s Alzheimer\u2019s Drug Has Another Shot at Success","Summary":""},{"Date":"Jan. 12, 2022 at 1:36 p.m. ET","Headline":"Stocks Close Up\u2014Barely. Investors Somehow Find an Upside to High Inflation.","Summary":""},{"Date":"Jan. 12, 2022 at 10:13 a.m. ET","Headline":"Medicare pulls back on coverage of an Alzheimer\u2019s drug","Summary":""},{"Date":"Jan. 12, 2022 at 9:44 a.m. ET","Headline":"Biogen\u2019s stock tumbles after the U.S. proposes restricting access to its Alzheimer\u2019s disease drug","Summary":""},{"Date":"Jan. 12, 2022 at 9:33 a.m. ET","Headline":"Biogen Got Bad News on Its Alzheimer\u2019s Drug. Why It Hurt Eli Lilly, Too.","Summary":""},{"Date":"Jan. 12, 2022 at 8:11 a.m. ET","Headline":"Biogen Stock Is Tumbling Because Its Alzheimer\u2019s Drug Just Got Some Really Bad News","Summary":""},{"Date":"Jan. 12, 2022 at 6:49 a.m. ET","Headline":"Powell Said All the Right Things. But Inflation Has a Mind of Its Own.","Summary":""},{"Date":"Jan. 11, 2022 at 9:02 a.m. ET","Headline":"Vir Stock Jumps as U.S. Buys 600,000 More Glaxo Covid Antibody Doses","Summary":""},{"Date":"Jan. 13, 2022 at 8:01 a.m. ET","Headline":"Guggenheim downgrades Biogen to neutral from buy after U.S. proposes limiting access to Alzheimer's drug","Summary":"Shares of Biogen Inc.  were down 0.9% in premarket trading on Thursday after Guggenheim analysts downgraded the stock to neutral, from buy. Analysts there cite the need to wait and see how the  proposing limited access to ..."},{"Date":"Jan. 24, 2022 at 6:04 p.m. ET","Headline":"FDA halts use of antibody drugs that don\u2019t work against omicron","Summary":""},{"Date":"Jan. 25, 2022 at 3:55 p.m. ET","Headline":"DeSantis threatens Florida suit against FDA over revoked authorization of drugs deemed ineffective against omicron variant","Summary":""},{"Date":"Jan. 25, 2022 at 2:54 p.m. ET","Headline":"Pfizer and BioNTech launch study of omicron vaccine, and FDA halts use of two COVID antibody treatments","Summary":""},{"Date":"Jan. 25, 2022 at 10:10 a.m. ET","Headline":"How Omicron Is Changing Vaccine and Therapeutic Strategies","Summary":""},{"Date":"Jan. 28, 2022 at 8:25 a.m. ET","Headline":"Lilly to scrap further development of Olumiant as a lupus treatment","Summary":"Shares of Eli Lilly & Co.  were down 0.9% in premarket trading on Friday after the company said it decided to scrap further development of Olumiant as a possible lupus treatment, based on results from two Phase 3 clinical ..."},{"Date":"Jan. 26, 2022 at 6:33 a.m. ET","Headline":"Fed Day Is Here as Volatility Hits Fever Pitch. What to Watch.","Summary":""},{"Date":"Jan. 30, 2022 at 7:39 p.m. ET","Headline":"The Auto Chip Shortage May Be Improving, According to This Company\u2019s Earnings","Summary":""},{"Date":"Jan. 30, 2022 at 7:21 p.m. ET","Headline":"Amazon, AMD, Alphabet, Exxon Mobil, General Motors, and Other Stocks to Watch This Week","Summary":""},{"Date":"Feb. 3, 2022 at 10:58 a.m. ET","Headline":"Eli Lilly Posts an Earnings Beat and Maintains Its 2022 Forecast","Summary":"Shares of Eli Lilly & Co.  rose 0.4% in premarket trading Thursday, after the drug giant reported fourth-quarter profit and revenue that rose above expectations, as COVID-19 antibodies revenue topped $1 billion, which was ..."},{"Date":"Feb. 3, 2022 at 6:38 a.m. ET","Headline":"Eli Lilly stock gains after earnings rise above expectations, as COVID-19 antibodies revenue top $1 billion","Summary":"Shares of Eli Lilly & Co.  rose 0.4% in premarket trading Thursday, after the drug giant reported fourth-quarter profit and revenue that rose above expectations, as COVID-19 antibodies revenue topped $1 billion, which was ..."},{"Date":"Feb. 7, 2022 at 4:19 p.m. ET","Headline":"Amgen stock rises after COVID drugs boost Q4 profit","Summary":"Shares of Amgen Inc.  rose more than 3% in the extended session Monday after the drug maker reported an adjusted quarterly profit above Wall Street expectations and said sales rose in part due to COVID-19 products. Amgen s..."},{"Date":"Feb. 7, 2022 at 6:51 a.m. ET","Headline":"Four drug makers raked in $14 billion in sales of COVID-19 treatments in 2021. How will they do this year?","Summary":""},{"Date":"Feb. 11, 2022 at 4:40 p.m. ET","Headline":"Lilly's COVID-19 treatment gets FDA's emergency-use approval","Summary":"Eli Lilly & Co.  said late Friday that the U.S. Food and Drug Administration has issued an emergency-use authorization for bebtelovimab, the pharma company's antibody treatment for COVID-19. Bebtelovimab now can be used fo..."},{"Date":"Feb. 11, 2022 at 1:35 p.m. ET","Headline":"SVB Leerink analyst doesn't expect cancer drug developed by Innovent and Lilly to be approved","Summary":"Investors should expect to see fewer Food and Drug Administration approvals of copycat PD-L1 therapies after an advisory committee recommended against approving an experimental cancer drug, according to SVB Leerink analyst..."},{"Date":"Feb. 10, 2022 at 5:29 p.m. ET","Headline":"Lilly to supply up to U.S. 600,000 doses of COVID-19 treatment","Summary":"Eli Lilly and Co.  said late Thursday it has inked a deal with the U.S. government to supply up to 600,000 doses of its investigational COVID-19 drug bebtelovimab for at least $720 million. The U.S. will accept the doses o..."},{"Date":"Feb. 10, 2022 at 4:38 p.m. ET","Headline":"FDA advisers say regulators should wait to approve China-developed lung cancer drug","Summary":""},{"Date":"Feb. 15, 2022 at 5:25 p.m. ET","Headline":"S&P 500 suffers biggest 3-day string of declines since October 2020 as investors monitor Russia-Ukraine crisis","Summary":"ImmunoGen Inc. shares  jumped 7% in premarket trade Tuesday, after the company announced a license agreement with Eli Lilly & Co.  of its Novel Camptothecin ADC Platform for up to $1.7 billion in potential payments. Campto..."},{"Date":"Feb. 15, 2022 at 6:40 a.m. ET","Headline":"ImmunoGen shares jump 7% premarket on news of license deal with Lilly worth up to $1.7 billion","Summary":"ImmunoGen Inc. shares  jumped 7% in premarket trade Tuesday, after the company announced a license agreement with Eli Lilly & Co.  of its Novel Camptothecin ADC Platform for up to $1.7 billion in potential payments. Campto..."},{"Date":"Feb. 23, 2022 at 4:45 a.m. ET","Headline":"Why AstraZeneca Could Be a Sound Long-Term Bet","Summary":"Eli Lilly & Co.  said Tuesday it will invest $700 million in a new facility in Boston aimed at developing RNA-based therapies. The company expects to have 250 scientists working at the site within the next five years. Lill..."},{"Date":"Feb. 22, 2022 at 11:23 a.m. ET","Headline":"Lilly to spend $700 million on Boston facility to develop RNA therapies","Summary":"Eli Lilly & Co.  said Tuesday it will invest $700 million in a new facility in Boston aimed at developing RNA-based therapies. The company expects to have 250 scientists working at the site within the next five years. Lill..."},{"Date":"Mar. 3, 2022 at 3:37 p.m. ET","Headline":"Hospitalized Covid-19 Patients Can Gain From Lilly Arthritis Drug, Data Show","Summary":""},{"Date":"Mar. 4, 2022 at 10:50 a.m. ET","Headline":"Preliminary U.K. research says Lilly drug can reduce the risk of death among severely ill COVID-19 patients","Summary":"A new study found that baricitinib, a rheumatoid arthritis drug developed by Eli Lilly & Co.  and Incyte Corp. , reduced the risk of death among patients who have been hospitalized with severe COVID-19. The new , which was..."},{"Date":"Mar. 4, 2022 at 10:48 a.m. ET","Headline":"Some cities and counties re-evaluate mask rules based on weekly CDC data","Summary":""},{"Date":"Mar. 9, 2022 at 9:59 a.m. ET","Headline":"Russia-Ukraine War Won\u2019t Affect Pharmaceutical Sales, but It Could Disrupt Trials, Companies Say","Summary":""},{"Date":"Mar. 11, 2022 at 8:24 p.m. ET","Headline":"Pharma Exposure to the Ukraine War? Clinical Trials","Summary":""},{"Date":"Mar. 11, 2022 at 9:43 a.m. ET","Headline":"CEO St\u00e9phane Bancel Made $18.2M Last Year, Another Sign Moderna Is in the Big Leagues","Summary":""},{"Date":"Mar. 17, 2022 at 10:50 a.m. ET","Headline":"The FDA Has a New Chief. Here Are 5 Key Decisions on Drugs to Watch.","Summary":""},{"Date":"Mar. 22, 2022 at 10:05 a.m. ET","Headline":"This group of stocks is flagging a rebound, and that\u2019s good news for the S&P 500, says technical analyst","Summary":""},{"Date":"Mar. 24, 2022 at 6:52 a.m. ET","Headline":"Eli Lilly's BLA for sintilimab can't be approved by FDA in present form","Summary":"Eli Lilly & Co.  said Thursday it received a complete response letter (CRL) from the U.S. Food and Drug Administration regarding its Biologics License Application (BLA) for its treatment for non-small cell lung cancer. The..."},{"Date":"Mar. 28, 2022 at 12:41 p.m. ET","Headline":"The BA.2 Covid Variant Is Already Changing the U.S. Response to the Pandemic","Summary":""},{"Date":"Apr. 6, 2022 at 6:28 a.m. ET","Headline":"Coronavirus tally: FDA pulls Glaxo COVID treatment ahead of panel meeting on next steps for 2022","Summary":"GlaxoSmithKline's  IV drug for COVID-19 should no longer be used because it is likely ineffective against the omicron subvariant that now accounts for most U.S. cases, federal health regulators said Tuesday, That leaves ju..."},{"Date":"Apr. 5, 2022 at 4:43 p.m. ET","Headline":"FDA pulls GlaxoSmithKline\u2019s COVID-19 drug as omicron subvariant dominates U.S. cases","Summary":""},{"Date":"Apr. 8, 2022 at 11:15 a.m. ET","Headline":"It\u2019s Lights Out for Biogen\u2019s Aduhelm. But There\u2019s Some Hope for Other Alzheimer\u2019s Drugs.","Summary":""},{"Date":"Apr. 7, 2022 at 10:42 p.m. ET","Headline":"Biogen Stock Is Falling After Medicare Limited Coverage of the Company\u2019s Alzheimer\u2019s Drug","Summary":""},{"Date":"Apr. 7, 2022 at 10:06 a.m. ET","Headline":"Novartis CEO Continues His Shake-Up, Says It Will Save More Than $1 Billion Annually","Summary":""},{"Date":"Apr. 7, 2022 at 7:57 a.m. ET","Headline":"BA.2 subvariant of omicron accounted for almost 94% of global cases in latest week, the latest sign of how dominant it has become","Summary":""},{"Date":"Apr. 11, 2022 at 6:46 a.m. ET","Headline":"Pfizer\u2019s New CFO Negotiated One of the Biggest Healthcare Deals in History. Is It a Sign of Things to Come?","Summary":""},{"Date":"Apr. 18, 2022 at 10:39 a.m. ET","Headline":"Nektar, Bristol Myers Squibb end clinical development of combination therapy including Opdivo","Summary":"Shares of Nektar Therapeutics Inc.  were down 35.9% in trading on Monday after the company announced Friday that it halted development of bempegaldesleukin in combination with Bristol Myers Squibb's  Opdivo. The combinatio..."},{"Date":"Apr. 18, 2022 at 9:48 a.m. ET","Headline":"Nektar Therapeutics Stock Tanks on More Failed Trials of Its Cancer Drug Bempeg","Summary":""},{"Date":"Apr. 24, 2022 at 5:50 p.m. ET","Headline":"Apple, Microsoft, Visa, Boeing, GM, Chipotle, and Other Stocks to Watch This Week","Summary":""},{"Date":"Apr. 22, 2022 at 8:38 p.m. ET","Headline":"Starlink Could Be the Key to a $100 Billion Valuation for Elon Musk\u2019s SpaceX","Summary":""},{"Date":"Apr. 26, 2022 at 9:19 a.m. ET","Headline":"Nektar Therapeutics Will Cut 70% of Its Staff After Trial Failure","Summary":""},{"Date":"Apr. 25, 2022 at 11:02 a.m. ET","Headline":"Merck, Lilly, Bristol Earnings This Week Could Prove Big Pharma\u2019s Defensive Value","Summary":""},{"Date":"Apr. 25, 2022 at 8:48 a.m. ET","Headline":"A sticking point in China competition bill: what to do about fake products","Summary":""},{"Date":"Apr. 28, 2022 at 9:46 a.m. ET","Headline":"Eli Lilly Beats Estimates and the Stock Jumps on Revenue Guidance Boost","Summary":"Eli Lilly & Co. Inc.  said Thursday that its experimental weight-loss drug, tirzepatide, demonstrated \"superior weight loss\" compared to placebo in a Phase 3 clinical trial that enrolled 2,539 participants. Lilly said the ..."},{"Date":"Apr. 28, 2022 at 9:00 a.m. ET","Headline":"Can a decades-old antidepressant keep COVID-19 patients out of the hospital?","Summary":"Eli Lilly & Co. Inc.  said Thursday that its experimental weight-loss drug, tirzepatide, demonstrated \"superior weight loss\" compared to placebo in a Phase 3 clinical trial that enrolled 2,539 participants. Lilly said the ..."},{"Date":"Apr. 28, 2022 at 8:54 a.m. ET","Headline":"Lilly says its experimental weight-loss treatment led to 20% weight loss in clinical-trial participants","Summary":"Eli Lilly & Co. Inc.  said Thursday that its experimental weight-loss drug, tirzepatide, demonstrated \"superior weight loss\" compared to placebo in a Phase 3 clinical trial that enrolled 2,539 participants. Lilly said the ..."},{"Date":"Apr. 28, 2022 at 6:45 a.m. ET","Headline":"Eli Lilly stock rallies after earnings beat expectations, as COVID-19 antibodies revenue jumps 81%","Summary":"Shares of Eli Lilly & Co.  rallied 1.8% in premarket trading Thursday after the drug maker reported first-quarter profit and revenue that beat expectations, as better-than-forecast COVID-19 antibodies results offset a Trul..."},{"Date":"May. 2, 2022 at 8:20 a.m. ET","Headline":"Lilly\u2019s experimental obesity drug may be a \u2018multibillion-dollar opportunity\u2019","Summary":""},{"Date":"Apr. 29, 2022 at 5:26 p.m. ET","Headline":"Alzheimer\u2019s Drugs Face a Crucial Test. It\u2019s Unclear Whether Medicare Will Pay for Them.","Summary":""},{"Date":"May. 6, 2022 at 1:07 p.m. ET","Headline":"Drug companies are making an accounting change after the SEC cracked down on Biogen","Summary":""},{"Date":"May. 10, 2022 at 2:26 p.m. ET","Headline":"Pfizer Is Spending $11.6 Billion on Biohaven. Its Plans Point to a Lot More M&A.","Summary":""},{"Date":"May. 10, 2022 at 11:41 a.m. ET","Headline":"Biogen Partner Eisai Files for Accelerated Approval of Alzheimer\u2019s Drug","Summary":""},{"Date":"May. 10, 2022 at 10:06 a.m. ET","Headline":"Pfizer to Buy Biohaven Pharmaceuticals for $11.6 Billion","Summary":""},{"Date":"May. 12, 2022 at 10:25 a.m. ET","Headline":"A Healthcare Revolution Is Coming. How to Invest.","Summary":"Eli Lilly & Co.  and Incyte  said Wednesday the Food and Drug Administration has approved the use of their Olumiant for the treatment of certain adults who are hospitalized with COVID-19. The treatment, also called baricit..."},{"Date":"May. 12, 2022 at 7:24 a.m. ET","Headline":"WHO head censored in China after criticizing zero-COVID policy, and U.S. cases are now up 52% from two weeks ago","Summary":"Eli Lilly & Co.  and Incyte  said Wednesday the Food and Drug Administration has approved the use of their Olumiant for the treatment of certain adults who are hospitalized with COVID-19. The treatment, also called baricit..."},{"Date":"May. 11, 2022 at 7:04 a.m. ET","Headline":"FDA approves Eli Lilly and Incyte's Olumiant for treatment of certain hospitalized adults with COVID-19","Summary":"Eli Lilly & Co.  and Incyte  said Wednesday the Food and Drug Administration has approved the use of their Olumiant for the treatment of certain adults who are hospitalized with COVID-19. The treatment, also called baricit..."},{"Date":"May. 14, 2022 at 12:20 p.m. ET","Headline":"The FDA Has Approved Eli Lilly\u2019s Diabetes Drug. But the Most Exciting Market May Be Something Else.","Summary":""},{"Date":"May. 16, 2022 at 9:12 a.m. ET","Headline":"Mizuho: Lilly's newly approved diabetes drug expected to bring in $14 billion in sales by 2030","Summary":"The Food and Drug Administration on Friday approved Eli Lilly & Co.'s  Mounjaro, a once-weekly injection for adults with type 2 diabetes. Patients enrolled in the Phase 3 clinical trial reported that the therapy reduced he..."},{"Date":"May. 20, 2022 at 2:06 p.m. ET","Headline":"Eli Lilly Gets Positive Opinion for Olumiant in Europe. The Stock Rises.","Summary":""},{"Date":"May. 21, 2022 at 10:15 a.m. ET","Headline":"Stocks Are Ready for a Bounce Higher After S&P 500 Rallies Out of Bear Market","Summary":""},{"Date":"May. 24, 2022 at 11:13 a.m. ET","Headline":"Biogen Needs a New CEO. Here Are Some Options.","Summary":""},{"Date":"May. 25, 2022 at 1:41 p.m. ET","Headline":"Lilly proposes two new manufacturing sites in Indiana","Summary":"Eli Lilly & Co. Inc.  said Wednesday that it plans to invest $2.1 billion in two new manufacturing sites in Indiana. The proposed sites are expected to create 500 jobs for Lilly workers. The company's stock is up 10.8% for..."},{"Date":"May. 25, 2022 at 8:43 a.m. ET","Headline":"An Unexpected Blue Wave Could Shake Up These Stocks","Summary":""},{"Date":"May. 29, 2022 at 8:58 a.m. ET","Headline":"A new generation of ulcerative colitis drugs is in development. Will they be blockbusters for Lilly and Pfizer?","Summary":""},{"Date":"May. 31, 2022 at 3:05 p.m. ET","Headline":"Eli Lilly stock pulls back from record high after disclosing sales by largest shareholder","Summary":"Shares of Eli Lilly & Co.  fell 4.0% in afternoon trading Tuesday, to pullback from the previous session's record close, after the drug maker disclosed that its largest shareholder sold nearly $64 million worth of its shar..."},{"Date":"May. 31, 2022 at 11:03 a.m. ET","Headline":"Sanofi Shares Fall As OTC Cialis Delay Adds to Troubles for Consumer Health Division","Summary":""},{"Date":"May. 31, 2022 at 8:40 a.m. ET","Headline":"Buy This Pharma Stock. Its Rally Is Just Getting Started","Summary":""},{"Date":"Jun. 8, 2022 at 6:22 p.m. ET","Headline":"New Obesity Drugs From Lilly and Novo Nordisk Generate Excitement","Summary":""},{"Date":"Jun. 11, 2022 at 9:42 a.m. ET","Headline":"There\u2019s No Miracle Cure for Obesity\u2014or Is There?","Summary":""},{"Date":"Jun. 16, 2022 at 9:52 a.m. ET","Headline":"Roche\u2019s Failed Alzheimer\u2019s Trial Could Have Implications for Lilly, Biogen","Summary":""},{"Date":"Jun. 17, 2022 at 3:04 p.m. ET","Headline":"The Days of Big Pharma Are Over. What the Era of Big Biotech Means for Investors.","Summary":""},{"Date":"Jun. 22, 2022 at 6:40 a.m. ET","Headline":"High Gas Prices and Recession Appear to Be the Cost of Defending Democracy","Summary":""},{"Date":"Jun. 21, 2022 at 2:29 p.m. ET","Headline":"FTC Sets Its Sights on Prescription Drug Middlemen and the High Cost of Insulin","Summary":""},{"Date":"Jun. 24, 2022 at 8:08 a.m. ET","Headline":"Zoom Stock and 2 Others With Recession-Resistant Earnings","Summary":""},{"Date":"Jun. 24, 2022 at 7:25 a.m. ET","Headline":"This dividend fund is down only 3% this year vs. the S&P\u2019s 20% decline. Here are the manager\u2019s top stock picks.","Summary":""},{"Date":"Jun. 29, 2022 at 6:58 a.m. ET","Headline":"Eli Lilly to supply another 150,000 doses of COVID treatment to the government","Summary":"Eli Lilly & Co.  said Wednesday that it will supply the U.S. government with an additional 150,000 doses of its COVID treatment bebtelovimab for about $275 million. Delivery of the doses will begin immediately and be compl..."},{"Date":"Jun. 28, 2022 at 3:39 p.m. ET","Headline":"Novartis Will Cut 8,000 Jobs Under CEO\u2019s Shake-Up Plan","Summary":""},{"Date":"Jul. 1, 2022 at 3:14 p.m. ET","Headline":"The U.S. bets billions of dollars on better COVID-19 boosters as it prepares for a spike in COVID-19 cases in the coming months","Summary":""},{"Date":"Jun. 30, 2022 at 5:32 p.m. ET","Headline":"Fries and Energy Drinks: Here Are the Best Performing Stocks in the S&P 500 This Quarter","Summary":""},{"Date":"Jul. 6, 2022 at 9:04 a.m. ET","Headline":"Alzheimer\u2019s Drug Is Up for Accelerated Approval. Outlook for Biogen, Eisai Is Uncertain.","Summary":""},{"Date":"Jul. 9, 2022 at 10:42 a.m. ET","Headline":"Eli Lilly\u2019s Growth Is Set to Soar Under CEO David Ricks","Summary":""},{"Date":"Jul. 11, 2022 at 7:54 a.m. ET","Headline":"Here Are the Top CEOs of 2022","Summary":""},{"Date":"Jul. 31, 2022 at 9:32 p.m. ET","Headline":"AMD, PayPal, Starbucks, Uber, Paramount, and Other Stocks to Watch This Week","Summary":""},{"Date":"Jul. 30, 2022 at 9:59 a.m. ET","Headline":"Coal Stages a Sudden Recovery. It Probably Won\u2019t Last.","Summary":""},{"Date":"Aug. 1, 2022 at 6:56 a.m. ET","Headline":"Tech Stocks Are Hot on Wall Street. Main Street\u2019s Worries Are Elsewhere.","Summary":""},{"Date":"Aug. 4, 2022 at 4:41 p.m. ET","Headline":"U.S. stocks end mixed as investors await July jobs report","Summary":"Eli Lilly & Co.  shares fell 3.6% in pre-market trading on Thursday after the company reported second-quarter results that came in below Wall Street's forecast. The company's stock ended Wednesday's session down 2% at $313..."},{"Date":"Aug. 4, 2022 at 4:23 p.m. ET","Headline":"The Dow Wavered, Alibaba Gained\u2014and What Else Happened in the Stock Market Today","Summary":"Eli Lilly & Co.  shares fell 3.6% in pre-market trading on Thursday after the company reported second-quarter results that came in below Wall Street's forecast. The company's stock ended Wednesday's session down 2% at $313..."},{"Date":"Aug. 4, 2022 at 9:28 a.m. ET","Headline":"Alibaba, Eli Lilly, Walmart and More Stock Market Movers Thursday","Summary":"Eli Lilly & Co.  shares fell 3.6% in pre-market trading on Thursday after the company reported second-quarter results that came in below Wall Street's forecast. The company's stock ended Wednesday's session down 2% at $313..."},{"Date":"Aug. 4, 2022 at 7:21 a.m. ET","Headline":"Eli Lilly stock falls 3% after Q2 top and bottom line results miss Wall Street's forecast","Summary":"Eli Lilly & Co.  shares fell 3.6% in pre-market trading on Thursday after the company reported second-quarter results that came in below Wall Street's forecast. The company's stock ended Wednesday's session down 2% at $313..."},{"Date":"Aug. 4, 2022 at 6:59 a.m. ET","Headline":"Eli Lilly Stock Sinks After Fiscal-Year Forecast Is Slashed","Summary":""},{"Date":"Aug. 4, 2022 at 6:47 a.m. ET","Headline":"Tech Is Rallying. So Why Is the Sector\u2019s Biggest Global Investor Cashing In?","Summary":""},{"Date":"Aug. 6, 2022 at 10:17 a.m. ET","Headline":"Pharmaceutical CEOs use earnings calls to criticize drug-pricing proposal","Summary":""},{"Date":"Aug. 5, 2022 at 8:16 a.m. ET","Headline":"Global tally of COVID cases down 9% in latest week, but infections are still climbing in the U.S.","Summary":""},{"Date":"Aug. 8, 2022 at 2:52 p.m. ET","Headline":"Indiana Abortion Law Has Eli Lilly, Cummins Rethinking Expansion There","Summary":""},{"Date":"Aug. 7, 2022 at 5:00 p.m. ET","Headline":"Biden administration, Eli Lilly condemn Indiana\u2019s new abortion ban","Summary":""},{"Date":"Aug. 12, 2022 at 5:54 p.m. ET","Headline":"The Big Winners\u2014and Losers \u2014in the Inflation Bill","Summary":""},{"Date":"Aug. 12, 2022 at 7:28 a.m. ET","Headline":"Oil Price Bounce Fuels Fears That Inflation Battle Is Not Over","Summary":""},{"Date":"Aug. 12, 2022 at 9:10 p.m. ET","Headline":"At Last, Weight-Loss Drugs That Actually Work. They Could Be the Blockbusters of the Decade.","Summary":""},{"Date":"Aug. 18, 2022 at 3:51 p.m. ET","Headline":"U.S. Plans Reduced Role in Distributing Covid Vaccines: Report","Summary":""},{"Date":"Aug. 19, 2022 at 7:42 a.m. ET","Headline":"The Dollar Will Stay Strong. That Spells More Pain for Companies.","Summary":""},{"Date":"Aug. 18, 2022 at 1:45 p.m. ET","Headline":"Weight-Loss Drugs That Work and a Black Pioneer: Community Conversations","Summary":""},{"Date":"Aug. 25, 2022 at 10:07 a.m. ET","Headline":"Novartis Is Spinning Off Its Generics Unit, Joining Pack of Pure-Play Drugmakers","Summary":""},{"Date":"Sep. 3, 2022 at 10:44 a.m. ET","Headline":"This outperforming fund manager looks for four traits  in stocks \u2014 and has found them in these nine companies","Summary":""},{"Date":"Sep. 2, 2022 at 5:56 p.m. ET","Headline":"Stocks Could Have a Messy Fall. Time to Embrace the Risks.","Summary":""},{"Date":"Sep. 15, 2022 at 5:40 p.m. ET","Headline":"Raytheon\u2019s Guidance Shows How a New Law Can Hurt Free Cash Flow","Summary":""},{"Date":"Sep. 14, 2022 at 7:48 a.m. ET","Headline":"AstraZeneca, Eli Lilly and Roche among pharmaceutical companies upgraded for high returns on R&D investments, analysts say","Summary":""},{"Date":"Sep. 22, 2022 at 4:25 p.m. ET","Headline":"U.S. stocks close down, on track for weekly loss, in wake of Fed rate hike and Powell speech","Summary":"Shares of Eli Lilly & Co. Inc.  gained 2.5% in premarket trading on Thursday after UBS upgraded the stock to buy from neutral, saying Mounjaro, the company's newly approved Type 2 diabetes drug, could be \"the biggest drug ..."},{"Date":"Sep. 22, 2022 at 2:52 p.m. ET","Headline":"UBS: Lilly's Type 2 diabetes and obesity treatment could be 'one of the best-selling drugs in history'","Summary":"Shares of Eli Lilly & Co. Inc.  gained 2.5% in premarket trading on Thursday after UBS upgraded the stock to buy from neutral, saying Mounjaro, the company's newly approved Type 2 diabetes drug, could be \"the biggest drug ..."},{"Date":"Sep. 22, 2022 at 12:41 p.m. ET","Headline":"Buy Eli Lilly Stock. Its Obesity Drug Will Be a Blockbuster, Analyst Says.","Summary":""},{"Date":"Sep. 22, 2022 at 10:46 a.m. ET","Headline":"Can We Beat Alzheimer\u2019s? Biogen and Eisai\u2019s Latest Drug Trial Will Offer Clues.","Summary":""},{"Date":"Sep. 23, 2022 at 5:18 p.m. ET","Headline":"Healthcare Learned a Lot From Covid. 12 Ways to Invest Now.","Summary":""},{"Date":"Sep. 29, 2022 at 11:51 a.m. ET","Headline":"Novartis Can Outperform Wall Street Expectations, CEO Says","Summary":""},{"Date":"Sep. 28, 2022 at 4:23 p.m. ET","Headline":"Dow closes up nearly 550 points in rebound from bear-market lows as bond yields fall after BOE intervention","Summary":""},{"Date":"Sep. 28, 2022 at 11:17 a.m. ET","Headline":"New Alzheimer\u2019s Drug Success Was a Shock. Now There Are 5 Big Questions.","Summary":""},{"Date":"Sep. 28, 2022 at 7:26 a.m. ET","Headline":"Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer\u2019s drug success as shares soar","Summary":""},{"Date":"Oct. 2, 2022 at 6:32 p.m. ET","Headline":"An Alzheimer\u2019s Drug\u2019s Big Surprise: What It Means","Summary":""},{"Date":"Oct. 6, 2022 at 3:44 p.m. ET","Headline":"\u2018There\u2019s no way that patients are going to be able to afford that.\u2019 Why aren\u2019t new drugs that can help you lose weight more widely used?","Summary":"Eli Lilly and Co.  said Thursday that its experimental obesity drug received a Fast Track designation from the Food and Drug Administration. The drug maker also said it plans to begin a rolling submission to the FDA for ti..."},{"Date":"Oct. 6, 2022 at 10:11 a.m. ET","Headline":"Lilly Gets Fast Track Designation for Obesity Drug","Summary":"Eli Lilly and Co.  said Thursday that its experimental obesity drug received a Fast Track designation from the Food and Drug Administration. The drug maker also said it plans to begin a rolling submission to the FDA for ti..."},{"Date":"Oct. 6, 2022 at 8:21 a.m. ET","Headline":"Lilly gets Fast Track designation for its experimental obesity drug","Summary":"Eli Lilly and Co.  said Thursday that its experimental obesity drug received a Fast Track designation from the Food and Drug Administration. The drug maker also said it plans to begin a rolling submission to the FDA for ti..."},{"Date":"Oct. 11, 2022 at 2:55 p.m. ET","Headline":"Amgen Stock Takes Off as Morgan Stanley Flags Room for Gains","Summary":""},{"Date":"Oct. 7, 2022 at 10:31 a.m. ET","Headline":"Bank of America: Lilly\u2019s tirzepatide could be the first $100 billion drug","Summary":""},{"Date":"Oct. 19, 2022 at 8:49 a.m. ET","Headline":"Biogen and 10 Other Healthcare Stocks Thriving in This Bear Market","Summary":"Eli Lilly and Co.  said Tuesday it has entered an agreement to acquire Akouos Inc. , a company developing a portfolio of viral gene therapies for the treatment of inner ear conditions including hearing loss, for up to $610..."},{"Date":"Oct. 18, 2022 at 4:49 p.m. ET","Headline":"U.S. stocks finish higher for 2nd day in a row as earnings season starts strong","Summary":"Eli Lilly and Co.  said Tuesday it has entered an agreement to acquire Akouos Inc. , a company developing a portfolio of viral gene therapies for the treatment of inner ear conditions including hearing loss, for up to $610..."},{"Date":"Oct. 18, 2022 at 10:21 a.m. ET","Headline":"Akouos Stock Soars as Eli Lilly Buys Genetic Therapies Company for $610 Million","Summary":"Eli Lilly and Co.  said Tuesday it has entered an agreement to acquire Akouos Inc. , a company developing a portfolio of viral gene therapies for the treatment of inner ear conditions including hearing loss, for up to $610..."},{"Date":"Oct. 18, 2022 at 7:01 a.m. ET","Headline":"Eli Lilly to acquire Akouos for up to about $610 million and develop gene therapies for hearing loss","Summary":"Eli Lilly and Co.  said Tuesday it has entered an agreement to acquire Akouos Inc. , a company developing a portfolio of viral gene therapies for the treatment of inner ear conditions including hearing loss, for up to $610..."},{"Date":"Oct. 29, 2022 at 8:21 a.m. ET","Headline":"Buffett\u2019s Berkshire Chases Musk\u2019s Tesla on Market Value","Summary":""},{"Date":"Oct. 30, 2022 at 6:09 p.m. ET","Headline":"Fed Meeting, Jobs Data, Uber and PayPal Earnings, and More to Watch this Week","Summary":""},{"Date":"Nov. 2, 2022 at 8:22 a.m. ET","Headline":"Lilly\u2019s new diabetes drug doubled sales expectations. It may also be used to treat obesity","Summary":"Eli Lilly & Co. Inc.  said its new Type 2 diabetes treatment Mounjaro brought in $187.3 million in sales in the , beating the FactSet consensus of $79.0 million. It was the therapy's first full quarter on the U.S. market a..."},{"Date":"Nov. 2, 2022 at 6:40 a.m. ET","Headline":"Recession Is the Dark Cloud Hanging Over Powell\u2019s Inflation-Busting Fed","Summary":"Eli Lilly & Co. Inc.  said its new Type 2 diabetes treatment Mounjaro brought in $187.3 million in sales in the , beating the FactSet consensus of $79.0 million. It was the therapy's first full quarter on the U.S. market a..."},{"Date":"Nov. 1, 2022 at 4:30 p.m. ET","Headline":"U.S. stocks end lower as investors weigh economic data, brace for Fed decision on interest rates","Summary":"Eli Lilly & Co. Inc.  said its new Type 2 diabetes treatment Mounjaro brought in $187.3 million in sales in the , beating the FactSet consensus of $79.0 million. It was the therapy's first full quarter on the U.S. market a..."},{"Date":"Nov. 1, 2022 at 12:14 p.m. ET","Headline":"Eli Lilly Stock Slips After Earnings Beat. Forecast Is the Issue.","Summary":"Eli Lilly & Co. Inc.  said its new Type 2 diabetes treatment Mounjaro brought in $187.3 million in sales in the , beating the FactSet consensus of $79.0 million. It was the therapy's first full quarter on the U.S. market a..."},{"Date":"Nov. 1, 2022 at 7:36 a.m. ET","Headline":"Lilly's new Type 2 diabetes drug had $187 million in sales in the third quarter","Summary":"Eli Lilly & Co. Inc.  said its new Type 2 diabetes treatment Mounjaro brought in $187.3 million in sales in the , beating the FactSet consensus of $79.0 million. It was the therapy's first full quarter on the U.S. market a..."},{"Date":"Nov. 1, 2022 at 6:54 a.m. ET","Headline":"Lilly beats adjusted earnings and revenue target but trims its 2022 view","Summary":"Eli Lilly & Co.  shares dipped 1.1% in premarket trades on Tuesday after the drug maker trimmed its 2022 earnings outlook, but posted stronger-than-expected third-quarter results. Lilly's net income rose 31% to $1.45 billi..."},{"Date":"Nov. 1, 2022 at 1:15 a.m. ET","Headline":"3 Things to Watch When Pfizer Announces Earnings","Summary":""},{"Date":"Nov. 4, 2022 at 6:39 a.m. ET","Headline":"Elon Musk Looks Set to Put His Own Twist on Jobs Friday","Summary":""},{"Date":"Nov. 3, 2022 at 2:52 p.m. ET","Headline":"Novo Nordisk Says the Weight-Loss Drug Shortage Will Be Fixed by Year End","Summary":""},{"Date":"Nov. 8, 2022 at 6:51 a.m. ET","Headline":"History Says a Midterm Bounce Is Coming. It May Have Already Happened.","Summary":""},{"Date":"Nov. 9, 2022 at 11:30 a.m. ET","Headline":"Sports Betting, Marijuana, and the Minimum Wage: Key Ballot Results","Summary":""},{"Date":"Nov. 11, 2022 at 2:02 p.m. ET","Headline":"2022\u2019s Top Healthcare Stocks Tumble, Losers Gain, in Dramatic Selloff","Summary":""},{"Date":"Nov. 14, 2022 at 10:47 a.m. ET","Headline":"Biogen in Pole Position After Roche\u2019s Alzheimer\u2019s Drug Disappoints","Summary":""},{"Date":"Nov. 16, 2022 at 8:44 a.m. ET","Headline":"Zoetis, CVS, and 3 More Healthcare Stocks With Room to Climb","Summary":""},{"Date":"Nov. 15, 2022 at 9:01 a.m. ET","Headline":"Elon Musk Upended Twitter Verification. It\u2019s a Big Problem for Brands.","Summary":""},{"Date":"Nov. 15, 2022 at 7:14 a.m. ET","Headline":"One Alzheimer\u2019s drug has failed, but investors are still betting on Biogen and Lilly treatments","Summary":""},{"Date":"Nov. 15, 2022 at 6:57 a.m. ET","Headline":"Retailers Prepare for Another Reveal on Inflation. It\u2019s Key Intelligence for the Fed.","Summary":""},{"Date":"Nov. 18, 2022 at 8:24 p.m. ET","Headline":"How a Hot Norwegian Battery Start-Up Beat the SPAC Deep Freeze","Summary":""},{"Date":"Nov. 26, 2022 at 12:44 p.m. ET","Headline":"Elon Musk teases a new three-color Twitter verification plan: \u2018We\u2019ll see how it goes\u2019","Summary":""},{"Date":"Nov. 30, 2022 at 2:15 p.m. ET","Headline":"What to know about the Alzheimer\u2019s drug data coming out this week","Summary":""},{"Date":"Nov. 30, 2022 at 8:01 a.m. ET","Headline":"Alzheimer\u2019s Breakthrough Is Boost for Biogen, Eli Lilly Despite Side-Effect Concerns","Summary":""},{"Date":"Dec. 2, 2022 at 6:52 a.m. ET","Headline":"It\u2019s Jobs Day. Whatever the Market Says, Fed\u2019s Still Bullish on Economy","Summary":"Eli Lilly & Co.  said Wednesday night that its experimental Alzheimer's treatment did a better job at clearing amyloid plaque than Eisai and Biogen's Aduhelm in a Phase 3 clinical trial. Amyloid plaque is a biomarker assoc..."},{"Date":"Dec. 2, 2022 at 6:28 a.m. ET","Headline":"Chinese cities announce further easing of COVID curbs, though police are still patrolling streets to stop protests","Summary":"Eli Lilly & Co.  said Wednesday night that its experimental Alzheimer's treatment did a better job at clearing amyloid plaque than Eisai and Biogen's Aduhelm in a Phase 3 clinical trial. Amyloid plaque is a biomarker assoc..."},{"Date":"Dec. 1, 2022 at 8:20 a.m. ET","Headline":"Lilly said its Alzheimer's drug clears more amyloid plaque than Aduhelm","Summary":"Eli Lilly & Co.  said Wednesday night that its experimental Alzheimer's treatment did a better job at clearing amyloid plaque than Eisai and Biogen's Aduhelm in a Phase 3 clinical trial. Amyloid plaque is a biomarker assoc..."},{"Date":"Dec. 1, 2022 at 2:30 a.m. ET","Headline":"This Top Pro Invests in Healthcare Trailblazers. 4 of Her Favorite Plays.","Summary":""},{"Date":"Dec. 6, 2022 at 6:37 a.m. ET","Headline":"Investors Desperately Want to See the Market Bottom Out. It\u2019s Not Happening Yet.","Summary":""},{"Date":"Dec. 5, 2022 at 5:23 p.m. ET","Headline":"Covid Cases Are Rising. L.A. Could Bring Back Masks.","Summary":""},{"Date":"Dec. 12, 2022 at 5:57 p.m. ET","Headline":"Twitter Relaunches Paid Verification. Why Brands May Still Hold Back on Ads.","Summary":"Eli Lilly & Co.  said Monday that its board has authorized a 15% increase in the pharma company's quarterly dividend to $1.13 a share. The dividend is payable on March 10 to shareholders of record on Feb. 15, the company s..."},{"Date":"Dec. 12, 2022 at 3:37 p.m. ET","Headline":"Lilly's board OKs 15% dividend increase","Summary":"Eli Lilly & Co.  said Monday that its board has authorized a 15% increase in the pharma company's quarterly dividend to $1.13 a share. The dividend is payable on March 10 to shareholders of record on Feb. 15, the company s..."},{"Date":"Dec. 14, 2022 at 6:46 a.m. ET","Headline":"Falling Inflation Is Good News for the Fed. Just Don\u2019t Get Too Excited.","Summary":"Eli Lilly & Co.  announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide. The..."},{"Date":"Dec. 13, 2022 at 5:04 p.m. ET","Headline":"Pfizer Lays Out Plan to Grow Revenue Ahead of $17 Billion Hit","Summary":"Eli Lilly & Co.  announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide. The..."},{"Date":"Dec. 13, 2022 at 4:36 p.m. ET","Headline":"Dow ends 100 points higher, stocks book back-to-back gains as Wall Street gauges cooler inflation report, awaits Fed rate decision","Summary":"Eli Lilly & Co.  announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide. The..."},{"Date":"Dec. 13, 2022 at 11:09 a.m. ET","Headline":"Eli Lilly Stock Falls on Disappointing 2023 Earnings Outlook","Summary":"Eli Lilly & Co.  announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide. The..."},{"Date":"Dec. 13, 2022 at 6:54 a.m. ET","Headline":"Eli Lilly sets guidance for 2023 and stock falls as EPS lags current consensus","Summary":"Eli Lilly & Co.  announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide. The..."},{"Date":"Dec. 16, 2022 at 7:50 a.m. ET","Headline":"Lilly, Sosei to develop new treatments for diabetes and metabolic diseases","Summary":"Eli Lilly & Co. Inc.  and Sosei Group Corp.  said Friday they  plan to develop and commercialize therapies for diabetes and metabolic diseases. Lilly is paying the Japanese drug maker an upfront payment of $37 million, wit..."},{"Date":"Dec. 17, 2022 at 7:41 a.m. ET","Headline":"This momentum-stock strategy can be a winner regardless of whether the Federal Reserve pivots","Summary":""},{"Date":"Dec. 17, 2022 at 4:00 a.m. ET","Headline":"Nucor, CVS, and 11 More Companies That Raised Their Dividends This Week","Summary":""},{"Date":"Dec. 22, 2022 at 9:54 a.m. ET","Headline":"Stocks remain overpriced, even vs. the dot-com bubble. But you can still find good picks in these 2 sectors.","Summary":"Shares of ProQR Therapeutics NV  soared 56.3% in premarket trading on Thursday after the company said it expanded an RNA editing deal with Eli Lilly & Co. Inc.  aimed at making new genetic medicines. The companies had firs..."},{"Date":"Dec. 22, 2022 at 9:12 a.m. ET","Headline":"ProQR's stock jumps on expanded RNA deal with Lilly","Summary":"Shares of ProQR Therapeutics NV  soared 56.3% in premarket trading on Thursday after the company said it expanded an RNA editing deal with Eli Lilly & Co. Inc.  aimed at making new genetic medicines. The companies had firs..."},{"Date":"Dec. 23, 2022 at 10:18 a.m. ET","Headline":"6 Defensive Healthcare Stocks for 2023","Summary":""},{"Date":"Dec. 23, 2022 at 4:59 a.m. ET","Headline":"New Alzheimer\u2019s Drug Could Be Priced Up to $20,000 a Year: Group","Summary":""},{"Date":"Jan. 4, 2023 at 7:51 a.m. ET","Headline":"Tesla stock wipes out three-day bounce, falls to lowest price in more than 2 years","Summary":""},{"Date":"Jan. 7, 2023 at 1:11 p.m. ET","Headline":"Dozens in Congress beat stock market in 2022 despite downturn on Wall Street: analysis","Summary":""},{"Date":"Jan. 6, 2023 at 2:38 p.m. ET","Headline":"On anniversary of the Capitol attack, companies face new pressures to disclose political spending","Summary":""},{"Date":"Jan. 6, 2023 at 7:41 a.m. ET","Headline":"Amid criticism for its handling of another Alzheimer\u2019s drug, FDA will decide this week whether to approve lecanemab","Summary":""},{"Date":"Jan. 6, 2023 at 7:00 a.m. ET","Headline":"Why Pfizer Is Pulling Back on Early-Stage Rare Disease Research, Selling Some Major Assets","Summary":""},{"Date":"Jan. 8, 2023 at 6:32 p.m. ET","Headline":"It\u2019s Pharma Time: Why Merck and Lilly Are Buys, but Not Pfizer.","Summary":""},{"Date":"Jan. 12, 2023 at 5:22 p.m. ET","Headline":"California is latest state to sue drug companies over high insulin prices","Summary":""},{"Date":"Jan. 14, 2023 at 2:00 a.m. ET","Headline":"Tanking Biotech Stocks Will Mean a Big Year for Deals. Who Could Benefit.","Summary":""},{"Date":"Jan. 19, 2023 at 7:16 p.m. ET","Headline":"FDA rejects Eli Lilly\u2019s proposed Alzheimer\u2019s treatment, says more data needed","Summary":""},{"Date":"Jan. 21, 2023 at 9:19 a.m. ET","Headline":"Why the FDA didn\u2019t grant an approval to Lilly\u2019s Alzheimer\u2019s drug","Summary":""},{"Date":"Jan. 21, 2023 at 8:08 a.m. ET","Headline":"S&P 500, Dow score best day in 2 weeks, Nasdaq erases weekly loss as Netflix, Alphabet jump","Summary":""},{"Date":"Jan. 20, 2023 at 11:21 a.m. ET","Headline":"The FDA Rejected Lilly\u2019s Alzheimer\u2019s Drug. Why It\u2019s Only a Setback.","Summary":""},{"Date":"Jan. 20, 2023 at 9:03 a.m. ET","Headline":"Price Negotiations Are About to Reshape the Drug Industry","Summary":""},{"Date":"Jan. 25, 2023 at 2:56 a.m. ET","Headline":"Eli Lilly, Novo Nordisk Get a Share-Price Pop From Weight-Loss Drugs","Summary":""},{"Date":"Jan. 24, 2023 at 6:42 a.m. ET","Headline":"Eli Lilly to invest additional $450 million in Research Triangle Park facility, to add at least 100 jobs","Summary":""},{"Date":"Jan. 26, 2023 at 6:53 a.m. ET","Headline":"Dow, IBM, and SAP Keep the Layoffs Coming. It\u2019s Spreading Beyond Tech.","Summary":""},{"Date":"Jan. 28, 2023 at 11:04 a.m. ET","Headline":"Gas Prices Are Rising. Refiner Stocks Are Riding the Wave\u2014for Now.","Summary":""},{"Date":"Jan. 31, 2023 at 7:50 a.m. ET","Headline":"Pfizer Stock Falls on Downbeat Guidance as Company Braces for Covid Vaccine Drop-Off","Summary":""},{"Date":"Feb. 2, 2023 at 5:18 p.m. ET","Headline":"Lilly and Novo Stock Sold Off. Don\u2019t Blame Their Diet Drugs.","Summary":""},{"Date":"Feb. 2, 2023 at 4:33 p.m. ET","Headline":"These Stocks Are Moving the Most Today: Meta, Align, Coinbase, Harley, Okta, and More","Summary":""},{"Date":"Feb. 2, 2023 at 4:29 p.m. ET","Headline":"S&P 500 surges to end at over five-month high, Nasdaq closes up 3.3% as Meta leads rally in tech sector stocks","Summary":""},{"Date":"Feb. 2, 2023 at 10:41 a.m. ET","Headline":"Eli Lilly Stock Falls as Mounjaro Sales Fall Short. Earnings Still Crushed.","Summary":""},{"Date":"Feb. 2, 2023 at 7:45 a.m. ET","Headline":"Purdue president and former Indiana governor Mitch Daniels won\u2019t run for U.S. Senate seat being vacated by Republican Mike Braun","Summary":""},{"Date":"Feb. 2, 2023 at 7:18 a.m. ET","Headline":"Eli Lilly\u2019s stock falls after Q4 revenue miss","Summary":""},{"Date":"Feb. 3, 2023 at 8:04 a.m. ET","Headline":"Meta movin\u2019 up: How Wall Street warmed up to Facebook once again","Summary":""},{"Date":"Feb. 3, 2023 at 7:10 a.m. ET","Headline":"Lilly\u2019s Type 2 diabetes drug Mounjaro didn\u2019t sell enough to impress, analysts say","Summary":""},{"Date":"Feb. 3, 2023 at 6:32 a.m. ET","Headline":"Apple Is Not the Economy. Why the Fed\u2019s More Bullish Than Tech.","Summary":""},{"Date":"Jan. 30, 2023 at 8:43 a.m. ET","Headline":"Apple and Amazon Earnings, a Fed Decision, Jobs Data, and More to Watch This Week","Summary":""},{"Date":"Feb. 15, 2023 at 9:43 a.m. ET","Headline":"Inside the NASH drug boom: New drugs for a \u2018silent\u2019 liver disease that affects millions near FDA approval","Summary":""},{"Date":"Feb. 5, 2023 at 9:53 a.m. ET","Headline":"Pfizer Is Moving Beyond Covid. Why Its Stock Is a Buy.","Summary":""},{"Date":"Feb. 18, 2023 at 9:29 a.m. ET","Headline":"14 dividend stocks that rose 100% or more in 5 years as the payouts doubled","Summary":""},{"Date":"Feb. 24, 2023 at 2:21 p.m. ET","Headline":"Boeing, Adobe and Autodesk stocks sink, Beyond Meat\u2019s soars, and other stocks on the move","Summary":""},{"Date":"Feb. 23, 2023 at 5:24 p.m. ET","Headline":"Nektar stock drops more than 30% after study involving lupus treatment will not go forward","Summary":""},{"Date":"Feb. 21, 2023 at 6:48 p.m. ET","Headline":"\u2018Biosimilars\u2019 Were Supposed to Tame Costs for Drugs Like Humira. It Isn\u2019t Working.","Summary":""},{"Date":"Mar. 2, 2023 at 9:02 a.m. ET","Headline":"Eli Lilly\u2019s Insulin Price Cap Squeezes Other Drug Makers","Summary":""},{"Date":"Mar. 2, 2023 at 6:49 a.m. ET","Headline":"Crypto Banker Silvergate Should Pay More Attention to Jamie Dimon Than Sam Bankman-Fried","Summary":""},{"Date":"Mar. 1, 2023 at 11:49 a.m. ET","Headline":"Why Lilly\u2019s Insulin Price Cuts Could Boost the Stock","Summary":""},{"Date":"Mar. 1, 2023 at 10:07 a.m. ET","Headline":"Lilly to cut price of insulin for people with commercial health insurance","Summary":""},{"Date":"Mar. 3, 2023 at 9:11 a.m. ET","Headline":"Insulin costing $35 a month \u2018should be the new standard in America,\u2019 Eli Lilly CEO says. But could this happen?","Summary":""},{"Date":"Mar. 6, 2023 at 11:38 a.m. ET","Headline":"FDA Will Weigh Full Approval for Alzheimer\u2019s Drug. Why It Matters for Biogen Stock.","Summary":""},{"Date":"Mar. 8, 2023 at 7:54 a.m. ET","Headline":"Why Weight Watchers is buying a company that prescribes popular weight-loss drugs like Ozempic","Summary":""},{"Date":"Mar. 7, 2023 at 6:50 a.m. ET","Headline":"The Data Will Speak Louder Than Powell. Fed Rate Is Veering Toward 6%.","Summary":""},{"Date":"Mar. 9, 2023 at 7:54 a.m. ET","Headline":"Lilly\u2019s drug aimed at preventing Alzheimer\u2019s fails","Summary":""},{"Date":"Mar. 16, 2023 at 4:24 p.m. ET","Headline":"Sanofi to cap price of Lantus insulin at $35","Summary":""},{"Date":"Mar. 15, 2023 at 7:11 p.m. ET","Headline":"Biden says he\u2019s \u2018intensely\u2019 focused on lowering drug prices","Summary":""},{"Date":"Mar. 28, 2023 at 8:19 a.m. ET","Headline":"Viking\u2019s stock rallies as it announces trial for oral version of obesity drug","Summary":""},{"Date":"Apr. 2, 2023 at 4:22 p.m. ET","Headline":"Twitter revokes blue check mark from main New York Times account","Summary":""},{"Date":"Apr. 11, 2023 at 5:01 p.m. ET","Headline":"WW International Stock Is the Latest Way to Ride the  Obesity-Drug Wave","Summary":""},{"Date":"Apr. 17, 2023 at 6:03 p.m. ET","Headline":"Nektar stock pops as more than half of San Francisco office loses jobs, new CFO appointed","Summary":""},{"Date":"Apr. 17, 2023 at 11:25 a.m. ET","Headline":"Eli Lilly to invest another $1.6 billion, add 200 more jobs to its new manufacturing sites in Indiana","Summary":""},{"Date":"Apr. 18, 2023 at 9:33 a.m. ET","Headline":"IPO for J&J\u2019s Consumer Health Division is Coming Soon, CFO Says","Summary":""},{"Date":"Apr. 21, 2023 at 6:57 p.m. ET","Headline":"China\u2019s Consumer-Led Growth Looks More Like a Bounce, Not a Recovery","Summary":""},{"Date":"Apr. 23, 2023 at 10:19 p.m. ET","Headline":"Microsoft, Visa, First Republic, Amazon, Exxon Mobil, and More Stocks to Watch This Week","Summary":""},{"Date":"Apr. 25, 2023 at 2:30 p.m. ET","Headline":"Biogen Earnings Beat Expectations. All Eyes Are on the Alzheimer\u2019s Drug.","Summary":""},{"Date":"Apr. 24, 2023 at 4:35 p.m. ET","Headline":"Nasdaq Composite ends slightly lower ahead of tech-sector earnings onslaught","Summary":""},{"Date":"Apr. 24, 2023 at 4:19 p.m. ET","Headline":"Bed Bath and Fox shares drop, Albemarle\u2019s stock rallies, and more stocks on the move","Summary":""},{"Date":"Apr. 24, 2023 at 6:54 a.m. ET","Headline":"Eli Lilly to sell hypoglycemia treatment for up to $1.1 billion in cash and milestone payments to Amphastar","Summary":""},{"Date":"Apr. 27, 2023 at 11:52 a.m. ET","Headline":"Eli Lilly Results Disappoint. Hopes for Obesity Drug Are Lifting the Stock.","Summary":""},{"Date":"Apr. 27, 2023 at 9:33 a.m. ET","Headline":"An undiscovered universe of stocks is trading at \u2018near generational lows,\u2019 asset manager says","Summary":""},{"Date":"Apr. 27, 2023 at 7:01 a.m. ET","Headline":"Eli Lilly stock up premarket as company\u2019s Q1 revenue beats and it raises guidance","Summary":""},{"Date":"Apr. 27, 2023 at 6:15 a.m. ET","Headline":"New Drug Trial Results Set Eli Lilly\u2019s Mounjaro Up for Obesity Approval","Summary":""},{"Date":"Apr. 28, 2023 at 8:31 a.m. ET","Headline":"Eli Lilly\u2019s next-generation obesity drug helped patients lose up to 34 pounds in clinical trial","Summary":""},{"Date":"Apr. 28, 2023 at 7:01 a.m. ET","Headline":"First Republic Bank Faces a Critical Weekend. What to Expect.","Summary":""},{"Date":"Apr. 30, 2023 at 7:00 a.m. ET","Headline":"Shareholder Resolutions Target Climate, Abortion, CEO Pay","Summary":""},{"Date":"May. 3, 2023 at 4:41 p.m. ET","Headline":"Dow ends more than 250 points lower after Fed delivers quarter-point rate hike, signals possible pause in tightening cycle","Summary":""},{"Date":"May. 3, 2023 at 4:31 p.m. ET","Headline":"These Stocks Are Moving the Most Today: Eli Lilly, Ruth\u2019s Hospitality Group, Estee Lauder, AMD, and More","Summary":""},{"Date":"May. 3, 2023 at 12:20 p.m. ET","Headline":"Eli Lilly stock jumps 5% after Alzheimer\u2019s treatment slows disease progression in major trial","Summary":""},{"Date":"May. 3, 2023 at 10:48 a.m. ET","Headline":"Eli Lilly Drug Aids Alzheimer\u2019s Patients but Safety Is an Issue","Summary":""},{"Date":"May. 3, 2023 at 8:19 a.m. ET","Headline":"This top-performing macro fund says the economic cycle is bottoming. Here\u2019s why.","Summary":""},{"Date":"May. 3, 2023 at 7:48 a.m. ET","Headline":"Eli Lilly jumps upon Alzheimer trial results, AMD and Starbucks drop after earnings, and other stocks on the move","Summary":""},{"Date":"May. 5, 2023 at 4:11 p.m. ET","Headline":"New Alzheimer\u2019s drug trial seen as \u2018potentially very important\u2019","Summary":""},{"Date":"May. 4, 2023 at 1:20 p.m. ET","Headline":"Kenvue Stock Jumps in IPO of Former J&J Consumer-Health Business","Summary":""},{"Date":"May. 4, 2023 at 8:42 a.m. ET","Headline":"Weight-Loss Drugs Will Be Blockbusters. Here\u2019s the Stock to Buy.","Summary":""},{"Date":"May. 4, 2023 at 6:39 a.m. ET","Headline":"Powell Says Banking System \u2018Sound and Resilient.\u2019 Try Telling That to PacWest Investors.","Summary":""},{"Date":"May. 9, 2023 at 2:45 p.m. ET","Headline":"Biotech Layoffs Keep Coming as Funding Squeeze Drags On","Summary":""},{"Date":"May. 8, 2023 at 10:29 a.m. ET","Headline":"Lilly and Biogen Want Medicare to Cover New Alzheimer\u2019s Drugs. It\u2019s Not Happening.","Summary":""},{"Date":"May. 12, 2023 at 4:42 p.m. ET","Headline":"Eli Lilly nears J&J market cap","Summary":""},{"Date":"May. 12, 2023 at 8:07 a.m. ET","Headline":"Prescription-drug costs in spotlight as pharmacy benefit reform advances in Senate","Summary":""},{"Date":"May. 17, 2023 at 12:38 p.m. ET","Headline":"Pfizer, Amgen, and 7 More Cheap Healthcare Stocks for Investors to Consider","Summary":""},{"Date":"May. 18, 2023 at 7:08 a.m. ET","Headline":"Eli Lilly says mid-stage trial of rheumatoid arthritis met its main efficacy goal","Summary":""},{"Date":"May. 23, 2023 at 3:05 p.m. ET","Headline":"New Weight-Loss Pills Are Coming. What to Know.","Summary":""},{"Date":"May. 23, 2023 at 8:45 a.m. ET","Headline":"These stock pickers led the health-fund category over the past 5 years. Here\u2019s where they\u2019re investing now.","Summary":""},{"Date":"May. 23, 2023 at 6:36 a.m. ET","Headline":"There Are Two Kinds of Shareholder Activism. Only This One\u2019s Good for Investors.","Summary":""},{"Date":"May. 27, 2023 at 11:02 a.m. ET","Headline":"The dark side of the weight-loss-drug craze: eating disorders, medication shortages, dangerous knockoffs","Summary":""},{"Date":"May. 31, 2023 at 2:53 p.m. ET","Headline":"This Large-Cap Growth Fund Has Trounced Its Peers for a Decade","Summary":""},{"Date":"Jun. 2, 2023 at 8:03 a.m. ET","Headline":"Eli Lilly releases new data on breast cancer, lymphoma treatments","Summary":""},{"Date":"Jun. 1, 2023 at 1:44 p.m. ET","Headline":"Medicare unveils plan for coverage of new Alzheimer\u2019s drugs","Summary":""},{"Date":"Jun. 2, 2023 at 1:15 a.m. ET","Headline":"It\u2019s Not Just AI. 5 Trends That Will Change How You Invest.","Summary":""},{"Date":"Jun. 15, 2023 at 9:14 a.m. ET","Headline":"Alphabet, United Airlines, and 4 Other Stocks With Plenty of Momentum","Summary":""},{"Date":"Jun. 17, 2023 at 1:05 p.m. ET","Headline":"5 fast facts about berberine, the weight-loss supplement blowing up on TikTok","Summary":""},{"Date":"Jun. 20, 2023 at 4:16 p.m. ET","Headline":"These Stocks Moved the Most Today: Alibaba, Dice, Lemonade, Arcellx, Avis, and More","Summary":""},{"Date":"Jun. 20, 2023 at 11:51 a.m. ET","Headline":"Alibaba, Nio stocks fall, Rivian and Nikola shares rally and other stocks on the move","Summary":""},{"Date":"Jun. 20, 2023 at 9:36 a.m. ET","Headline":"Student-loan payments are coming back \u2014 and these are the stocks most at risk","Summary":""},{"Date":"Jun. 20, 2023 at 9:25 a.m. ET","Headline":"Eli Lilly to Buy DICE Therapeutics in $2.4 Billion Autoimmune Disease Push","Summary":""},{"Date":"Jun. 20, 2023 at 7:01 a.m. ET","Headline":"Dice Therapeutics rallies as it agrees to be bought by Lilly","Summary":""},{"Date":"Jun. 20, 2023 at 3:23 a.m. ET","Headline":"Hit Wegovy weight-loss drug on track for $4 billion in U.S. sales despite supply constraints, analyst says","Summary":""},{"Date":"Jun. 22, 2023 at 3:30 a.m. ET","Headline":"More News Is Coming on Lilly, Novo Nordisk\u2019s New Weight-Loss Drugs","Summary":""},{"Date":"Jun. 21, 2023 at 1:29 p.m. ET","Headline":"FDA approves Eli Lilly and Boehringer Ingelheim\u2019s Jardiance for children 10 and older with type 2 diabetes","Summary":""},{"Date":"Jun. 21, 2023 at 6:00 a.m. ET","Headline":"The Fed Hasn\u2019t Tamed Shoppers Yet. That\u2019s Good for FedEx, Bad for Powell.","Summary":""},{"Date":"Jun. 23, 2023 at 3:50 p.m. ET","Headline":"Eli Lilly Leads the Way in Obesity, Alzheimer\u2019s Treatments Under Dave Ricks","Summary":""},{"Date":"Jun. 26, 2023 at 7:22 a.m. ET","Headline":"No more needles? A daily pill may work as well as Wegovy shots to treat obesity.","Summary":""},{"Date":"Jun. 28, 2023 at 12:15 p.m. ET","Headline":"Here Are Barron\u2019s Top CEOs of 2023","Summary":""},{"Date":"Jun. 27, 2023 at 8:52 a.m. ET","Headline":"Eli Lilly Stock Jumps. Its  Weight-Loss Shot Melts More Pounds Than Its Pill.","Summary":""},{"Date":"Jun. 27, 2023 at 8:12 a.m. ET","Headline":"Pfizer Makes a Call on Obesity Pill. Investors Aren\u2019t Happy.","Summary":""},{"Date":"Jun. 27, 2023 at 8:10 a.m. ET","Headline":"Weight-loss drugs in development aim to replace injections with pills","Summary":""},{"Date":"Jun. 27, 2023 at 7:53 a.m. ET","Headline":"Eli Lilly shares gain after investigational obesity treatment helps patients lose up to 58 pounds, on average","Summary":""},{"Date":"Jun. 27, 2023 at 6:27 a.m. ET","Headline":"Fed Will Pay High Price to Bring Down Inflation. Investors Should Take Note.","Summary":""},{"Date":"Jun. 27, 2023 at 2:00 a.m. ET","Headline":"Mergers Are Down, but These 2 Sectors Are Booming","Summary":""},{"Date":"Jun. 30, 2023 at 5:54 p.m. ET","Headline":"Eli Lilly Is Riding the Weight-Loss Wave. Why Its Dominance Could Last for Years.","Summary":""},{"Date":"Jun. 30, 2023 at 6:56 a.m. ET","Headline":"Ozempic and other weight-loss drugs boost pharmacy sales at Rite Aid","Summary":""},{"Date":"Jun. 29, 2023 at 10:06 a.m. ET","Headline":"Sigilon Therapeutics\u2019 stock soars 550% after Eli Lilly agrees to acquire company","Summary":""},{"Date":"Jun. 29, 2023 at 8:32 a.m. ET","Headline":"Medicare coverage of weight-loss drugs? Don\u2019t count on it, analysts say.","Summary":""},{"Date":"Jun. 30, 2023 at 6:39 p.m. ET","Headline":"Cardlytics and Motorcar Parts of America Stock See Action From Activist Investors","Summary":""},{"Date":"Jul. 7, 2023 at 1:17 p.m. ET","Headline":"Biogen\u2019s Alzheimer\u2019s Drug Rollout Could Be Slow","Summary":""},{"Date":"Jul. 7, 2023 at 10:49 a.m. ET","Headline":"Biogen\u2019s big Alzheimer\u2019s drug win fails to boost the stock as analysts see slow Leqembi rollout","Summary":""},{"Date":"Jul. 7, 2023 at 7:50 a.m. ET","Headline":"FDA approves Alzheimer\u2019s treatment Leqembi, clearing the way for Medicare coverage","Summary":""},{"Date":"Jul. 7, 2023 at 7:29 a.m. ET","Headline":"Biogen\u2019s stock slides premarket as analysts take mixed view of Alzheimer\u2019s disease drug approval","Summary":""},{"Date":"Jul. 6, 2023 at 10:53 a.m. ET","Headline":"4 Big Pharma Stocks On Sale Right Now","Summary":""},{"Date":"Jul. 12, 2023 at 2:43 p.m. ET","Headline":"Shares of Lilly and Novo Are Down. Are Ozempic Safety Concerns to Blame?","Summary":""},{"Date":"Jul. 12, 2023 at 7:23 a.m. ET","Headline":"EU regulator is reviewing weight-loss drugs Ozempic and Wegovy for risk of suicidal thoughts and self-harm","Summary":""},{"Date":"Jul. 14, 2023 at 4:36 p.m. ET","Headline":"JPMorgan, Citigroup, State Street, UnitedHealth, AT&T, and More Stock Market Movers","Summary":""},{"Date":"Jul. 14, 2023 at 11:26 a.m. ET","Headline":"Eli Lilly Adds to Obesity Drug Pipeline With Deal to Buy Versanis Bio","Summary":""},{"Date":"Jul. 14, 2023 at 8:14 a.m. ET","Headline":"Eli Lilly to acquire Versanis Bio, expanding obesity-treatment pipeline","Summary":""},{"Date":"Jul. 12, 2023 at 3:59 p.m. ET","Headline":"Drug manufacturers\u2019 deal making will plow ahead despite antitrust scrutiny, according to analysts","Summary":""},{"Date":"Jul. 15, 2023 at 8:43 a.m. ET","Headline":"This stock investing strategy has blown away the S&P 500. Here\u2019s a way to refine it for quality.","Summary":""},{"Date":"Jul. 18, 2023 at 2:13 p.m. ET","Headline":"Alzheimer\u2019s Drugs May Be a Big-Pharma Payday. Lilly and Biogen Are Facing Off.","Summary":""},{"Date":"Jul. 18, 2023 at 8:53 a.m. ET","Headline":"Look Past Big Tech Stocks. Here Are 40 Picks From Our Roundtable Pros.","Summary":""},{"Date":"Jul. 18, 2023 at 8:39 a.m. ET","Headline":"Biogen, Eli Lilly likely to split the Alzheimer\u2019s drug market, analysts say","Summary":""},{"Date":"Jul. 18, 2023 at 6:28 a.m. ET","Headline":"The Tech Stock Rally Has Reached a Critical Moment. Watch Tesla, Netflix Earnings.","Summary":""},{"Date":"Jul. 17, 2023 at 11:41 a.m. ET","Headline":"Eli Lilly Says Alzheimer\u2019s Treatment Slows Cognitive, Functional Decline","Summary":""},{"Date":"Jul. 17, 2023 at 10:15 a.m. ET","Headline":"Eli Lilly\u2019s Alzheimer\u2019s treatment shows promise in early stages of disease \u2014 but safety concerns remain","Summary":""},{"Date":"Jul. 19, 2023 at 8:04 a.m. ET","Headline":"At-home Alzheimer\u2019s testing is on the horizon, researchers say","Summary":""},{"Date":"Jul. 18, 2023 at 5:36 p.m. ET","Headline":"The Fight Against Alzheimer\u2019s Goes Beyond Plaque. Tangles Are a Target, Too.","Summary":""},{"Date":"Jul. 22, 2023 at 10:47 a.m. ET","Headline":"These 13 S&P 500 stocks stand out for expected growth through 2025","Summary":""},{"Date":"Jul. 21, 2023 at 8:03 p.m. ET","Headline":"Lilly Joins Biogen as Alzheimer\u2019s Drugs Finally Emerge","Summary":""},{"Date":"Jul. 21, 2023 at 5:30 p.m. ET","Headline":"Drug Stock Vertex May See Boost From Non-Opioid Painkillers, Says Analyst","Summary":""},{"Date":"Jul. 21, 2023 at 5:05 a.m. ET","Headline":"As Ozempic\/Wegovy frenzy continues, Morgan Stanley lifts forecasts for weight-loss drugs to $77 billion","Summary":""},{"Date":"Jul. 24, 2023 at 9:03 a.m. ET","Headline":"American Manufacturing\u2019s Revival\u2014and 7 Stocks to Play the Trend","Summary":""},{"Date":"Jul. 23, 2023 at 10:01 a.m. ET","Headline":"With Microsoft, Meta and Alphabet earnings hanging on AI, more investors are asking: \u2018How are you going to pay for that?\u2019","Summary":""},{"Date":"Jul. 25, 2023 at 10:44 a.m. ET","Headline":"Biogen to slash 1,000 jobs as it looks to save $700 million","Summary":""},{"Date":"Jul. 31, 2023 at 2:50 p.m. ET","Headline":"Quest Diagnostics launches first at-home blood test to assess risk of developing Alzheimer\u2019s disease","Summary":""},{"Date":"Jul. 31, 2023 at 12:30 p.m. ET","Headline":"Drugmakers Want to Crush Medicare\u2019s Pricing Power. They\u2019ll Probably Succeed.","Summary":""},{"Date":"Jun. 27, 2023 at 2:10 p.m. ET","Headline":"Eli Lilly, Pfizer, and Others Are Working on Weight-Loss Pills. What to Know.","Summary":""},{"Date":"Aug. 2, 2023 at 7:41 a.m. ET","Headline":"Pfizer\u2019s stock drops as earnings fall sharply amid lower sales for its COVID products","Summary":""},{"Date":"Aug. 2, 2023 at 7:19 a.m. ET","Headline":"This aggressive stock fund has had a wild ride \u2014 but it has beaten rivals and the S&P 500","Summary":""},{"Date":"Aug. 4, 2023 at 6:58 p.m. ET","Headline":"Summer Travel Is Hot. For Some Travel Stocks, It\u2019s Not.","Summary":""},{"Date":"Aug. 4, 2023 at 4:33 p.m. ET","Headline":"The Biotech Game Is Changing. Watch for Disruptions, Says RBC.","Summary":""},{"Date":"Aug. 4, 2023 at 10:40 a.m. ET","Headline":"Eli Lilly Stock Is on a Tear. Expect More Gains After Earnings.","Summary":""},{"Date":"Aug. 4, 2023 at 8:01 a.m. ET","Headline":"Eli Lilly reports positive results in trial of tretment for non-small cell lung cancer","Summary":""},{"Date":"Aug. 7, 2023 at 6:50 a.m. ET","Headline":"Nektar Therapeutics\u2019 stock jumps premarket after it says data presented by Eli Lilly for a skin treatment was incorrectly calculated","Summary":""},{"Date":"Aug. 7, 2023 at 6:43 a.m. ET","Headline":"The Fed Is Aiming for a Soft Landing. What It Means for Earnings.","Summary":""},{"Date":"Aug. 4, 2023 at 4:57 p.m. ET","Headline":"Ozempic Is All the Rage. And That Might Explain a Mysterious Stock Selloff.","Summary":""},{"Date":"Aug. 9, 2023 at 12:56 p.m. ET","Headline":"As obesity drugs help people eat less, these food companies could be the biggest losers","Summary":""},{"Date":"Aug. 9, 2023 at 12:36 p.m. ET","Headline":"Eli Lilly Rises Again as Stock Upgraded Following Mounjaro Sales Surge","Summary":""},{"Date":"Aug. 9, 2023 at 7:47 a.m. ET","Headline":"Novo Nordisk\u2019s Wegovy shows positive results in reducing risk of cardio events, not just weight loss","Summary":""},{"Date":"Aug. 9, 2023 at 2:00 a.m. ET","Headline":"For Dieters, Obesity Drugs Are a Magic Pill. Snack Makers Might Be the Real Losers.","Summary":""},{"Date":"Aug. 8, 2023 at 4:33 p.m. ET","Headline":"These Stocks Moved the Most Today: Eli Lilly, UPS, Beyond Meat, Novo Nordisk, and More","Summary":""},{"Date":"Aug. 8, 2023 at 4:32 p.m. ET","Headline":"Dow ends down 160 points after weak China data, Moody\u2019s downgrade on regional banks","Summary":""},{"Date":"Aug. 8, 2023 at 12:05 p.m. ET","Headline":"Eli Lilly\u2019s stock soars toward best day in 23 years after strong earnings, upbeat Mounjaro outlook","Summary":""},{"Date":"Aug. 8, 2023 at 10:28 a.m. ET","Headline":"Novo Nordisk jumps on positive Wegovy comment, but Beyond Meat stock skids as revenue slumps and other stocks on the move","Summary":""},{"Date":"Aug. 8, 2023 at 10:26 a.m. ET","Headline":"Eli Lilly Stock Is Flying After Strong Results. Obesity Drugs Delivered the Goods.","Summary":""},{"Date":"Aug. 8, 2023 at 10:25 a.m. ET","Headline":"New Data May Push Insurers to Cover Novo, Lilly Obesity Drugs","Summary":""},{"Date":"Aug. 8, 2023 at 9:21 a.m. ET","Headline":"The U.S. may have lost jobs last month, one Wall Street strategist says","Summary":""},{"Date":"Aug. 8, 2023 at 8:14 a.m. ET","Headline":"Wegovy\u2019s success in reducing cardio risk is \u2018an important win,\u2019 and a \u2018best-case scenario,\u2019 say Wolfe analysts","Summary":""},{"Date":"Aug. 8, 2023 at 7:24 a.m. ET","Headline":"Just When You Think Banks Are Safe Again, Moody\u2019s Sounds the Alarm","Summary":""},{"Date":"Aug. 6, 2023 at 2:00 p.m. ET","Headline":"Disney, UPS, BioNTech, Palantir, and More Stocks to Watch This Week","Summary":""},{"Date":"Aug. 11, 2023 at 8:15 p.m. ET","Headline":"Pricier Back-to-School Gear Favors Discount Retailers","Summary":""},{"Date":"Aug. 11, 2023 at 6:14 a.m. ET","Headline":"The Inflation Numbers Were Good. Why the Fed Still Won\u2019t Be Happy.","Summary":""},{"Date":"Aug. 10, 2023 at 8:27 a.m. ET","Headline":"Viking Therapeutics stock gets boost from positive news that obesity drugs reduced risk of heart attacks and strokes","Summary":""},{"Date":"Aug. 15, 2023 at 9:07 a.m. ET","Headline":"Amazon Pharmacy launches automatic coupons for $35 insulin","Summary":""},{"Date":"Aug. 16, 2023 at 8:14 p.m. ET","Headline":"George Soros loads up on AI stocks like Microsoft and Meta, while shedding Salesforce","Summary":""},{"Date":"Aug. 16, 2023 at 12:30 a.m. ET","Headline":"6 Pharma and Life Sciences Stocks That Are Actually Up This Year","Summary":""},{"Date":"Aug. 22, 2023 at 9:45 a.m. ET","Headline":"These 20 dividend stocks have been the best income growers in the S&P 500","Summary":""},{"Date":"Aug. 22, 2023 at 8:32 a.m. ET","Headline":"Eli Lilly reports positive results from study of thyroid cancer treatment","Summary":""},{"Date":"Aug. 25, 2023 at 12:31 p.m. ET","Headline":"Novo Nordisk\u2019s Wegovy Helped Heart-Failure Patients. What\u2019s Next?","Summary":""},{"Date":"Aug. 29, 2023 at 3:26 p.m. ET","Headline":"Eli Lilly and Other Pharma Stocks Are Ignoring Medicare\u2019s 10 Drug List","Summary":""},{"Date":"Aug. 29, 2023 at 3:22 p.m. ET","Headline":"Eliquis, Jardiance among first 10 drugs selected for Medicare price negotiations","Summary":""},{"Date":"Aug. 28, 2023 at 3:00 a.m. ET","Headline":"Biden Administration to Reveal Which Pharma Blockbusters Medicare Will Pay Less For","Summary":""},{"Date":"Aug. 31, 2023 at 5:26 p.m. ET","Headline":"It\u2019s Still Tech\u2019s Year. These Stocks Led the Market in August.","Summary":""},{"Date":"Aug. 30, 2023 at 3:56 p.m. ET","Headline":"Medicare\u2019s Plan to Negotiate Drug Discounts Won\u2019t Hit Pharma Hard, Analysts say","Summary":""},{"Date":"Aug. 30, 2023 at 6:46 a.m. ET","Headline":"Crypto Scores Big Win Over the SEC. Why the Battle\u2019s Far From Over.","Summary":""},{"Date":"Aug. 30, 2023 at 1:57 a.m. ET","Headline":"Global dividends hit record $568 billion, but pace of U.S. payouts slows for sixth straight quarter","Summary":""},{"Date":"Aug. 30, 2023 at 12:01 a.m. ET","Headline":"Global Dividends Hit a Record High, Driven by Banks","Summary":""},{"Date":"Sep. 1, 2023 at 12:19 p.m. ET","Headline":"Drug Developer Stocks Are Risky. Why a Picks-and-Shovels Approach Makes Sense.","Summary":""},{"Date":"Sep. 5, 2023 at 5:43 a.m. ET","Headline":"Novo Nordisk Is Now Europe\u2019s Biggest Company, Driven by Weight-Loss Drug. How Eli Lilly Could Benefit.","Summary":""},{"Date":"Sep. 8, 2023 at 5:54 p.m. ET","Headline":"These 6 Food Stocks Have Gotten Hit Hard. It\u2019s Time to Chow Down.","Summary":""},{"Date":"Sep. 7, 2023 at 11:39 a.m. ET","Headline":"Weight-Loss Drug Market Can Hit $100 Billion, J.P. Morgan Says. That Makes Eli Lilly Stock a Big Winner.","Summary":""},{"Date":"Sep. 20, 2023 at 3:00 a.m. ET","Headline":"6 Healthcare Stocks Analysts Still Like","Summary":""},{"Date":"Sep. 22, 2023 at 8:49 a.m. ET","Headline":"Eli Lilly, Boehringer Ingelheim\u2019s Jardiance gets FDA approval for chronic kidney disease","Summary":""},{"Date":"Sep. 22, 2023 at 8:27 a.m. ET","Headline":"Eli Lilly set to dominate obesity drug market into the next decade, analysts say","Summary":""},{"Date":"Sep. 21, 2023 at 9:25 a.m. ET","Headline":"Weight-Loss Drugs Like Wegovy Are Bad News for These Stocks","Summary":""},{"Date":"Sep. 26, 2023 at 2:30 p.m. ET","Headline":"Ozempic and Other Weight-Loss Drugs Have Pummeled This Stock. It May Be a Buy.","Summary":""},{"Date":"Sep. 21, 2023 at 9:16 a.m. ET","Headline":"How Ozempic and Wegovy Could Break the Healthcare System","Summary":""},{"Date":"Sep. 29, 2023 at 11:19 a.m. ET","Headline":"Structure Stock Soars. Its Obesity Pill Could Challenge Lilly, Novo.","Summary":""},{"Date":"Oct. 2, 2023 at 5:27 p.m. ET","Headline":"Why the Weight-Loss Drug Hype Looks Overdone","Summary":""},{"Date":"Oct. 2, 2023 at 2:04 p.m. ET","Headline":"Eli Lilly Gets FDA Letter About Eczema Drug Concerns","Summary":""},{"Date":"Oct. 2, 2023 at 12:28 p.m. ET","Headline":"This fund shows that industry expertise can help you make a lot of money in the stock market","Summary":""},{"Date":"Oct. 2, 2023 at 6:59 a.m. ET","Headline":"Eli Lilly gets FDA complete response letter for skin treatment after inspection of third-party facility","Summary":""}]